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AKT Function and Human Oncogenesis 
Sungman Park 
ABSTRACT 
 
Accumulated evidence indicates that, by the phosphorylation of its physiological 
substrates, Akt promotes cell survival, proliferation and angiogenesis.  While a number 
of Akt targets have been identified, the mechanism by which Akt regulates cell survival 
and growth and induces malignant transformation still remains elusive.  During the last 
5 years, I have shown that AKT1 cross-talks with Src/Stat3 pathway.  AKT1 is a direct 
target gene of Stat3.  Protein/mRNA levels and promoter activity of AKT1 are 
significantly induced by constitutively active Src and Stat3.  Knockdown of Stat3 or 
dominant-negative Stat3 reduced AKT1 expression induced by constitutively active Src.  
Blockage of AKT1 expression largely reduced Stat3 function in cell survival and 
angiogenesis.  Furthermore, I have shown that proapoptotic protein 24p3 is a major 
target of Akt to mediate IL3 signaling in hematopoietic cells.  Forkhead transcription 
factor FOXO3a directly binds to and activates 24p3 promoter leading to expression of 
24p3 in response to IL3 withdrawal.  Akt phosphorylates FOXO3a and inhibits its 
action toward 24p3.  Finally, I have identified a novel transcription factor TZP that 
interacts with Akt and p53.  Expression of TZP inhibits cell growth and survival and 
induces both G1 and G2/M cell cycle arrest.  TZP directly binds to the p53 promoter and 
induces p53 transcription.  In addition, TZP interacts with p53 and prevents p53 from 
Mdm2-mediated degradation.  In response to genotoxic stress, both TZP and p53 were 
upregulated and knockdown of TZP reduced p53 expression.  Akt phosphorylated TZP 
resulting in its translocation from the nucleus into the cytoplasm, and thus inhibits TZP 
function.  These data indicate that Akt induced by STAT3 confers oncogenesis through 
inhibition of the transcription factors.   
 
      iv 
  
 
CHAPTER 1 
 
Review of Role of PI3K/AKT Pathway in Oncogenesis 
 
The maintenance of normal cell function and tissue homeostasis is dependent on 
the precise regulation of multiple signaling pathways that regulate cellular determination 
such as proliferation, differentiation, cell growth arrest, or programmed cell death 
(apoptosis and autophagy).  Cancer arises from clones of mutated cells that break out 
this balance and proliferate inappropriately without compensatory apoptosis.  
Uncontrolled cell growth occurs as a result of disturbed signal transduction that 
modulates or alters cellular behavior or function to keep the critical balance between the 
rate of cell-cycle progression (cell division) and cell growth (cell mass) on one hand, and 
programmed cell death (apoptosis and autophagy) on the other (1, 2). 
The PI3K/Akt pathway regulates a variety of cellular processes including nutrient 
metabolism, cell growth, proliferation, cell cycle control, survival, differentiation, 
migration, and angiogenesis (3).  Deregulation of the PI3K/Akt pathway has been 
related to the development of diseases such as diabetes, autoimmunity, and cancer (4-7).  
The link between activation of the PI3K/Akt pathway and cancer makes this pathway an 
attractive target for therapeutic strategies.  Accumulated reports show that activation of 
receptor protein-tyrosine kinases (RTK) and cytokine receptor is one of the major 
resources for activating PI3K/Akt pathway.  
 
Protein Tyrosine Kinases (PTKs) 
 
Protein tyrosine kinases (PTKs) are enzymes that catalyze the phosphorylation of 
tyrosine residues.  There are two classes of PTKs: receptor PTKs and cellular non-
receptor PTKs.  Of the 91 protein tyrosine kinases identified thus far, 59 are receptor 
        1 
tyrosine kinases and 32 are non-receptor tyrosine kinases (Fig. 1).  These enzymes are 
involved in cellular signaling pathways and regulate key cell functions such as  
 
Figure 1. Human receptor protein-tyrosine kinases.  The prototypic receptor for each 
family and the known members are indicated below the receptor. (A) The first six RTK 
receptors classes among the 19 human RTK classes. We can observe that the extracellular 
region is very different between all the RTKs, and, on the other hand, that the intracellular 
region is very conserved. (B) The new domain prediction of RTK. It shows some 
classification modifications and updated domain prediction from the latest domain 
databases SMART and Pfam.  Abbreviation of the prototypic receptors: EGFR, 
epidermal growth factor receptor; InsR, Insulin receptor; PDGFR, platelet-derived growth 
factor receptor; FGFR, fibroblast growth factor receptor; EphR, ephrin receptor. (Referred 
to Grassort J et al. (2003) Nucleic Acids Research 31, 353–358) 
proliferation, differentiation and cell survival.  Deregulation of these enzymes, through 
mechanisms such as point mutations or overexpression, can lead to various forms of 
cancer as well as benign proliferative conditions.  Indeed, more than 70% of the known 
oncogenes and proto-oncogenes involved in cancer code for PTKs. 
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Receptor PTKs possess an extracellular ligand binding domain, a transmembrane 
domain and an intracellular catalytic domain.  The transmembrane domain anchors the 
receptor in the plasma membrane, while the extracellular domains bind growth factors.   
Characteristically, the extracellular domains are comprised of one or more identifiable 
structural motifs, including a cysteine-rich region, fibronectin III-like domain, 
immunoglobulin-like domains, EGF-like domain, cadherin-like domain, kringle-like 
domain, factor VIII-like domain, glycine-rich region, leucine-rich region, acidic region 
and discoidin-like domain (Fig. 1). 
 
 
Figure 2. Activation of receptor protein tyrosine kinase. (Copyright © 2005 
Pearson Education, Inc., publishing as Benjamin Cummings) 
  
The intracellular kinase domain of receptor PTKs can be divided into two classes: those 
containing a stretch of amino acids separating the kinase domain and those in which the 
kinase domain is continuous.  Activation of the kinase is achieved by ligand binding to 
the extracellular domain, which induces dimerization of the receptor.  Receptors thus 
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activated are able to autophosphorylate tyrosine residues outside the catalytic domain via 
cross-phosphorylation.  The results of this auto-phosphorylation are stabilization of the 
active receptor conformation and the creation of phosphotyrosine docking sites for 
proteins which transduce signals within the cell (Fig. 2).  Signaling proteins which bind 
to the intracellular domain of receptor tyrosine kinases in a phosphotyrosine-dependent  
manner include RasGAP, PI3-kinase, phospholipase Cγ, phosphotyrosine phosphatase 
SHP and adaptor proteins such as Shc, Grb2 and Crk (8, 9). 
In contrast to receptor PTKs, cellular non-receptor PTKs are located in the 
cytoplasm, nucleus or anchored to the inner leaflet of the plasma membrane.  They are 
grouped into eight families: SRC, JAK, ABL, FAK, FPS, CSK, SYK and BTK (reviewed 
in 10).  Each family consists of several members.  With the exception of homologous 
kinase domains (Src Homology 1, or SH1 domains), and some protein- protein 
interaction domains (SH2 and SH3 domains), they have little in common structurally.  
Of those cellular PTKs whose functions are known, many, such as SRC, are involved in 
cell growth.  In contrast, FPS PTKs are involved in differentiation (11), ABL PTKs are 
involved in growth inhibition (12), and FAK is associated with cell adhesion (13).  
Some members of the cytokine receptor pathway interact with JAKs, which 
phosphorylate the transcription factors, STATs (14, 15).  Still other PTKs activate 
pathways whose components and functions remain to be determined. 
There are four main mechanisms of oncogenic transformation by PTKs.  First, retroviral 
transduction of a proto-oncogene corresponding to a PTK is a common transforming 
mechanism in rodents and chickens.  Second, genomic rearrangements, such as 
chromosomal translocations resulting in formation of oncogenic fusion proteins 
containing a PTK catalytic domain and an unrelated protein that provides a dimerization 
function.  Third, gain-of-function mutations or small deletions are associated with 
several malignancies.  Finally, PTK overexpression is a major mechanism in PTK-
induced transformation.  In general, the transforming effect can be ascribed to enhanced 
constitutive kinase activity with quantitatively or qualitatively altered downstream 
signaling (16). 
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Cytokine Receptors 
 
Cytokines act on their target cells by binding specific membrane receptors.  The 
receptors and their corresponding cytokines have been divided into several families based 
on their structure and activities.  Hematopoietin family receptors are dimers or trimers 
with conserved cysteines in their extracellular domains and a conserved Trp-Ser-X-Trp-
Ser sequence (17).  Examples are receptors for IL-2 through IL-7 and GM-CSF. 
Interferon family receptors have the conserved cysteine residues, but not the Trp-Ser-X-
Trp-Ser sequence, and include the receptors for IFNα, IFNβ, and IFNγ.  Tumor necrosis 
factor family receptors have four extracellular domains; they include receptors for soluble  
TNFα and TNFβ as well as membrane-bound CD40 (important for B cell and 
macrophage activation) and Fas (which signals the cell to undergo apoptosis).   
 
 
Figure 3. Human cytokine receptor superfamily. (Copyright © 2005 
Pearson Education, Inc., publishing as Benjamin Cummings) 
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Chemokine family receptors have seven transmembrane helices and interact with G 
protein.  This family includes receptors for IL-8, MIP-1 and RANTES (reviewed in 18) 
(Fig. 3). 
 
 
Figure 4.  Interaction of cytokine and cytokine receptors. (Referred to Oppenheim JJ et 
al. Cytokine Reference. Academic Press (2001)) 
 
Hematopoietin cytokine receptors are the best characterized.  They generally 
have two subunits, one cytokine-specific and one signal transducing.  An example is the 
GM-CSF subfamily, where a unique “α” subunit specifically binds GM-CSF, IL3, or IL-5 
with low affinity and a shared “β” subunit signal transducer also increases cytokine- 
        6 
binding affinity.  Cytokine binding promotes dimerization of the α and β subunits, 
an IL-2
 
rface ligands on 
effecto
        7 
which then associate with cytoplasmic tyrosine kinases to phosphorylate proteins which 
activate mRNA transcription.  GM-CSF and IL3 act on hematopoietic stem cells and 
progenitor cells and activate monocytes.  With IL-5, they also stimulate eosinophil 
proliferation and basophil degranulation.  All three receptors phosphorylate the same 
cytoplasmic protein.  Antagonistic GM-CSF and IL3 activities can be explained by their 
competition for limited amounts of β subunit (reviewed in 19).  The IL-2R subfamily of 
receptors for IL-2, IL-4, IL-7, IL-9, and IL-15 have a common signal-transducing γ chain. 
Each has a unique cytokine-specific chain.  IL-2 and IL-15 are trimers, and share 
R β chain.  Monomeric IL-2R α has low affinity for IL-2, dimeric IL-2R βγ has 
intermediate affinity, and trimeric IL-2R αβγ binds IL-2 with high affinity.  IL-2R α 
chain (Tac) is expressed by activated but not resting T cells.  Resting T cells and NK 
cells constitutively express low number of IL-2R βγ.  Antigen activation stimulates T  
cell expression of high affinity IL-2R trimers as well as secretion of IL-2, allowing
autocrine stimulation of T cell proliferation in an antigen-specific manner.  Antigen 
specificity of the immune response is also maintained by the close proximity of antigen-
presenting B cells and macrophages with their helper T cells, so that cytokines are 
secreted in the direction of and close to the membrane of the target cell.  X-linked severe 
combined immunodeficiency (X-scid) is caused by a defect in IL-2R family chain, which 
results in loss of activity from this family of cytokines (reviewed in 20). 
The TNF receptor family molecules CD40 and Fas bind to cell su
r T cells: CD40L and FasL.  CD40 is expressed on B cell and macrophage plasma 
membrane.  T cell CD40L binding to B cell CD40 stimulates B cell proliferation and 
isotype switching.  T cell CD40L binding to macrophage CD40 stimulates macrophages 
to secrete TNFα and become much more sensitive to IFNγ.  T cell FasL binding to Fas 
leads to the activation of caspases that initiate apoptosis of the cell expressing membrane 
Fas.  Activated lymphocytes express Fas, so that FasL-positive Tc cells can regulate the 
immune response by eliminating activated cells.  An immune deficiency disease linked 
to expression of a mutant Fas is characterized by over-proliferation of lymphocytes (21). 
 
PI-3 Kinases 
     PI-3 Kinase family 
Based on substrate preference and sequence homology, PI3Ks are divided into 
three 
 various PI3K isoforms are illustrated in figure 5.  In 
mamm
A PI3K is a heterodimer that consists of a p85 regulatory subunit and a 
p110 c
crucial in mediating the activation of class IA PI3K 
by rece
      8 
 
 
 
classes (Fig. 5).  In vivo, class I PI3Ks primarily generate 
phosphatidylinositol(PtdIns)-3,4,5-trisphosphate from PtdIns(4,5)P2, whereas class III 
PI3Ks generate PtdIns(3)P from PtdIns.  Class II PI3Ks preferentially generate 
PtdIns(3)P and PtdIns(3,4)P2 in vitro, and might generate PtdIns(3)P, PtdIns(3,4)P2 and 
possibly PtdInsP3 in vivo (22).  
The domain structures of
als, numerous genes encode different isoforms of PI3Ks (23).  All PI3K isoforms 
are widely expressed, with the exception of the class IA p55γ subunit, which is enriched 
in the brain and the testes, and the p110δ subunit, which is predominantly expressed in 
lymphocytes. 
Class I
atalytic subunit.  Three genes, PIK3R1, PIK3R2 and PIK3R3, encode the p85α, 
p85β and p55γ isoforms of the p85 regulatory subunit, respectively.  The PIK3R1 gene  
also gives rise to two shorter isoforms, p55α and p50α, through alternative transcription-
initiation sites.  The class IA p85 regulatory isoforms have a common core structure 
consisting of a p110-binding domain flanked by two Src-homology 2 (SH2) domains.  
The two longer isoforms, p85α and p85β, also have an extended N-terminal region 
containing a Src-homology 3 (SH3) domain and a BCR homology (BH) domain flanked 
by two proline-rich (P) regions (23). 
The p85 regulatory subunit is 
ptor tyrosine kinases (RTKs).  The SH2 domains of p85 bind to phospho-tyrosine 
residues in the sequence context pYxxM on activated RTKs or adaptor molecules (such 
as IRS1) (24).  This binding relieves the basal inhibition of p110 by p85 and recruits the 
p85–p110 heterodimer to its substrate (PtdIns(4,5)P2) at the plasma membrane (25, 26). 
 
  
  
Figure 5. Mammalian PI 3-kinase family and their domain structures. (Referred to 
Three genes — PIK3CA, PIK3CB and PIK3CD — encode the highly 
homolo
Engelman JA et al. (2006) Nature Review Genetics. 7, 606-619) 
 
gous p110 catalytic subunit isoforms p110α, p110β and p110δ, respectively (23).  
They possess an N-terminal p85-binding domain that interacts with the p85 regulatory 
subunit, a Ras-binding domain (RBD) that mediates activation by the small GTPase Ras, 
a C2 domain, a phosphatidylinositol kinase homology (PIK) domain and a C-terminal 
catalytic domain.  The PIK and catalytic domains of p110 are homologous to domains 
found in a family of protein kinases that includes mTOR (mammalian target of 
rapamycin), ATM (ataxia telangiectasia mutated), ATR (ataxia telangiectasia Rad3 
related) and DNA-PK (DNA-dependent serine/threonine protein kinase), indicating that 
these proteins share an ancient evolutionary origin. 
        9 
Cla  P s a ro  consisss IB I3K i  hete dimer ting of a p101 regulatory subunit and a 
p110γ 
p110-like catalytic subunit.  The 
three is
 restricted to PtdIns and generate PtdIns(3)P.  
Signaling by PI3Ks 
 
The effects of polyphosphoinositides in cells are mediated through the specific 
binding
are activated by growth factor receptor tyrosine kinases (RTKs; 
left).  
 
receptors 
(GPCR
catalytic subunit. Although p110γ shares extensive homology with the class IA 
p110 proteins, p101 is distinct from p85 proteins.  Two other regulatory subunits, p84 
and p87PIKAP, have been described recently (27, 28). 
Members of class II PI3Ks consist of only a 
oforms of class II PI3Ks — PIK3C2α, PIK3C2β and PIK3C2γ — are encoded 
by distinct genes.  All three isoforms share significant sequence homology with the class 
I p110 subunits.  In addition, class II PI3Ks have an extended divergent N terminus, and 
additional PX and C2 domains at the C terminus.  A remarkable feature of this class 
PI3Ks is that they can utilize Ca++/ATP for their in vivo lipid kinase activity through the 
binding between C2 domain and Ca++ (29). 
Class III PI3Ks have a substrate specificity
These PI3Ks are homologous to Vps34 (vacuolar protein-sorting defective 34), the only 
PI3K in yeast, which plays a very important role in protein trafficking from Golgi to the 
vacuole and autophagy (30).
 
 to at least two lipid-binding protein domains, the FYVE and pleckstrin-homology 
(PH) domains. (Fig. 6). 
Class IA PI3Ks 
Both insulin and insulin growth factor 1 (IGF1) receptors use the insulin receptor 
substrate (IRS) family of adaptor molecules (shown to the right of the RTK) to engage 
class IA PI3Ks, whereas other receptors, such as the platelet-derived growth factor 
(PDGF) receptor, recruit class IA PI3Ks directly (shown to the left of the RTK). 
By contrast, class IB PI3Ks are activated by G-protein-coupled 
s) by binding to Gβγ (right).  PTEN (phosphatase and tensin homologue) 
dephosphorylates phosphatidylinositol-3,4,5-trisphosphate (PIP3) and therefore 
terminates PI3K signaling.  The 5′-phosphatase SHIP converts PIP3 to phosphatidyl- 
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inositol-3,4-bisphosphate (PI-3,4-P2). 
 
 
Figure 6. Mechanism of class I phosphatidylinositol 3-kinase (PI3K) activation. Class IA PI3Ks 
The FYVE domain, named after the first four proteins (F
are activated by growth factor receptor tyrosine kinases (RTKs; left). Both insulin and insulin 
growth factor 1 (IGF1) receptors use the insulin receptor substrate (IRS) family of adaptor 
molecules (shown on the right of the RTK) to engage class IA PI3Ks, whereas other receptors, 
such as the platelet-derived growth factor (PDGF) receptor, recruit class IA PI3Ks directly (shown 
to the left of the RTK). By contrast, class IB PI3Ks are activated by G-protein-coupled receptors 
(GPCRs) by binding to Gβγ (right). PTEN (phosphatase and tensin homologue) dephosphorylates 
phosphatidylinositol-3,4,5-trisphosphate (PIP3) and therefore terminates PI3K signalling. The 5′-
phosphatase SHIP converts PIP3 to phosphatidylinositol-3,4-bisphosphate (PI-3,4-P2) (REF. 1). 
Gα, guanine nucleotide binding protein (G protein), α; Gβγ, guanine nucleotide binding protein (G 
protein), βγ; p110 and p110γ, catalytic subunits of PI3K; p85 and p101, regulatory subunits of 
PI3K; SHIP, SH2-domain-containing inositol-5-phosphatase.  (Referred to Engelman JA et al. 
(2006) Nature Review Genetics. 7, 606-619) 
 
ab1, YOTB, Vac1, and 
EEA1)
of about 100 
amino 
 that contain this motif, is an ~80-amino acid sequence containing four conserved 
cysteine residues that coordinate two Zn++ ions (31).  The structure data clearly show 
that FYVE domains only bind to PtdIns(3)P, but not the other lipids (32).  FYVE 
domains appear to be less widespread than PH domain.  To date, 22 different FYVE 
domain-containing proteins have been found in mammals, and the majority of FYVE 
domain-containing proteins have been implicated in membrane trafficking. 
PH (Pleckstrin homology) domains are globular protein domains 
acids found in over 150 proteins to date.  Some PH domains bind phospholipids 
with high affinity.  Residues in PH domains essential for high-affinity binding to PIs 
have recently been identified (33, 34).  These residues lie at the N-terminus, in a KX7-
13R/KXRHyd motif, where X is any amino acid and Hyd is a hydrophobic amino acid 
(30).  A subset of PH domains preferentially bind to PtdIns(3,4)P2, and PtdIns(3,4,5)P3 
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(30, 35
gnaling by class I PI3Ks, especially IA PI3Ks, has been extensively studied.  
PtdIns(
tudied due to their specific 
structu
Regulation of PI3Ks 
 
PtdIns(3,4,5)P3, a product of PI3-kinase, plays a regulatory role in a vast array of 
biologi
PTEN was first identified in 1997 by three independent groups, so it is also 
known 
). 
Si
3,4)P2/PtdIns(3,4,5)P3-binding PH domains are found in diverse array of proteins 
including protein kinases (e.g. PKB, PDK1, Btk), nucleotide-exchange factors (e. g. Vav, 
GRP1, ARNO, Sos1, Tiam1), GTP-activating factors (e. g. GAP1m, centaurins), 
phospholipases (e. g. PLCγ2) and adaptor proteins (35, 36). 
Signaling by class II PI3Ks has not been widely s
res, however, the association of class II PI3Ks with cellular membrane 
compartments indicates that they might be involved in sorting events or vesicle formation.  
Signaling by class III PI3Ks has been mainly placed on membrane trafficking events 
because they share high homology with Vps34, which is clearly found to be involved in 
yeast membrane trafficking.  For example, PtdIns(3)P-mediated recruitment of the 
SARA (Smad anchor for receptor activation) protein to TGF-β receptor is crucial for this 
pathway (37, 38).  EE1A is an effector of Rab5 which itself also binds to human Vps34 
and p85α/p110β and EE1A has been found to be essential for the trafficking of protein 
from Golgi complex to the lysosome (39). 
 
cal responses to extracellular signals, including proliferation, differentiation, 
apoptosis, vesicle trafficking, cell morphology and cell migration.  The level of this 
phospholipid is low in resting cells but increases rapidly in response to growth 
factor/cytokine-stimulated plasma membrane recruitment and activation of PI3-kinase, 
therefore, the negative regulation becomes important.  So far, three enzymes, SHIP, 
SHIP2 and PTEN, have been shown to play key roles in regulating the level of PI-3,4,5-
P3. 
as MMAC or TEP1, and PTEN is found to be the major 3-phosphatase of 
phosphoinositol-(3,4,5)-triphosphate, and signals down to regulate PI3K/Akt pathway.   
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Consistent with the role of PTEN in PI3K/Akt signaling, PTEN negatively regulates cell 
P, has received 
conside
kt/PKB 
Origins and Cloning of Akt 
 
Akt, also named protein kinase B (PKB) and RAC, is a serine/threonine protein 
kinase 
survival by causing apoptosis and/or G1 cell cycle arrest.  Dysfunctional/absent PTEN 
leads to high levels of Akt phosphorylation, and germline mutations of PTEN tumor-
suppressor gene have been found to result in a wide spectrum of phenotypes including 
Cowden syndrome (40, 41).  PTEN has also been shown to bind FAK (Focal Adhesion 
Kinase) and inhibit FAK kinase activity via dephosphorylation (42).   
An SH2-containing inositol 5’ phosphatase protein, SHI
rable attention because it functions as a negative regulator for PI3K pathway.  
Based on current knowledge of PTEN and SHIP, SHIP mainly converts PI-3,4,5-P3 to PI-
3,4-P2.  However, PTEN can convert PI-3,4,5-P3 to PI-4,5-P2.  PTEN-/- cells exhibits 
high basal level of Akt activation while only slightly elevated level of Akt 
phosphorylation has been observed in SHIP-/- cells (40).  So the exact difference 
between PTEN and SHIP is still under investigation even though they share similar 
biological function. 
 
A
 
with homology to protein kinases A and C (43–46).  The AKT oncogene was 
isolated from the directly transforming murine retrovirus AKT8, which was isolated from 
an AKR mouse thymoma cell line (43) and spontaneous lymphoma (43).  This virus, 
termed AKT8, produced foci of malignant transformation in the mink lung epithelial cell 
line CCL-64 (44).  A unique feature of AKT8 was its inability to induce focus formation 
in other cell lines such as NIH3T3 fibroblasts, which suggested that the virus contained a 
previously unidentified oncogene.  Sequencing the defective retrovirus from mink lung 
epithelial cells infected with AKT8 revealed that it encodes a serine/threonine protein 
kinase, namely Akt1 (45).  Subsequently, Akt2 was cloned and shown to encode a 
closely related kinase that is frequently amplified in human ovarian cancer (46).  They  
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contain nsensus sequences characterist rotein kinase catalytic domain and share 
 
Akt gene family 
 
to, three members of Akt encoded by three separate genes have been identified in 
uitously expressed in mammals, although the 
levels 
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 co ic of a p
more than 68% similarity to protein kinase C and cAMP-dependent protein kinase. 
Moreover, Akt1 and Akt2 have a unique N-terminal region originally designed as Akt 
homology (AH) domain (45, 46).  Thus, Akt family of serine/threonine kinases was 
identified.  
 
Hither
mammalian cells.  All three genes have more than 85% sequence identity and their 
protein products share the same structural organization (Fig. 7).  The first amino-
terminal 100 amino acids are a pleckstrin homology (PH) domain that binds to 
phospholipids.  A short glycine-rich region locates between PH and catalytic domains, 
and links the PH motif to the catalytic domain.  All Akt members are assumed to have 
identical or similar substrate specificity.  The last 70 amino acids of the carboxyl 
terminal tail contain a putative regulatory domain. In v-Akt, a truncated viral group-
specific antigen, gag, is fused in frame to the full-length Akt1 coding region through a 
short 5’ untranslated region of Akt1 (47). 
All three Akt members are ubiq
of expression vary among the tissues (47).  Akt1 is evenly expressed in most 
tissues.  The uppermost expression of Akt2 was observed in the insulin-responsive 
tissues such as skeletal muscle, heart, liver, and kidney, suggesting that this isoform is of 
important to insulin signaling.  This is further substantiated by the observation that Akt2 
expression in developing embryos is also highest in the insulin-responsive tissues, 
including liver, brown fat, and skeletal muscle.  A peculiar pattern of Akt1 expression 
was detected in brain, where it is markedly increased in regenerating neurons.  Unlike 
the two other members, Akt3 shows a more limited pattern of expression.  Higher levels 
of Akt3 were detected in testis and brain and low levels in the adult pancreas, heart, and 
kidney (48, 49, 50).  The expression pattern of the three members may not always 
reflect their activities.  
   
Di f the diffferent kinase activity levels o ferent members have been observed in 
certain 
Biochemical features of Akt 
 
Activation of Akt depends on the integrity of the PH domain, which binds to PI3K 
produc
) in 
 
igure 7. Structural organization of the three major Akt/PKB isoforms is shown in comparison 
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tissues and during differentiation, which is not necessarily correlated with their 
level of expression (51, 52). 
 
t PtdIns-3,4,5-P3, and on the phosphorylation of Thr308 (Thr309 in Akt2 and  
Thr305 in Akt3) in the activation loop and Ser473 (Ser474 in Akt2 and Ser472 in Akt3
the C-terminal activation domain.  Yang et al provided a molecular explanation for 
regulation of Akt activation through Ser474 phosphorylation by analyzing the crystal  
 
F
to virally encoded v-Akt Akt/PKB variants contain a plecsktrin homology domain (PH), a 
catalytic domain, and a putative regulatory fragment at the C-terminus (RD).  v-Akt is an in-
frame fusion of Akt-1 with a portion of retroviral group-specific antigen (gag).  Amino acid 
positions are shown for mouse proteins. Threonine and serine residues whose phosphorylation 
is required to induce activities of the enzymes are indicated. See text for details (Referred to 
Kim D et al. (2005) Front Biosci. 10, 975-987.) 
 
 
structures of the unphosphorylated and Thr309-phosphorylated states of the Akt2 kinase 
 
igure 8. Proposed model for Akt/PKB regulation by receptor tyrosine kinases.  
or tyrosine kinases by ligands such as epidermal growth factor and platelet-derived 
Activation of Akt 
 
Akt exists in the cytosol of unstimulated cells in a low-activity conformation.   
 
domain (53).  Activation by Ser474 phosphorylation occurs via a disorder-to-order 
transition of the alpha-C helix with concomitant restructuring of the activation segment 
and reconfiguration of the kinase bilobal structure.  These conformational changes are 
mediated by a phosphorylation-promoted interaction of the hydrophobic motif with a 
channel on the N-terminal lobe induced by the ordered alpha-C helix and are mimicked 
by peptides corresponding to the hydrophobic motif of Akt. 
 
F
Activation of recept
growth factor leads to autophosphorylation of specific tyrosine residues on the intracellular portion of the 
receptor. Recruitment of phosphoinositol 3-kinase (PI3K) then occurs, via binding of the SH2 domains of 
the regulatory subunit p85 to the phosphotyrosine residues on the receptor, which leads to a 
conformational change in the kinase, and consequently to activation. 3'-phosphoinositides generated by 
activated PI3K (black circles) then mediate the membrane recruitment Akt/PKB from the cytosol to the 
plasma membrane via its PH domains, and change the kinase from an inactive to an active state. A change 
in the conformation of Akt/PKB upon lipid binding has been predicted based on biochemical data. 
Akt/PKB is then phosphorylated on Thr308 and/or Ser473 by PDK1, and by an as yet unidentified Ser473 
kinase. Activated Akt/PKB mediates its intracellular effects, and then becomes inactivated by the action of 
phosphatases such as PP2A, which dephosphorylate pThr308 and pSer473 and return Akt/PKB to its 
inactive conformation in the cytosol. PTEN or SHIP, which are two known phosphatases, act to 
downregulate Akt/PKB activation by dephosphorylating PtdIns(3,4,5)P3 (Referred to Kim D et al. (2005) 
Front Biosci. 10, 975-987.). 
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Upon activation of PI3K, PtdIns(3,4,5)P3/PtdIns(3,4)P2 are synthesized at the plasma 
e indicated that Akt can be activated in cells by a mechanism 
indepen
 
I3k/Akt pathway in human cancer 
Akt amplification 
 
Akt was first identified as a component of a fusion product of the retroviral 
oncoge
membrane and then Akt interacts through its PH domain with these lipids.  This causes 
the translocation of Akt from the cytosol to the inner leaflet of the plasma membrane and 
leads to a conformational change, which converts Akt into a substrate for PDK1, perhaps 
by exposing the Thr308 and Ser473 phosphorylation sites.  PDK1 then phosphorylates 
Thr308.  PDK1 in this location of the cell also forms a complex with 
PtdIns(3,4,5)P3/PtdIns(3,4)P2.  Although the role of PDK1 in Thr308 phosphorylation is 
well established, the mechanism of Ser473 phosphorylation is controversial.  A number 
of candidate enzymes responsible for this modification have been put forward, including 
integrin-linked kinase, PDK1 when in a complex with the kinase PRK2, Akt itself, 
through autophosphorylation, PKCα, PKCβII, DNA-dependent kinase, and the rictor-
mTOR complex (Fig. 8).  
Several reports hav
dent of PI3K activation, for example in response to heat shock, or increases in 
intracellular Ca2+ or cAMP.  Akt is activated by heat shock in NIH3T3 fibroblasts and 
this response was not inhibited by wortmannin (50).  However, we and others showed 
that Akt1 and Akt2, activated by heat shock as well as oxidative stress are completely 
suppressed by the PI3K inhibitors wortmannin and LY294002 (54, 55). Agonists that 
increase Ca2+ levels in cells have been reported to activate Akt in a PI3K-independent 
manner through the Ca2+/calmodulin-dependent protein kinase kinase (CAMKK) (55). 
The stimuli of Akt activation from extensive studies in different fields are summarized in 
the Table 1.  
 
P
 
ne v-akt that causes leukaemia in mice (45).  A number of studies have 
discovered Akt gene amplifications in human cancers.  The work that originally  
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identified Akt as a potential human oncogene detected amplification of Akt1 in a single 
PI3K gene amplification 
 
The PIK3CA gene, which encodes the p110α catalytic subunit of PI3K, is located 
on chro  
Activation of upstream regulators of PI3K 
 
PI3K is activated as a result of the ligand-dependent activation of tyrosine kinase 
recepto
gastric carcinoma (44).  Akt2 gene amplification has been found in ovarian, pancreatic, 
gastric, and breast tumors (44, 45).  Akt2 amplification was mostly associated with 
high-grade aggressive ovarian tumors and appears to occur as part of the frequent 
amplification of the 19q13.1–q13.2 chromosomal region (46).  One study documented 
Akt3 mRNA overexpression and selective activation of the protein by growth factors in 
hormone-independent breast and prostate cancer cell lines (56).  Overall, these studies 
indicate that Akt gene amplification, especially Akt2, may be a frequent occurrence in 
several human cancers (57). 
 
mosome 3q26, a region that is frequently amplified in a number of human cancers. 
Recent studies have revealed amplification of PIK3CA in ovarian (58) and cervical (59) 
tumors.  Furthermore, corresponding cell lines harboring this alteration display 
enhanced PI3K catalytic activity and growth that is strongly suppressed by PI3K 
inhibitors, suggesting that PI3K has oncogenic property at least in these tumor types. 
 
rs, G-protein-coupled receptors, or integrins.  Receptor-independent activation 
can also occur, for example, in cells expressing constitutively active Ras proteins (60, 61). 
As cell surface receptors are frequently overexpressed and/or activated in many human 
cancers (62), downstream signaling pathways are often activated.  One of the most 
extensively studied examples is the erbB2 tyrosine kinase receptor, which is 
overexpressed in a large number of breast and other cancers (63).  ErbB2 is an orphan 
receptor with no defined ligand, which acts as a dimerization partner for other members 
of the erbB family.  ErbB2-containing heterodimers are potent activators of multiple  
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signaling pathways involved in proliferation, invasion, and survival (64).  Studies in 
PTEN mutation 
 
PTEN (Phosphatase and Tensin homolog deleted on Chromosome 10) is a dual-
functio
itol 
triphos
breast cancer cells, primary breast tumors, and transgenic mice, all indicate that erbB2, 
when overexpressed, is constitutively associated with erbB3 (65).  Because erbB3 
possesses seven phosphorylatable tyrosine residues that act as binding sites for the SH2 
domains of the p85 regulatory subunit of PI-3K (64), erbB2–erbB3 dimerization robustly 
activate the PI3K/Akt pathway.  This provides a basis for data showing that tumor cells 
overexpressing erbB2 display constitutive Akt activity (66). 
 
n lipid and protein phosphatase that was originally identified as a tumor 
suppressor gene frequently mutated in the advanced stages of a number of human cancers, 
particularly glioblastoma, endometrial, and prostate cancers.  Additionally, germline 
mutations in PTEN induce the rare autosomal dominant inherited human cancer 
syndrome known as Cowden's disease, which is associated with increased risk of 
developing breast and other cancers (67).  The results of studies in which PTEN has 
been overexpressed in various cell lines suggest that PTEN acts as a tumor suppressor by 
inhibiting cell growth (68) and increasing susceptibility to apoptosis and anoikis (69). 
The main physiological lipid substrate for PTEN is phosphatidyl-inos
phate (PIP3), the product of PI3K.  PTEN-null embryonic fibroblasts show 
elevated PIP3 levels and constitutive Akt activity, indicating that PTEN acts to restrain the 
pathway in the unstimulated cells.  Absence of PTEN also strongly correlates with 
activation of Akt in tumor cell lines.  Conversely, reintroduction of PTEN in cells 
lacking PTEN down-regulates Akt phosphorylation as well as reversing the 
phosphorylation of Akt cellular substrates such as BAD (68, 69, 72).  PTEN and 
phosphorylated AKT levels were inversely correlated in a large majority of samples with 
primary acute leukemias and non-Hodgkin lymphomas as well as in cell lines from these 
malignancies (70, 71).  In addition, frequent overexpression of Akt has also been 
detected in human malignancies (72).  Mutation of Akt2 has also been found in  
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Table 1.  List of stimuli that activate Akt. 
 regulate G Other activiators Tyrosine Kinase Stimuli thatprotein coupled receptor 
Angiopoietin-1 Bradykinin Pertussis toxin 
α-CD28 antibodies C5a Zinc 
Epidermal growth factor chol ium Carba Cadm
Basic fibroblast growth ted oncogene α 
factor 
Growth-rela
(GROα) Hypoxia 
Fibronectin n itroprusside Endotheli Sodium n
Gas6 FMet-Leu-Phe Exercise 
α-integrin antibodies µ-Opioids H2O2
Interleukins 3 
(regulated on 
eat shock 
RANTES 
activation, normal T cell 
expressed and secreted) 
H
Insulin Fluid shear Platelet activating factor 
Insulin-like growth factor sis factor α  Tumor necro
α-killer cell inhibitory osphatase inhibitors receptor antibodies Ph  
Leukaemia inhibitory ate  factor Vanad
Nerve growth factor id Okadaic ac  
N-methyl-D-aspartate 
(NMDA)   
Platelet-derived growth  factor  
Stem cell factor   
Vascular endothelial 
growth factor   
 
colorectal cancer (73). 
Substrates of Akt 
 
To understand the physiological functions of Akt, it is important to identify its 
substra
 
tes.  It was originally established that the minimum motif in a peptide enabling 
Akt phosphorylation is Arginie-Xaa-Arginie-Yaa-Zaa-Serine/Threonine-
Hyd(RXRXXS/T), where Xaa is any amino acid, Yaa and Zaa are preferably small 
residues other than glycine, and Hyd is a bulky hydrophobic residue (phenylalanine or  
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leucine) (74). 
le of dozen proteins have been identified as Akt substrates (Table 3),  
which 
unction of Akt 
Akt and cell survival 
 
Akt has an anti-apoptotic effect in many cell types.  In the anti-apoptotic 
machin
 
nd possibly later stages 
of apo
A coup
include BAD (Ser136) (75), glycogen synthase kinase 3 (GSK3) (76), 6-
phosphofructo-2-kinase (77), caspase-9 (78), endothelial nitric-oxide synthase (79, 80), 
IκB kinase (81, 82), phosphodiesterase 3B (83), rac1 (84), raf-1 protein kinase (85, 86), 
mammalian target of rapamycin (mTOR) (87), breast cancer susceptibility gene 1 
(BRCA1) (88), insulin receptor substrate 1 (IRS-1) (89), and forkhead transcription 
factors (90, 91), cAMP- responsive element binding protein (CREB) (92), human 
telomerase reverse transcriptase (hTERT) (93) and MDM2 (94, 95).  Although a number 
of physiological substrates of Akt have been reported, the detailed mechanism by which 
Akt regulates cell growth and survival has not been well documented, and putative 
critical substrates remain to be fully characterized. 
 
F
 
ery, BAD, Forkhead transcription factor family proteins, human caspase-9 and 
IκB kinase have been reported to be the downstream targets of Akt.  BAD can form 
heterodimer with anti-apoptotic proteins Bcl-2 or Bcl-XL and therefore, prevent them 
from exerting their anti-apoptotic function. Akt can phosphorylate BAD at Ser136 (75), 
binds to 14-3-3 scaffold protein and is subjected to degradation, even though and Akt also 
induce BAD phosphorylation at Ser112 through PAK1 (p21-activating kinase 1) (96). 
After phosphorylation at Ser112 and Ser136, phosphorylated BAD phosphorylation at Ser 
155 has been reported to be important for binding to 14-3-3 (97). 
Caspase-9 is a protease that is essential in the initiation a
ptosis, by forming apoptosomes with Apaf-1 and cytochrome c.  Human 
procaspase-9 has been reported to be phosphorylated and inhibited by Akt (98).  It is 
still unclear how important and/or general event is for Akt-mediated regulation of  
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Table 2. Frequency of mutations in the PI3K-AKT pathway in cancers 
uency Genetic mutations Cancer type Percentage freq
PIK3CA (p110α) 
Breast 26% (176/684) 
Colon 26% (88/337) 
Glioma 8% (14/182) 
Hepatocellular 36% (26/73) 
Ovarian 10% (35/365) 
Lung 2% (4/253) 
Mutations 
Gastric  7% (24/338)
Head and neck  42% (54/128)
Thyroid 9% (12/128) 
Lung: 
Squamous cell 
Adenocarcinoma 
 
66% (46/70) 
5% (4/86) 
Breast 9% (8/92) 
Gastric 36% (20/55) 
Oesophageal adenocacinoma 6% (5/87) 
Amplification 
) Cervical 69% (11/16
PTEN 
Glioblastoma 54% (98/180) 
Prostate 35% (88/250) 
Breast 23% (37/164) 
Melanoma 37% (53/143) 
Loss of Heterozygosity 
Gastric 47% (14/30) 
Glioblastoma ) 28% (122/432
Prostate 12% (26/218) 
Breast 0% (0/164) 
Melanoma  8% (15/185)
Mutations 
Gastric 0% (0/30) 
AKT 
Ovarian 12% (18/147) 
Pancreatic 20% (7/35) 
Breast 3% (3/106) 
Gastric 20% (1/5) 
Amplifications 
d neck ) Head an 30% (12/40
PIK3RI (p85α) 
Ovarian 4% (3/80) Mutations 
Colon 2% (1/60) 
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apoptosis, because the site in which Akt phosphorylates human caspase-9 is not 
Akt and mTOR signaling 
 
PI3K/Akt has recently emerged as an important mediator to regulate nutrients- 
and gro
conserved in the mouse, rat and monkey homologues (99).  
 
wth factor-induced targeting of the rapamycin (TOR) pathway.  TOR (mTOR in 
mammals, also known as FRAP, RAFT, or RAPT) is an evolutionarily conserved 
serine/threonine kinase that regulates both cell growth and cell cycle progression by 
integrating signals from nutrients (amino acids and energy) and growth factors (100-104). 
The best-known biochemical function of mTOR is to regulate protein translation by 
initiation of mRNA translation and ribosome synthesis leading to an increased rate of cell 
mass and size, which is required to support the rapid proliferation.  If the rate of cell 
growth is unable to keep up with a rapid rate of cell division, then cell proliferation 
cannot be continued, since cells would gradually lose cellular mass and cellular size with 
each cell division cycle, resulting in inevitable cell death.  Studies in several organisms 
with rapamycin, which directly binds to and inhibits TOR function, have shown that 
inhibition of TOR pathway limits the rate of cell growth and induces cell cycle arrest in 
G1 phase and cell death.  Therefore, mTOR and its downstream targets have recently 
been appreciated as an important cascade for tumorigenesis and novel therapeutic targets 
for cancer (103, 104).  Using a murine lymphoma model, Akt promotes tumorigenesis 
and drug resistance by disrupting apoptosis, and disruption of Akt signaling using the 
mTOR inhibitor rapamycin reverses chemoresistance in lymphomas expressing Akt, but 
not in those with other apoptotic defects (105).  eIF4E (Human eukaryotic translation 
initiation factor 4E), a translational regulator that acts downstream of Akt and mTOR, 
recapitulated Akt's action in tumorigenesis and drug resistance but was unable to confer 
sensitivity to rapamycin and chemotherapy.  Akt signals through mTOR and eIF4E as an 
important mechanism of oncogenesis and drug resistance in vivo and reveals how 
targeting apoptotic programs can restore drug sensitivity in a genotype-dependent manner. 
It has been shown that mTOR feedback regulates Akt.  In Drosophila and  
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mammalian cells, TOR nd its socia r are necessary for serine-473 
Akt and transcription factors 
 
A recent study has shown that Akt regulates cellular processes through 
phosph
scription factor nuclear factor-κB (NFκB)/Rel family is a key regulator of 
the imm
 a as ted protein ricto
phosphorylation of Akt, and a reduction in rictor or mTOR expression inhibited an Akt 
effector.  The rictor-mTOR complex directly phosphorylated Akt/PKB on serine-473 in 
vitro and facilitated threonine-308 phosphorylation by PDK1 (106). 
 
orylation of transcription factors.  The role of Akt in regulation of the 
Forkhead(FH or FoxO) transcription factors was first identified by findings from the 
genetic analysis of C. elegans (90, 107).  Phosphorylation sites for Akt are highly 
conserved among Forkhead isoforms and species.  So far, three isoforms of Forkhead 
proteins (FKHR/FoxO1, FKHRL1/FoxO3 and AFX/FoxO4) are directly phosphorylated 
by Akt (91, 108-111).  Phosphorylation of Forkhead by Akt results in the nuclear 
exclusion of Forkhead, leading to decreased transcriptional activity that is required for 
promoting apoptosis.  The target genes for the Forkhead family are thought to be 
extracellular ligands, including the Fas ligand, TRAIL (TNF-related apoptosis-inducing 
ligand) and TRADD (TNF receptor type 1 associated death domain), and intracellular 
components for apoptosis such as Bim (bcl-2 interacting mediator of cell death), Bcl-6, 
and p27 (112). 
The tran
une response, and deregulation of its activity is implicated in the development of 
diseases such as autoimmune disease and cancer (113).  In most cases, activation of 
NFκB is dependent on the phosphorylation and degradation of IκB, an inhibitor of NFκB, 
by IκB kinase (IKK) complex.  Akt has been shown to regulate IKK activity in both 
direct and indirect manner.  Akt interacts with and phosphorylates IKKα on Thr23 in a 
PI3K-dependent manner that is required for NFκB activation in response to TNFα 
stimulation (81).  Another study has shown that Akt phosphorylates Ser/Thr kinase Tpl-
2 (or Cot) on Ser 400, resulting in IKK complex activation (114).  This NFκB activation 
by Akt might result in the inhibition of apoptosis by induction of cell survival genes that  
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are transcriptionally activated by NFκB (
tionship between phosphorylated Akt and 
FOXO
MP response element (CRE)-binding 
protein
 
ar receptor Nurr77 is required for T-cell antigen receptor-
mediate
tor (ER)α, the members of the nuclear 
recepto
log 2) at serine-21 and suppresses its 
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113). 
Hu et al. investigated the pathologic rela
3A in primary tumors (115).  FOXO3A was excluded from the nuclei of some 
tumors lacking phosphorylated Akt, suggesting an Akt-independent mechanism of 
regulating FOXO3A localization.  This phenomenon is due to IKK physical interaction 
with, phosphorylation, and inhibition of FOXO3A, which leads to proteolysis of 
FOXO3A via the ubiquitin-dependent proteasome pathway.  Cytoplasmic FOXO3A 
correlated with expression of IKKβ or phosphorylated Akt in many tumors and was 
associated with poor survival in breast cancer.   
A transcription factor, CREB (cyclic A
), is phosphorylated by Akt1 on Ser133.  This process results in increased affinity 
of CREB to its co-activator CRB, and transcriptional activation of CREB (92, 116). 
CREB is one of the targets of Akt in cell survival signaling, but a detailed mechanism 
remains to be elucidated. 
The orphan nucle
d cell death (117).  This transcription factor is phosphorylated by Akt on Ser 350 
(118).  Phosphorylation of Nurr77 by Akt causes suppression of Nurr77 activity and 
partial inhibition of apoptosis induced by PMA and calcium. These observations suggest 
that Akt is implicated in early T-cell development. 
Androgen receptor (AR) and estrogen recep
r transcription factor group, play an important role in cell growth and survival 
(119, 120). Akt phosphorylates AR on Ser 210 and Ser 790 and ERα on Ser 167, which 
regulate their transactivational activity (120, 121). 
Akt phosphorylates EZH2 (enhancer of zeste homo
methyltransferase activity by impeding EZH2 binding to histone H3, which results in a 
decrease of lysine-27 trimethylation and derepression of silenced genes. These results 
imply that AKT regulates the Histone methylation, through phosphorylation of EZH2, 
which may contribute to oncogenesis (122). 
 
 
  
Table 3 List of substrates of active Akt
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Reference 
.  . 
Substrates Sites 
AHNAK Ser5535 t al., 2001 JCB Sussmann e
Arfaptin 2 Ser260 Rangone et al., 2005 JBC 
ArgBP2γ Ser232, Thr234, Thr379 Yuan et al., JBC 2005 
ARK5 Ser600 Suzuki et al.,2003 JBC 
ASK1 (MAP3K5) Ser83 Kim et al., 2001 MCB 
AS160 Ser588, Thr642 Kane et al., 2002 JBC 
ATP citrate lyase Ser455 Berwick et al., 2002 JBC 
Bad Ser75, Ser99 del Peso at al., 1997 Science 
D tt t l 1997 C llCaspase 9 alpha Ser196 Cardone et al., 1998 Science 
CRHSP24 Ser52 Auld et al., Biochem J. 2005 
Ezrin, Cytovillin, Villin 2  Thr567 Shiue et al., 2004 JBC 
Filamin C) Ser2213 Murray et al., 2004 Biochem J. 
Forkhead Thr24, Ser256, Ser319 Brunet et al., 1999 Cell 
R t l 1999 JBCGABA (A) receptor* Ser410 Wang et al., 2003 Neuron 
GSK3α Ser19 Cross et al., 1995 Nature 
GSK3β Ser9 Cross et al., 1995 Nature 
HAND2, dHAND  ?  J. Biochem Ser114 Murakami et al., 2004 Eur
HO-1 heme oxygenase 1 Ser188 Salinas et al., 2004 FEBS Lett. 
Huntingtin Ser421 Humbert et al.,2002 Dev Cell 
Iκ-B kinase α Thr23 Ozes et al., 1999 Nature 
IRS-1 Ser270, Ser307, Ser330, Ser527 Paz et al., 1999 JBC 
mTor Ser2448 Nave et al., 1999 Biochem. J. 
PAK1 Ser21 Zhou et al., MCB 
p21 WAF er 146 1361 Thr145, S Li et al., 2002 JBC 277:11352-1
p27 Kip1 Thr157 Shin et al., 2005 JBC 
PIPPin RNA binding 
t i
Ser58 Auld et al., 2005 Biochem. J 
PTP-1B Ser50 Ravichandran et al.,2001 Mol. Endocrinol. 
PFK-2 Ser466, Ser483 Deprez et al., 1997 JBC 
PRAS40 Thr246 Kovacina et al., 2003 JBC 
p47phox Ser304, Ser328 Chen et al., 2003 J. Immunol. 
14-3-3-zeta Ser58 Powell et al., 2002 JBC 
Raf-1 = c-Raf 99 Science Ser259 Zimmermann and Moelling 19
MKK4 = SEK1 Ser78 Park et al., 2002 JBC 
METTL1 tRNA methylase Ser27 Cartlidge et al., 2005 EMBO J. 
Synip (only by AKT2 ) Ser99 Yamada et al., 2005 J. Cell. Biol. 
Tau Thr212, Ser214 Ksiezak-Reding et al., 2003 BBA 
Tuberin = TSC2 Ser939 Manning et al., 2002 Mol. Cell 
WNK1 Thr60 Vitari et al., 2003 Biochem J. 
YAP1 Yes ass. protein Ser127 Basu et al.,2005 Mol. Cell. 
YB-1 Y-box binding
protein 1 
 gene Ser102 Sutherland et al., 2005 Onco
Akt and cell cycle  
 
p21cip1/waf1 is a cyclin/CDK (cyclin-dependent kinase) inhibitor which plays a 
importa le in m
, another major cyclin/CDK inhibitor, is also regulated by Akt-dependent 
phosph ti
nt ro aintaining cell cycle progression, and its impaired function is one of 
the major abnormalities in human cancer (123).  p21 is reported to be a direct target of 
Akt, and phosphorylation of this protein by Akt results in the inhibition of its function to 
arrest the cell cycle.  Zhou et al. were the first to describe Akt-mediated phosphorylation 
and regulation of p21 (95).  They reported that phosphorylation of p21 on Thr145 by 
Akt inhibits nuclear localization of p21, leading to activation of cyclin/CDK required for 
HER-2/neu-dependent tumor cell growth.  Other groups have suggested different 
mechanisms for the regulation of p21 by phosphorylation.  Rossig et al. reported that 
phosphorylation of the Thr145 of p21 prevents formation of the complex between p21 
and proliferating cell nuclear antigen (PCNA) that causes DNA replication and cell 
proliferation (124).  Phosphorylation of p21 on Thr145 also decreases the affinity of 
Cdk2 and Cdk4 to p21, which causes enzymatic activation of these Cdks.  They showed 
no significant effect of p21 phosphorylation on its subcellular localization.  Another 
report showed that p21 could be phosphorylated on Ser146 as well as Thr145 (125).  
Phosphorylation of Thr145 reduces affinity to PCNA, whereas phosphorylation of Ser146 
enhances protein stability of p21.  Phosphorylation of these sites shows little effect of 
p21 on complex formation and inhibition of the cyclin/CDK complex.  The authors also 
suggested the possibility that p21 is a chemoresistance target of Akt-overexpressing 
cancer cells.  These observations indicate that some experimental conditions or the 
genetic background of cells, such as erbB2 overexpression, might affect the regulation of 
p21 by Akt.  
p27kip1
oryla on.  In 2002, three reports described direct phosphorylation of p27 by Akt 
in breast cancer cells (126-128).  Akt phosphorylates p27 on Thr157, which is located in 
its nuclear localization signal (NLS), leading to the nuclear exclusion of p27, activation 
of cyclin/Cdk and cell cycle progression.  In primary breast cancer cells, cytoplasmic 
retention of p27 correlates with prognosis, suggesting that the subcellular localization of  
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p27 mi get for breast cancer.  
ost 
importa
 
kt and mouse models 
Genes encoding activated forms of Akt and Ras were transferred, in a tissue-
specific
e, an Akt1-null mouse model was created.  
Homoz
ght be a therapeutic tar
The protein product of the tumor suppressor gene p53 is one of the m
nt regulators for cell cycle progression and apoptosis in response to genotoxic 
stresses (129).  Murine double minute 2 (MDM2) is an oncogene product and functions 
as an ubiquitin E3 ligase of p53 and also is transcriptionally induced by p53 (130).  It 
directly binds to p53 and targets it for ubiquitination.  In 2001, two groups reported that 
Akt-dependent phosphorylation might contribute to nuclear localization of MDM2 (94, 
131). Two putative phosphorylation sites, Ser166 and Ser186, were determined by site-
directed mutagenesis.  Another group showed that Ser186 was not an Akt site (132). 
Ogawara et al. reported that neither Akt nor point mutants for MDM2 on Ser166 and 
Ser186 showed any effect on subcellular localization of MDM2, but did show a 
PI3K/Akt-dependent increase of p53 ubiquitination (133).  The precise effect of Akt on 
MDM2 is still controversial.  Taken together, MDM2 should be, at least, an Akt target in 
the regulation of cell growth, but the detailed mechanism needs to be further investigated.  
 
A
 
 manner, to astrocytes and neural progenitors in mice (134).  Although neither 
activated Akt nor Ras alone was sufficient to induce glioblastoma multiform (GBM) 
formation, the combination of activated Ras and Akt induced high-grade gliomas with the 
histological features of human GBMs.  These tumors appeared to arise after gene 
transfer to neural progenitors, but not after transfer to differentiated astrocytes.  
Increased activity of RAS is found in many human GBMs, and Akt activity is increased 
in most of these tumors, implying that combined activation of these 2 pathways 
accurately models the biology of this disease. 
By targeted disruption of the Akt1 gen
ygous mice were viable but smaller than wild type littermates, and they did not 
display a diabetic phenotype.  Upon exposure to genotoxic stress, their life span was 
shorter.  The Akt1-null mice showed increased spontaneous apoptosis in testes and  
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thymi. here w s an a nuatio  of sp enesis in the Akt1-null male mice, and 
sulin to lower blood 
glucose
ouse platelets and is activated by platelet agonists in a PI3 
kinase-
ll  
 T a tte n ermatog
thymocytes were more sensitive to γ-irradiation and dexamethasone-induced apoptosis.  
Akt1-null mouse embryo fibroblasts were also more susceptible to apoptosis induced by 
TNF, anti-Fas, ultraviolet irradiation, and serum withdrawal (135). 
Mice deficient in Akt2 are impaired in the ability of in
 because of defects in the action of the hormone on liver and skeletal muscle.  
Ablation of Akt2 in mice resulted in a mild but statistically significant fasting 
hyperglycemia due to peripheral insulin resistance and nonsuppressible hepatic glucose 
production accompanied by inadequate compensatory hyperinsulinemia (136).  In 
addition, Garofalo et al. showed that mice lacking Akt2 exhibited mild growth deficiency 
and an age-dependent loss of adipose tissue or lipoatrophy, with all observed adipose 
depots dramatically reduced by 22 weeks of age (137).  Akt2-deficient mice exhibit 
insulin-resistant with elevated plasma triglycerides, fasting hyperglycemia, 
hyperinsulinemia, glucose intolerance, and impaired muscle glucose uptake.  In males, 
insulin resistance progressed to a severe form of diabetes accompanied by pancreatic β 
cell failure; in contrast, female Akt2-deficient mice remained mildly hyperglycemic and 
hyperinsulinemic until at least 1 year of age.  Thus, Akt2-deficient mice exhibit growth 
deficiency similar to that reported for mice lacking Akt1, indicating that both Akt2 and 
Akt1 participate in the regulation of growth.  The marked hyperglycemia and loss of 
pancreatic β cells and adipose tissue in Akt2-deficient mice suggested that Akt2 plays 
critical roles in glucose metabolism and the development or maintenance of proper 
adipose tissue and islet mass for which other Akt/PKB isoforms are unable to compensate 
fully.  
Akt2 is expressed in m
dependent pathway.  Deletion of the Akt2 gene in mice impaired platelet 
aggregation, fibrinogen binding, and granule secretion, especially in response to low 
concentrations of agonists that activate the G protein-coupled receptors for thrombin and 
thromboxane A2.  Loss of Akt2 also impaired arterial thrombus formation and stability 
in vivo, despite having little effect on platelet responses to collagen and ADP (138). 
Akt3-knockout mice only exhibit an uniformly reduced brain size, affecting a
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major brain regions, suggesting a centra f Akt3 in postnatal development of the 
ng. et al.  DKO 
mice s
Loss of Akt1, but not Akt2, resulted in defective ischemia and VEGF-induced 
angiog
 
respon
l role o
brain (139).  In addition, although Akt1- and Akt3-deficient brains are reduced in size to 
approximately the same degree, the absence of Akt1 reduces cell number, whereas the 
lack of Akt3 results in smaller and fewer cells (139).  mTOR signaling is attenuated in 
the brains of Akt3-/- but not Akt1-/- mice, suggesting that differential regulation of this 
pathway contributes to an isoform-specific regulation of cell growth.   
Akt1/Akt2 double-knockout (DKO) mice were developed by Pe
howed severe growth deficiency and died shortly after birth.  These mice 
displayed impaired skin development due to a proliferation defect, skeletal muscle 
atrophy due to marked decrease in individual muscle cell size, and impaired bone 
development.  The defects were similar to the phenotype of IGF-1 receptor (IGF1R)-
deficient mice, suggesting that Akt may serve as an important downstream effector of 
IGF1R during mouse development.  DKO mice also displayed impeded adipogenesis 
through decreased induction of PPARG (peroxisome proliferative activated receptor, γ) 
(140). 
enesis and severe peripheral vascular disease in mice.  Akt1-knockout mice also 
had reduced endothelial progenitor cell (EPC) mobilization in response to ischemia. 
Introduction of EPCs from wild type mice, but not EPCs from Akt1-/- mice, into wild type 
mice improved limb blood flow after ischemia.  Loss of Akt1 reduced basal 
phosphorylation of several Akt substrates, migration of fibroblasts and endothelial cells, 
and nitric oxide release.  This suggested that Akt1 exerts an essential role in blood flow 
control, cellular migration, and nitric oxide synthesis during postnatal angiogenesis (141). 
In vitro endothelial cells from Akt1-null mice showed impaired migration in 
se to VEGF and bound 3 times less fibrinogen than wild type cells.  Akt1-null 
mice showed significantly enhanced angiogenesis, which was associated with impaired 
blood vessel maturation and increased vascular permeability.  The neovasculature in 
Akt1-null mice had decreased basement membrane thickness and decreased laminin 
deposition.  These changes were associated with reduced expression of 
thrombospondin-1 (THBS1) and -2 (THBS2).  This result implied that Akt1 is  
        30 
responsible for the regulation of vascular permeability, angiogenic responses, and 
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Chapter 2 
 
Molecular cloning and characterization of the human AKT1 promoter uncovers its 
upregulation by the Src/Stat3 pathway 
 
Abstract 
 
Akt1, also known as protein kinase B α (PKBα), is frequently activated in human 
cancers and has been implicated in many cell processes by phosphorylation of 
downstream molecules.  However, transcriptional regulation of the Akt1 has not been 
documented.  Here, we report the isolation and characterization of the human AKT1 
promoter and demonstrate transcriptional upregulation of the AKT1 by the Src/Stat3 
pathway.  Protein and mRNA levels of AKT1 are elevated in cells expressing 
constitutively active Stat3 as well as in v-Src-transformed NIH3T3 cells.  Knockdown 
of Stat3 reduces the AKT1 expression induced by v-Src.  While the 4.2-Kb region 
upstream transcription start site of the AKT1 promoter contains five putative Stat3-
binding motifs, the promoter failed to be induced by Stat3 and/or Src.  Further analysis 
reveals that major Stat3 response elements are located within exon-1 and intron-1 regions 
of the AKT1 gene, which is upstream of AKT1 translation initiation site.  In addition, 
ectopic expression of wild type AKT1 in Stat3–/– MEF cells largely rescues serum 
starvation-induced cell death.  These findings indicate that the AKT1 promoter 
comprises the exon-1 and intron-1 in addition to the sequence upstream of transcriptional 
start site.  Our data further show that the AKT1 is a direct target gene of Stat3 and 
contributes to Stat3 antiapoptotic function.  
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Introduction 
Akt/PKB represents a subfamily of the serine/threonine protein kinases.  Three 
embers of this family, Akt1/PKBα, Akt2/PKBβ, and Akt3/PKBγ, have been identified 
-7).  Akt1/PKBα is the most extensively studied member and usually referred to Akt 
o
stress) and intracellular as) stimuli to regulate 
ell growth, survival, differentiation and metabolism (8-11).  Activation of Akt by 
growth factor depends on the integrity omain, which binds to PI3K products 
tdIns-3,4-P2 and PtdIns-3,4,5-P3, and on the phosphorylation of Thr308 (Thr309 in 
Akt2 an
 
 cell differentiation (21).  In addition, 
icroinjection of anti-Akt1 antibodies blocks cell cycle progression, whereas anti-Akt2 
ntibodies have no effect on cell cycle but attenuate muscle differentiation (22).   
Amplification of the Akt1 gene has been detected in a single gastric carcinoma  
 
m
(1
r PKB in the literature.  Akt is activated by extracellular (growth factor, cytokine and  
(altered receptor tyrosine kinase, Src and R
c
of the PH d
P
d Thr305 in Akt3) in the activation loop and Ser473 (Ser474 in Akt2 and Ser472 
in Akt3) in the C-terminal activation domain by PDK1 and ILK/DNA-PK (12-14).  The 
activity of Akt is negatively regulated by PTEN, a tumor suppressor gene that is mutated 
in a number of human malignancies.  PTEN encodes a dual-specificity protein and lipid 
phosphatase that reduces intracellular levels of PtdIns-3,4-P2 and PtdIns-3,4,5-P3 in cells 
by converting them to PtdIns-4-P1 and PtdIns-4,5-P2, respectively, thereby inhibiting the 
PI3K/Akt pathway.   
There are no significant differences between three members of Akt in terms of 
upstream regulators and downstream targets.  However, several lines of evidence 
suggest that the biological/physiological functions of Akt1, Akt2 and Akt3 are different. 
First, there are different levels of activation and protein expression in various cell types 
between Akt1, Akt2 and Akt3 (5, 15-18).  Second, multimeric complexes formed by 
Akt proteins are restricted to individual member, for example, Tcl1b binds to Akt1 and 
Akt2 but not Akt3, indicating the need to maintain specificity in interactions with other 
signaling proteins (19).  Third, although Akt1 and Akt2 proteins require membrane 
localization for activity, only Akt2 appears to accumulate in the cytoplasm during mitosis 
(20) and in the nucleus during muscle
m
a
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cell line (23), whereas the Akt2 is amplified in different types of human tumor (16-17, 24).  
ctopic expression of wild type Akt2, but not Akt1 and Akt3, results in invasion and 
metasta
 
AKT1 gene.  AKT1 is transcriptionally upregulated by Stat3 and 
Src.  E
g Akt, 
Stat3 a ).   
E
sis in human breast and ovarian cancer cells (25) and induces a malignant 
phenotype in mouse fibroblasts (20).  Finally, knockout mouse studies demonstrated 
distinct phenotype between Akt1, Akt2 and Akt3.  The mice deficient in the Akt2 are 
impaired in the ability of insulin to lower blood glucose because of defects in the action
of the hormone on skeletal muscle and liver, similar in some important features to type 2 
diabetes in human.  In contrast, Akt1-dificient mice do not display a diabetic phenotype.  
The mice are viable but display impairment in organismal growth with smaller organs 
than wild type littermates (26-28).  In contrast, a recent report shows that Akt3-/- 
knockout mice only exhibit a uniformly reduced brain size, affecting all major brain 
regions, suggesting a central role of Akt3 in postnatal development of the brain (29).   
While Akt1 signaling has been extensively investigated, its transcriptional 
regulation remains largely unknown.  In the present report, we have isolated and 
characterized the human AKT1 promoter.  Multiple putative Stat3-binding sites reside 
within the promoter and major Stat3 response elements are identified in the exon-1 and 
intron-1 regions of the 
levated expression level of AKT1 induced by Src is inhibited by dominant 
negative Stat3.  Stat3–/– MEFs display lower level of Akt1 and reintroduction of the 
AKT1 largely rescued cell death in response to serum starvation.  Therefore, our results 
provide the first evidence that the AKT1 is a direct Stat3 target and mediates Stat3 
survival signal. 
 
Material and methods 
 
Cell Culture, Plasmids, Materials and Transfection - Human epithelial kidney 
HEK293, MCF10A, MCF7, mouse fibroblast NIH3T3, Src transformed NIH3T3, and 
Stat3−⁄− mouse embryonic fibroblast (MEF) were grown in Dulbecco’s modified Eagle’s 
medium (DMEM) containing 10% fetal bovine serum.  The plasmids expressin
nd Src as well as dominant negative Stat3 have been described previously (30, 34
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The antibodies to Akt1 and Stat3 were purchased from Cell Signaling and Santa Cruz 
Biotechnology, respectively.  For transfection, the cells were seeded 18-24 h before 
transfection using Lipofectamine plus.  The sequence for Stat3 antisense oligonucleotide 
synthesized using phosphorothioate chemistry is 5’-AAAAAGTGCCCAGATTGCCC-3’.  
The sequence for control oligonucleotide is identical to the antisense oligonucleotide 
except for three mismatched bases (italics), 5’- AAAAAGAGGCCTGATTGCCC-3’. 
The sequence of Stat3 siRNA is 5'-AAC AUC UGC CUA GAU CGG CUA dTdT-3'; 3'-
dTdT GUA GAC GGA UCU AGC CGA U-5'.  
Transcription Start Site Mapping of Human AKT1 Gene - For the analysis of the 
AKT1 transcription start site, human MCF7 mRNA was reverse transcribed at 55°C 
using Supercript reverse transcriptase (Invitrogen) and a primer from the AKT1 exon-1 
specific reverse complement oligonucleotide 5'- TGACTTCTTTGACCCAGGCTGG-
 
3' 
(31).  
am the translational start site.  Two DNA fragments (-4293/+1 and -
293/+1888, Fig. 9C) were amplified with GC-RICH PCR System (Roche) using a 
e.  The amplified DNA fragments -4293/+1 and - 4293/+1888 
ere subcloned into the luciferase reporter vector pGL3 (Promega) at KpnI/BglII site.  
Progre
Synthesized cDNAs were amplified by polymerase-chain reaction using a series 
of forward primers specific for the DNA sequences within the 6,000 bp upstream of the 
translation start site and a reverse primer from the non-coding region of exon 1, and the 
products of these reactions were resolved by agarose gel electrophoresis.  
Cloning and Analysis of Human AKT1 Promoter – To clone the 5'-flanking region 
of the human AKT1 gene, 4 cosmid clones were obtained by screening a human placenta 
genomic cosmid library (Stratagene) using 5’ non-coding region (a 520-bp fragment from 
ATG site) of the AKT1 as a probe.  The cosmid clones were sequenced and compared 
with human genome database.  Three clones were found to contain 12~28-kb DNA 
fragments upstre
4
cosmid clone as templat
w
ssive deletion mutants of the pGL3- AKT1 promoter were created by PCR.  The 
integrity of constructs was confirmed by DNA sequencing.  The primers were used as 
follow: -4293(5’) 5’-CTTCGTGAACATTAACGACAGG GCCTGG-3’; -3392(5’) 5’-
GTTCAGGCAGAACCTCTGCAGACTCAGG-3’; -3356(5’) 5’-CTGG CCTGGGAGC 
TGCCCTGAGG-3’; -2741(5’) 5’- CTCTGCTTCCTCCCTGAATTCCTTCCTCC-3’; - 
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1603(5’) 5’-CAGCCTGAAAGTCAACCTAAGC -3’; -1361(5’) 5’-CAGCCCGGCCGC 
GCGCTCCCCG-3’; -460(5’) 5’-GGCTAGCCACAAAGGACTGTGACC-3’; -880(3’) 
5’- CCAGAATGGAGGAGCGGGAGCAGGAAGT-3’; -732(3’) 5’-GCCCCAGCCTCC 
CTCATGACCTT-3’; -305(3’) 5’-GCTTGCCCCTTAGATTGAGTAT-3’; -103(3’) 5’-
GGAGCTGTGTAGACTTCTCATACA-3’; +159(3’) 5’-GCTCTGGACAG CTGTCTG 
ACTCTGT-3’; +595(3’) 5’-GGCTGTGGAAAGACCCATGTTG-3’; +1809(3’) 5’- 
GCTTCCTTTGCTTCTCCCAGAGG-3.  
Luciferase Reporter Assay – NIH3T3 or HEK293 cells were cultured in 12-well 
plates 
cted using the 
RNeasy
 
  
and transiently transfected with AKT1-Luc, Src and/or Stat3.  The amount of 
DNA in each transfection was kept constant by the addition of empty vector.  After 36 h 
of transfection, luciferase activity was measured using a luciferase assay reagent 
(Promega).  Transfection efficiency was normalized by co-transfection with β-
galactosidase expressing vector.  The β-galactosidase activity was measured by using 
Galato-Light (Tropix).  Luciferase activity was expressed as relative luciferase activity.  
Northern and Western Blot Analysis – Northern blot analysis of total cellular 
RNA was performed according to standard procedures.  RNA was extra
 purification kits (QIAGEN Inc.).  Total RNA was electrophoresed in 1.0% 
formaldehyde-agarose gels, transferred to Duralon-UVTM membrane (Srtatagene), and 
then hybridized with randomly primed α-32P-labeled cDNA probes for AKT1. 
Membranes were exposed to autoradiography and the mRNA levels were visualized and 
quantified using PhosphorImager analysis (Molecular Dynamics).  Western blot analysis 
was performed as described previously (32).  Briefly, the cells were lysed with RIPA 
buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1% Triton x-100, 1% Sodium 
deoxycholate. 0.1% SDS, 1 mM EDTA. 1 mM PMSF, 5 µg/ml aprotinin and 5 µg/ml 
leupeptin), separated in SDS-PAGE and immunoblotted with appropriate antibodies as 
indicated in the figure legends. 
ChIP and EMSA Assay - ChIP assay was performed essentially as previously 
described (33).  Solubilized chromatin was prepared from a total of 2 X 107 
asynchronously growing HEK293 cells that were transfected with wild type Stat3 and v-
Src.  The chromatin solution was diluted 10-fold with ChIP dilution buffer (1.1% Triton
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–100, 1.2 mM EDTA, 167 mM NaCl, 16.7 mM Tris•HCl, pH 8.1, 0.01% SDS, protease 
 
 
NA were removed by incubation with 10 µg 
protein
CCCTA
GAGCCTCCAGCC-3’.  Amplified PCR products were 
resolve
      
inhibitors), and precleared with protein-A beads blocked with 2 µg sheared salmon sperm 
DNA and pre-immune serum.  The precleared chromatin solution was divided and 
utilized in immunoprecipitation assays with either an anti- Stat3 antibody or an anti-actin 
antibody.  Following wash, the antibody-protein-DNA complex was eluted from the
beads by resuspending the pellets in 1% SDS, 0.1 M NaHCO3 at room temperature for 
20 min.  After crosslinking, protein and R
ase K and 10 µg RNase A at 42 °C for 3 h.  Purified DNA was subjected to PCR 
with primers specific for 13 putative Stat3-binding sites within the AKT1 promoter. The 
sequences of the PCR primers used are as follows: region 1 forward (-4293): 5’-
CTTCGTGAACATTAACGACAGGGCC-3’, reverse (-4143): 5’-AATGGCCACCCTG 
ACTAAGGAGTGG-3’; region 2 forward (-4221): 5’- AACCCTTCACTGGTTTCTCT 
TCATCC-3’, reverse (-4056): 5’-TGCTGGAATATCCCACAATCACAGG-3’; region 3 
forward (-4134): 5’- TTCCCTCGCAGTCCCTTCTGCTGC-3’, reverse (-3840): 5’-
CTTCCTCTGAAGGTTCAGG-3’; region 4 forward (+233): 5’- ATCCAGAG 
GTCTTTGAGTCCAGCC-3’, reverse (+438): 5’-TGCCAGGACAGGGAACACAGG-
3’; region 5 forward (+413): 5’-AGGTGTGGTCTTCCCTGTCCTGGC-3’, reverse 
(+481): 5’-GCTACACTTAGAATGGCAGGAAGG-3’; region 6 forward (+447): 5’-
AGGCAGTGGGCCTTCCTGCCATTC-3’, reverse (+598): 5’-TCCC AACATGGGTCT 
TTCCACAGC-3’; region 7 forward (+831): 5’-GGATAAAGTGTGCTCAGGTGAGG 
G-3’, reverse (+1038): 5’-GGCGTCTCAGGTTTTGCCAGGGGG-3’; region 8 forward 
(+989): 5’-TCTCTTTGTCTCCAGCGCCCAGG- 3’, reverse (+1200): 5’- ATGAGGAA 
GAGAGGACCAGGATGC-3’; region 9 forward (+1262): 5’-GATCCATGGGTAGGA 
ACACCATGG-3’; reverse (+1419): 5’-TTCCCAGCCTCCCTAACCTGATGC-3’; 
region 10 forward (+1440): 5’- AGCCTGGGTCAAAGAAGTCAAAGG-3’, reverse 
(+1598): 5’-ATTCTAGGCTTA
d by 1.2% of agarose gel electrophoresis and visualized by BioImage. EMSA was 
performed as previously described (35).  
MTT Assay - MTT assay was done following the procedure described previously 
(36).  Briefly, conditional STAT3 -/- MEF cells (4 x 103 cells/well) were plated in 96- 
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well microtiter plates and infected with retrovirus expressing Cre for disrupting Stat3. 
After infection, wild-type Akt1 was transfected into the cells using LipofectAmine 
(Invitrogen).  Cells were serum starved, incubated with MTT (10 µl/well) and 
solubilized with 100 µl/well of 20% sodium dodecyl sulphate (SDS) in 50% DMF 
(pH4.7) at room temperature for 4 h.  Absorbance was determined in a Titertek plate 
reader at 570 nm.  The absorbance is directly related to viable cell number.  The 
experiment was repeated three times. 
 
Results 
 
Cloning of the Human AKT1 Promoter Reveals Multiple Putative Stat3 Binding
 
 
 
 
   
  
  
  
, 
 
 
Sites – To analyze the transcriptional regulation of the serine/threonine kinase AKT1, we
cloned the 5’ flanking region of the human AKT1 gene.  Sequence analyses revealed that 
the AKT1 gene consists of 12 exons.  The exon-1 is 1.4 kb and locates within the 5’    
untranslated region.  The translation initiation site ATG resides within the exon 2
(Fig. 9A).  The transcription start site, which was determined by 5’ race PCR, 
lies 1,888-bp upstream of the translation start site.  A putative TATA box was 
identified 7-bp upstream of the transcriptional start site.  Transcription element 
analyses (http://www.motif.genome.ad.jp) of 6,181 bp of upstream of translation 
initiation site of the AKT1 gene revealed multiple binding sites for Stat3, NFκB
AP1 and GC box within the these regions (Fig. 9B).  The transcription factor that 
has the most    binding sites in the AKT1 promoter is Stat3 (twelve putative Stat3 
binding sites; -4230/- 4223, -4143/-4136, -4053/-4046, -3287/-3278, - 2851/-2844,
+407/+414, +439/+448, +483/+491, +978/+986, +1047/+1055, +1324/+1331, and 
+1443/+1450).  Consensus sequences of Stat3 binding site are TT(N)4-6AA (37). 
These observations suggest that the AKT1 gene could be regulated by Stat3 at 
transcriptional level.  
 
Stat3 Increases AKT1 Expression at mRNA and Protein Levels – To directly 
demonstrate whether the AKT1 is transcriptionally regulated by Stat3, MCF-10A cells  
        43 
 
FIGURE 9. Human AKT1 promoter contains multiple Stat3-binding sites.  A, schematic 
representation of the human AKT1 genomic locus.  The exons are shown as boxes 1–12. 
B, the AKT1 promoter sequence.  Putative transcription factor binding sites are boxed. 
Transcriptional start site and boundaries of exon 1, intron 1, and exon 2 are indicated. 
Putative TATA box was boxed within the AP-1-binding site.  The translation initiation 
ite, ATG, was shaded.  C, a diagram displays the location of 12 putative Stat3-binding 
ites indicated by asterisk within the 6-kb AKT1 promoter. 
s
s
 
were infected with adenovirus expressing constitutively active Stat3 (Stat3C) and 
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dominant negative Stat3.  The cells infected with adeno-GFP vector were used as 
control.  Northern blot analysis showed that constitutively active Stat3C upregulates the 
AKT1 (Fig. 10A).  Further, immunoblotting study revealed an elevated protein level of 
AKT1 in the cells treated with constitutively active Stat3C (Fig. 10B).  Expression of 
dominant negative Stat3 slightly inhibited the mRNA and protein levels of AKT1 (Figs. 
10A and 10B).  As Stat3 is strongly activated by Src kinase (30), we next examined if 
expression level of AKT1 is elevated in v-Src transformed NIH3T3 cells.  As shown in 
Figs. 10C and 10D, both protein and mRNA levels of AKT1 were significantly increased 
in v-Src transformed NIH3T3 cells.  Further, blockage of Stat3 with antisense RNA 
considerably reduced v-Src-induced AKT1.  Moreover, upregulation of AKT1 was also 
detected in human breast cancer cell line MDAMB-468, which exhibits constitutively 
active Src and Stat3, but not in MDA-MB453, which does not.  Inhibition of Src/Stat3 
by Src inhibitor (PD180970) or Stat3-SiRNA reduced AKT1 protein level in MDA-MB-
468 (Figs. 10E and 10F).  In addition, conditional knockout of the Stat3 gene decreased 
Akt1 expression in mouse embryonic fibroblasts (Fig. 14A).  Based on these data, we 
concluded that the Akt1 is a downstream target of Stat3. 
 
Stat3 Transactivates the AKT1 Promoter – We further examined whether the 
AKT1 promoter is regulated by Stat3.  Luciferase reporter assay revealed that pGL3-
AKT1-4293/+1, which contains 5 putative Stat3 binding sites, was not stimulated by wild 
type or constitutively active Stat3 even when Stat3 was combined with v-Src (Figs. 11A 
and 11B).  However, ectopic expression of constitutively active Stat3 significantly 
induced the pGL3-Akt1-4293/+1888 activity (Fig. 11C), suggesting that major Stat3 
sponse elements reside in the region of the AKT1 gene between transcription start site 
rmed 
 (Fig. 
10), we assumed that the AKT1 promoter should be induced by Src through Stat3.  To 
  
re
and translation initiation site, which contains exon-1 and intron-1 (Fig. 9B). 
 
Src Induces AKT1 promoter Activity through Stat3 – As v-Src transfo
NIH3T3 cells express high levels of AKT1 that was attenuated by knockdown Stat3
test this hypothesis, luciferase reporter assay was performed with NIH3T3 cells  
      45 
FIGURE 10. Up-regulation of the 
AKT1 by Stat3 and Src.  A and B, 
constitutively active Stat3 increases 
AKT1 expression.  MCF10A cells 
were infected with adenovirus 
expressing constitutively active 
Stat3C, dominant negative Stat3, and 
green fluorescent protein (GFP). 
After incubation for 48 h, cells were 
subjected to Northern (A) and 
Western (B) blot analyses.  C, v-Src 
transformed NIH3T3 cells express 
elevated levels of Akt1.  pcDNA3 
and v-Src stably transfected NIH3T3 
cells were lysed and immunoblotted 
with the indicated antibodies.  D, 
blockage of Stat3 inhibits v-Src-
upregulated Akt1.  v-Src-
transformed NIH3T3 cells were 
transiently transfected with antisense 
oligonucleotides of Stat3 and control 
oligonucleotides.  Total RNA was 
isolated and subjected into Northern 
blot analysis with [32P] dCTP-
labeled Akt1 (top).  The second 
panel represents equal loading of 
total RNA.  Expression of Stat3 was 
examined by immunoblotting with 
anti-Stat3 antibody (third panel).  
Bottom panel shows equal protein 
 
loading. E, the AKT1 protein level is 
elevated in human breast cancer 
cells with activation of Src and Stat3, 
and inhibition of Src reduces AKT1 
were lysed and 
indicated 
antibodies. 
expression.  MDA-MB-468 cells 
expressing constitutively active Src 
and Stat3 were treated with or 
without a Src inhibitor, PD180970 
(250 ng for 24 h), and 
immunoblotted with the indicated 
antibodies.  MDA-MB-453 cells 
with low levels of Src and Stat3 
activity were used as control.  F, 
knockdown of Stat3 reduces AKT1 
expression.  MDA-MB-468 cells 
were transfected with Stat3-siRNA 
(+) or scramble siRNA (-) using 
Oligofectamine.  After 48 h of 
incubation, cells 
immunoblotted with the 
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transfected with v-Src, pGL3-AKT1-4293/+1888 and wild ty
12A, expression of v-Src alone induces the reporter activity 
expression of v-Src and Stat3 significantly stimulated th
Further, wild type Stat3 enhances v-Src induced the AKT1 pr
manner (Fig. 12B).  Notably, expression of dominant negative Stat3 considerably 
reduces the AKT1 promoter activity induced by v-Src (Fig. 
that Stat3 mediates Src stimulated AKT1 promoter activity. 
 
 
FIGURE 11. Constitutively active Stat3 induces AKT1-4293/+1888, but not AKT1-4293/+1 
luciferase activity.  NIH3T3 cells were transfected with AKT1-4293/+1-Luc (A and B) and 
AKT1-4293/+1888-Luc (C), β-galactosidase and expression constructs are indicated in the 
figure.  Following a 36-h culture, luciferase activity was measured and normalized to β-
galactosidase.  Results are the mean ± S.E. of three independent experiments performed in 
iplicate. 
        
pe Stat3.  As shown in Fig. 
about one-fold, whereas co-
e AKT1 promoter activity.  
omoter in a dose dependent 
12C).  These data indicate 
tr
47 
 
Stat3 Response Elements are primarily located within Exon-1/intron-1 Region – 
As shown in Fig. 9C, twelve putative Stat3 binding motifs were identified within ~6.0-kb 
region upstream translation initiation site of the AKT1 gene.  Src and Stat3 induced 
pGL3-AKT1-4293/+1888 but not pGL3-AKT1-4293/+1 activity (Fig. 11), implying that 
the Stat3 response elements reside in a region between transcription start site and 
translation initiation site.  To test this, we created a series of deletion mutants of the  
 
FIGURE 12. AKT1 promoter is activated by Src through Stat3.  A, v-Src, but not wild type 
Stat3 stimulates Akt1 promoter activity.  NIH3T3 cells were transfected with the indicated 
plasmids and subjected to luciferase reporter assay.  B and C, v-Src-induced AKT1 promoter 
activity was enhanced by coexpression of wild type Stat3 but reduced by dominant negative 
gion between -4293 and -3172, i.e., pGL3-AKT1 -3172/+1888 considerably reduced  
        
Stat3.  The transfection and luciferase reporter were performed as described in the legend to 
Fig. 5. 
 
AKT1 promoter.  Reporter assay showed that pGL3-AKT1 -325/+1888 was significantly 
induced by coexpression of v-Src/Stat3 (Figs. 11C and 13A), whereas deletion of a 
re
48 
 SIE oligonucleotides were used as 
positive control (right panel). 
 
        49 
FIGURE 13. Definition of the 
Stat3 response elements.  A and 
B, major Stat3 response elements 
located within the exon 1/intron 1 
region of the AKT1 promoter.  A 
series of deletion mutants of the 
AKT1 promoter (left) were 
introduced into NIH3T3 ce
together with or without 
lls 
v-
Src/Stat3 (A) or constitutively 
active Stat3C (B) and then 
subjected to luciferase reporter 
assay.  C, Stat3 binds to 4 sites 
of the AKT1 promoter in vivo. 
ChIP assay was performed as 
described under “Experimental 
Procedures.” Triple experiments 
showed that Stat3 directly binds 
to 4 sites of the AKT1 promoter. 
D, mutation of Stat3 DNA-binding 
sites within the AKT1 promoter 
abrogates the Src/Stat3-
stimulated promoter activity. 
Luciferase assay was performed 
in NIH3T3 cells transfected with 
the AKT1-Luc/-325/-1888 and its 
mutants as well as v-Src and 
Stat3.  E, Stat3 binds to DNA 
oligonucleotides corresponding to 
Stat3 SIE/GAS binding sites in the 
Akt1 promoter.  EMSA of 
double-stranded oligonucleotides 
containing Stat3-binding sites are 
indicated on the top.  Equal 
 
 
 
 
 
a 100 M excess of the unlabeled 
oligonucleotides (competitor). 
amounts of 32P-labeled
oligonucleotides were incubated
with nuclear extract prepared
from Stat3C-transfected HEK293
cells in the presence or absence of
the promoter activity.  Further, pGL3-AKT1-3172/+5
(Fig. 13A) indicating that the major Stat3 response 
regions, where there are 7 putative Stat3 binding mot
the promoter.  Notably, the results also suggest th
binding site(s) within -3172/-325 region because the
increased by deletion of this region as revealed by co
3172/+1888 and -325/+1888 (Figs. 13A and 13B).  T
bind to the Stat3-binding site within the AKT1 promot
Stat3 response elements in the promoter, we carried o
(ChIP) assay, which detects specific genomic DNA se
particular transcription factor in intact cells.  Human
transfected with wild-type Stat3 and v-Src and immuno
The Stat3 bound chromatin was subjected to PCR u
amplify region spanning each Stat3-binding site withi
in Fig. 13C, the anti-Stat3 antibody pulled down four
+978/+986, +1324/+1331, and +1443/+1450 (SB1, S
immunoprecipitation with an irrelevant antibody (ant
bands in these sites.  These results indicate that S
promoter.  By mutation of Stat3 binding consensus
325/+1888 that is highly induced by Src/Stat3 and 
further demonstrated that the Stat3 binding sites (SB6,
intron-1 region are required for Stat3 transactivation 
Moreover, EMSA assay revealed that Stat3 is capa
oligonucleotides corresponding to the four Stat3 SIE/G
Akt1 promoter (Fig. 13E).  Unlike SIE positive contro
detected in these four Stat3 binding sites within the
shown), which is also observed in other Stat3-induced
and c-Myc (34, 38, 39). 
AKT1 Mediates Stat3 Function – Both Stat3 and AKT1 play an essential role in  
95 failed to respond to v-Src/Stat3 
elements exist in exon-1/intron-1 
ifs, as well as in a distal region of 
e presence of a repression factor 
 promoter activity is significantly 
mparison of the activity between -
o determine if Stat3 could directly 
er in vivo and to further define the 
ut chromatin immunoprecipitation 
quences that are associated with a 
 kidney cell line, HEK293, were 
precipitated with a Stat3 antibody.  
sing oligonucleotide primers that 
n the AKT1 promoter.  As shown 
 Stat3 binding sites (-4230/-4223, 
B7, SB9 and SB10).  In contrast, 
i-actin) resulted in the absence of 
tat3 directly binds to the AKT1 
 sequences (TT→GG) in AKT1–
Stat3C (Figs. 13A and 13B), we 
 SB9 and SB10) within exon-1 and 
of the AKT1 promoter (Fig. 13D).  
ble of binding in vitro to DNA 
AS binding sites identified in the 
l, however, the supershift was not 
 promoter (Fig. 13E and data not 
 promoters, such as VEGF, Bcl-xL 
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cell survival (40- 45).  Because AKT1 is a direct target of Stat3, we reasoned that AKT1 
could mediate Stat3 function.  To test this hypothesis, conditional knockout of Stat3 
MEF cells were infected with Cre and adenovirus expressing wild type AKT1 (Fig. 14A). 
Cell survival was evaluated after serum withdrawal for 24 h and 48 h.  Triple 
experiments showed that Cre-infected Stat3 MEF increased cell death approximately 
30%. Ectopic expression of wild type AKT1 largely rescued knockdown Stat3-induced 
cell death (Fig. 14B).  It is noted that Akt1 protein level is considerably decreased in 
Stat3-knockout MEFs, further suggesting the critical role of Stat3 in transcriptional 
regulation of the AKT1 gene.  To further examine the effects of Akt1 on Stat3 cell 
survival signal, constitutively active Stat3-presenting breast cancer cell line MDA- MB-
468 was treated with Stat3-SiRNA or Akt1-SiRNA as well as the co-transfection of 
SiRNA-Stat3 and HA-Akt1 (Fig. 14C).  Tunel assay revealed that knockdown of either 
Stat3 or Akt1 induced cell death about 45~50% in response to serum starvation.  
However, reintroduction of Akt1 largely inhibits the apoptosis resulting from knockdown 
of Stat3 (Fig. 14D). 
 
Disussion 
 
Alterations of the AKT1 at the DNA level have been reported in a single gastric 
cancer (23).  However, a number of tumors exhibit elevated levels of mRNA, protein 
and/or kinase of AKT1 (46), implicating that the AKT1 is regulated at transcriptional, 
translational and/or posttranslational levels.  Posttranslational regulation of AKT1 has 
well been documented (47).  In this report, we cloned the human AKT1 promoter and 
demonstrated a number of transcription factor binding sites within the promoter. 
Notably, 12 putative Stat3-binding motifs were identified in the promoter, 4 of which 
were shown to directly bind to Stat3 in vivo and in vitro as revealed by ChIP and EMSA 
assays.  The promoter activity is significantly induced by constitutively active Stat3. 
Further, we demonstrate
 
 
d that ectopic expression of constitutively active Stat3 or v-Src 
ignificantly induces mRNA and protein levels of AKT1.  Knockdown Stat3 decreased 
Akt1 ex
s
pression in v-Src transformed cells and mouse embryonic fibroblasts.   
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 FIGURE 14. Reintroduction of the AKT1 into Stat3-/- MEFs rescues cell death induced by serum 
withdraw.  A, conditional knock-out of the Stat3 down-regulates Akt1.  Stat3 knock-out MEFs were 
infected with retrovirus expressing Cre or retrovirus vector alone and immunoblotted with anti-Stat3, 
-Akt1, and -actin antibodies (left panels).  Right panels show expression of AKT1 by reintroduction 
of the AKT1 into Stat3-/- MEFs.  B, Stat3- induced cell survival is mediated, at least in part, by 
AKT1. Stat3-/- MEFs infected with or without retrovirus-Cre and adeno-AKT1 were assayed for cell 
survival after serum withdraw for the indicated times.  C and D, knockdown of either Stat3 or Akt1 
induces apoptosis and the reintroduction of Akt1 rescues programmed cell death from knockdown of 
Stat3.  MDA-MB-468 cells were treated with the siRNA of Stat3 (lanes 2 and 3) or Akt1 (lane 5) as 
well as scramble siRNA (lanes 1 and 4).  HA-Akt1 was simultaneously introduced into the Stat3-
siRNA cells (lane 3).  Following 48 h of transfection and 16 h of serum starvation, apoptotic cells 
were assessed by Tunel assay and quantified.  Data are representative of three independent 
experiments.  E, schematic illustration of the regulation of Akt1 by the Src/Stat3 pathway. 
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Reintroduction of the AKT1 rescued the cell death in Stat3−⁄− MEFs.  We have 
noted that constitutively active, but not wild type Stat3 induces the AKT1 promoter 
activity (Fig. 12A).  However, knockout Stat3 in MEFs and breast cancer cells 
significantly reduced Akt1 expression (Figs. 14A and 14C).  These data suggest that 
basal level of Stat3, which could distribute to the cytoplasm and the nucleus, is required 
for expression of normal level of its target genes, such as AKT1.  Ectopic expression of 
wild type Stat3 may not increase the nuclear fraction of Stat3 and only constitutively 
active Stat3 could translocate into the nucleus and transactivate its target gene(s).  This 
notion is supported by the observations that Stat3 is persistently activated in many human 
cancers and transformed cell lines and that only the activated Stat3 transform cell in cell 
culture and induces tumor formation in nude mice (48, 49).  Akt and Stat3 pathways 
play an important role in cell processes associated with tumorigenesis such as cell 
survival, growth and angiogenesis (50-54).   
Cross-talk between these 2 pathways, however, has not been documented.  
Therefore, the data presented in this study provide the first evidence of the AKT1 gene as 
a direct downstream target of Stat3.  Recently, we have also observed that inhibition of 
AKT1 pathway induces hypoxia inducible factor (HIF)- 1α and that knockdown AKT1 
largely abrogates the HIF-1α expression stimulated by Stat3 (55).  These findings 
further support that Stat3 targets Akt to exert its function.  It has been shown that Src is 
a key molecule for activation of Akt pathway.  We and others have previously 
demonstrated that constitutively active Src induces Akt kinase activity through PI3K (11, 
56).  There is also evidence showing that Src directly binds to Akt and activates Akt 
e  
     
through phosphorylation of Akt at tyrosine-315 (57).  Inhibition of Src reduces Akt 
activation by growth factor(s).  In addition, Src mediates estrogen/estrogen receptor and 
androgen/androgen receptor activation of Akt (58-61).  In the present report, we present 
the evidence of Src regulation of Akt at transcriptional level through activation of Stat3 
(Fig. 12E).  It is noted that the Akt1 promoter activity induced by src is considerably 
lower than that by expression of constitutively active Stat3C (Figs. 11-13), suggesting 
that a repressive molecule(s) toward Akt1 promoter is regulated by Src kinase.   
In summary, we have isolated and characterized the AKT1 promoter.  Th
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er sequence analysis demonstrates Stat3 transcriptional regulation of the AKT1. 
Further, we have shown that Src/Stat3 induces Akt1 expression through directly binding 
to the promoter.  Blocking Stat3 by antisense or genetic knockout significantly 
decreases Akt1 expression.  Ectopic expression of AKT1 rescues cell survival 
phenotype from Stat3−⁄− MEF cells.  These findings are important for several reasons. 
First, they provide a mechanistic understanding of regulation of the AKT1 at 
transcriptional level.  Second, a direct link between AKT1 and Stat3 pathways has now 
been established.  Finally, pharmacologicals may have anti-growth effects in the tumor 
cells with activation of Stat3 or vice versa. 
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 Targeting Stat3 blocks both HIF-1 and VEGF expression induced by multiple 
oncogenic growth signaling pathways 
Abstract 
Vascular endothelial growth factor (VEGF) upregulation is induced by many 
ceptor and intracellular oncogenic proteins commonly activated in cancer, rendering 
olecular targeting of VEGF expression a complex challenge. While VEGF inducers 
bound, only two major transcription activators have been identified for its promoter: 
ypoxia inducible factor-1 (HIF-1) and signal transducer and activator of transcription 
tat3). Both HIF-1 expression and Stat3 activity are upregulated in diverse cancers. Here, 
e provide evidence that Stat3 is required for both basal and growth signal-induced 
xpression of HIF-1. Moreover, induction of VEGF by diverse oncogenic growth stimuli, 
cluding IL-6R, c-Src, Her2/Neu, is attenuated in cells without Stat3 signaling. We 
rther demonstrate that Stat3 regulates expression of Akt, which is required for growth 
gnal-induced HIF-1 upregulation. Targeting Stat3 with a small-molecule inhibitor 
locks HIF-1 and VEGF expression in vitro and inhibits tumor growth and angiogenesis 
 vivo. Furthermore, tumor cells' in vivo angiogenic capacity induced by IL-6R, which 
multaneously activates Jak/STAT and PI3K/Akt pathways, is abrogated when Stat3 is 
hibited. Activation of Stat3 signaling by various growth signaling pathway is prevalent 
 diverse cancers. Results presented here demonstrate that Stat3 is an effective target for 
hibiting tumor VEGF expression and angiogenesis. 
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Introduction 
A crucial role of vascular endothelial growth factor (VEGF) in angiogenesis and 
mor progression in both solid tumors and hematological malignancies has been well 
stablished (1-3).  Inhibiting VEGF F receptor signaling – alone or in 
com sis 
therapy in both animal ever, a large array of 
ncoproteins overactive in cancer cells act as VEGF inducers, creating a challenge for 
blocking tumor VEGF production.  Phosphatidylinosital-3-kinase (PI3K) and Akt 
gnaling plays an important role in the regulation of VEGF expression (8, 9).  Both 
PI3K a
 
mor angiogenesis in vivo (14) and 
locking Stat3 signaling in tumors can reduce tumor angiogenesis (16).  A role of Stat3 
 upregulating VEGF expression in diverse human cancers has also been demonstrated 
15-17).  Importantly, constitutive activation of Stat3 occurs at 50–90% frequency in a  
 
tu
e and/or VEG
bination with other treatments – has shown promise for tumor antiangiogene
models and cancer patients (4-7)  How
o
si
nd Akt are frequently activated in a wide range of human cancers by either gain-
of-function of oncogenic proteins or by loss-of-function of negative regulator, 
phosphatase and tensin homologue deleted on chromosome 10 (PTEN) (9, 10).  The 
PI3K/Akt signaling pathway upregulates expression of VEGF in both tumor and 
endothelial cells, and hypoxia inducible factor-1 (HIF-1) mediates PI3K/Akt-induced 
VEGF expression (8, 9, 11).  In addition to controlling angiogenesis, HIF-1 regulates 
metabolic adaptation to hypoxia and other critical aspects of tumor progression (9).  
HIF-1 consists of two subunits: an inducible HIF-1α subunit and a constitutively 
expressed HIF-1β subunit (9, 12, 13).  In solid tumors, HIF-1α is frequently upregulated 
by intratumoral hypoxia through loss of von Hippel-Lindau (VHL) or p53 function (9). 
Deregulation of growth signaling pathways in both solid and hematological malignancies 
is common, and upregulation of HIF-1 by abnormal growth signaling has been shown to 
be at the protein synthesis level and mediated by PI3K/Akt pathway. It has been 
demonstrated that inhibition of mTOR by rapamycin abrogates HIF-1α induction by 
growth signaling pathways (9). 
Recent studies have also identified Stat3 as a direct transcription activator of the 
VEGF gene (14, 15).  Activation of Stat3 leads to tu
b
in
(
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broad range of human cancers (18 - 22), suggesting that Stat3 activity contributes 
gnificantly to tumor VEGF overproduction. 
 
 
si
The Jak/STAT and PI3K/Akt are two parallel pathways mediating functions of 
many receptor and nonreceptor tyrosine kinases, including EGFR, Her-2 and c-Src (8, 10, 
14, 16, 22 - 24).  IL-6 receptor (IL-6R), which is frequently activated in a wide range of 
cancers (25), also signals through both Jak/STAT and PI3K/Akt pathways (19, 26).  
Overexpression and/or persistent activation of EGFR/Her-2, Src and IL-6R are known to 
promote tumor growth/survival and to induce VEGF expression and angiogenesis (8-10, 
12, 16, 20, 22, 23, 27, 28).  As IL-6 activates the PI3K/Akt pathway (26), engagement 
of IL-6R is predicted to affect HIF-1α expression.  Interestingly, it has been shown that 
blocking Stat3, but not PI3K activity, inhibits VEGF expression in tumor cells with 
constitutive IL-6R signaling (16), suggesting that Stat3 continues to activate VEGF 
expression in the absence of PI3K/Akt signaling. 
In this study, we show that Stat3 is obligatory for both basal and growth signal-
induced HIF-1α expression.  Moreover, VEGF upregulation by multiple oncogenic 
proteins/growth pathways is abrogated in the absence of Stat3 signaling.  We further 
demonstrate that Stat3 is required and sufficient for Akt1 expression.  Our results also 
show that targeting Stat3 by a small-molecule drug inhibits human melanoma growth and 
angiogenesis in a xenograft model.  Furthermore, tumor angiogenesis induced by IL-6, 
which simultaneously activates Jak/STAT and PI3K/Akt, is attenuated in Stat3 
knockdown tumor cells in vivo.  These results demonstrate that Stat3 is a key regulator 
of the VEGF gene; in addition to being a direct activator of the VEGF promoter, Stat3 is 
required for PI3K-Akt-mediated HIF-1 expression, a key regulator of the VEGF gene.  
As such, strategically developing Stat3 antagonists may effectively impair tumor 
angiogenesis. 
Materials and methods 
 
The following reagents were purchased from various companies as indicated: IL-6 
(BD Pharmingen); cycloheximide (Calbiochem); G418 (Cellgro); anti-VEGF monoclonal 
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antibody (R&D); anti-HIF-1α polyclonal antibody and anti-β-actin monoclonal antibody 
(Santa Cruz Biotechnology); anti-HIF-1α monoclonal antibody (NOVUS Biologicals); 
anti-Ph
NA3, was used as control.  Primary 
MEFs w
ons) were used for the Western blot analyses.  Horseradish peroxidase-
onjugated sheep anti-mouse and donkey anti-rabbit or anti-goat secondary antibodies 
:5000 dilutions, respectively.  The signal was developed with 
uperSignal West Pico Chemiluminescent Substrate (PIERCE). 
ospho-Akt (Cell Signaling). 
Generation of Stat3 knockdown tumor cell lines and Stat3 knockout mouse 
embryonic fibroblasts (MEFs) - MCF-7 breast cancer cells, DU145 prostate cancer cells 
and A2058 melanoma cells were cultured in high-glucose RPMI 1640 supplemented with 
10% FBS and penicillin–streptomycin.  The Stat3siRNA oligonucleotide, AATTAAAA 
AAGTCAGGTTGCTGGTCAAATTCTCTTGAAATTTGACCAGCAACCTGACTTCC, 
was inserted into pSilencer 1.0-U6 siRNA expression vector (Ambion).  To generate 
siRNA/Stat3 stable tumor cell clones, the siRNAStat3 expression vector was 
cotransfected with pcDNA3 into MCF-7 and A2058 cells using Lipofectamine 
(Invitrogen), followed by G418 (1 mg/ml) selection.  MCF-7 and A2058 clones stably 
transfected with the empty vector, pSilencer/pcD
ere prepared from Stat3flox mice (kindly provided by Drs S Akira and K Takeda 
of Osaka University, Japan).  To generate Stat3-/- MEFs, MEFs prepared from Stat3flox 
mice were transduced with retroviral Cre vector, and selected with puromycin.  Deletion 
of the Stat3 gene in a majority of the Cre-transduced cells was confirmed by PCR and 
Western blot analysis.  Control Stat3+/+ MEFs were generated from Stat3flox mice (29), 
but the MEFs were transduced with a control empty retroviral vector. 
Western blot analysis - MCF-7 cells and MEFs were serum starved for 20 h in 
serum-free medium before exposure to IL-6 for 6 h. 50 µg of nuclear or whole-cell 
extracts was used for Western blot analysis. HIF-1α rabbit polyclonal antibody (H-206) 
(1:500 dilution), HIF-1β mouse monoclonal antibody (1:1500 dilution), Akt1 mouse 
monoclonal, anti-phospho-Akt rabbit polyclonal and anti-VEGF monoclonal antibody 
(1: 1000 diluti
c
were used at 1:2000 and 1
S
Electrophoretic mobility shift assay (EMSA) - Stat3 DNA-binding assays were 
performed as described previously (19)  
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Northern blot analysis - TRIzol reagent (Invitrogen) was used to isolate total 
RNAs, which were fractionated by 1% agarose–formaldehyde gel electrophoresis, 
followed by transferring onto nylon membranes and hybridization with 32P-labeled 
human HIF-1α cDNA. 
Pulse-label assays - Pulse-label assays were performed according to previously 
described methods (8).  Briefly, MCF-7 tumor cells (2 106) were plated in a 10-cm 
dish, starved for 20 h and treated with 20 ng/ml IL-6 for 30 min in methionine-free 
acturer's procedure 
(Prome
DMEM.  Before harvesting cells, [35S]Met-Cys was added to final concentration of 0.3 
mCi/ml and pulse-labeled for 20–40 min. Preparation of extracts and 
immunoprecipitation with HIF-1α antibody was carried out as described (8). 
Cloning and analysis of human Akt1 promoter - To clone the Akt1 promoter, a 
DNA fragment containing Akt1 genomic sequences upstream of the translational start site 
was obtained by screening a human placenta genomic library (Stratagene) with a 5' 
cDNA fragment of the Akt1.  We used the following primers for subcloning of Akt1 
promoter region: (5') upstream region 5'-GGCTAGCCACAAAGGACTGTGACC-3'; (3') 
downstream region 5'-GCTTCCTTT GCTTCTCCCAGAGG-3'. PCR amplified 2.2-kb 
Akt1 promoter fragment was subcloned into the pGL3 vector at BglII-HindIII sites 
(Promega).  The construct was confirmed by DNA sequencing. Reporter assays were 
performed using the luciferase assay system according to the manuf
ga). 
Chromatin immunoprecipitation (ChIP) assays - Soluble chromatin was prepared 
from a total of 2 107 HEK293 cells that were transiently transfected with v-Src and wt-
Stat3 expression vectors.  Immunoprecipitation was performed with either an anti-
STAT3 antibody or an unrelated antibody (Akt1 antibody).  Following extensive 
washing, the immunoprecipitates were crosslinked and treated with proteinase K and 
RNase A. Purified DNA was subjected to PCR. The sequences of the PCR primers used 
are as follows: region 1 forward (+): 5'-GGATAAAGTGTGCTCAGGTGAGGG-3', 
reverse (-) : ATTCTAGGCTTAGAGCCTCCA GCC-3'; region 2 forward (+) : 5'-ACTC 
AGCA
eactions cover the 2.2 kb Akt1 promoter.  PCR  
AGCTCTCAGGCTCTGG-3', reverse (-) : 5'-CATTTACTGAACACC CACTTG 
CG-3'. The two fragments from the PCR r
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produc
 guidance and approved protocols.  2 
ts were resolved on an agarose gel and visualized by BioImage. 
In vivo tumor experiments and matrigel assays - Athymic (nu/nu) 6-week-old 
male mice (NCI) were maintained under pathogen-free conditions in accordance with 
established institutional 106 A2058 cells were 
injected to induce tumors. After tumors reached 3–5 mm in diameter, mice were injected 
(i.v.) with either vehicle (10% DMSO/PBS) or 5 mg/kg CPA-7 twice weekly.  Matrigel 
assays were performed as described previously (21).  Briefly, 2 106 MCF-7 tumor cells 
stably transfected with either an empty control vector or Stat3siRNA expression vector 
were suspended in 100 µl PBS and mixed with 0.5 ml Matrigel (Collaborative 
Biochemical Products) on ice, followed by subcutaneous injection into the abdominal 
midline
s (CD31-positive areas) were selected using the histogram and dropper tools.  
The Co  
r 
, 
 of nude nice.  On day 5, Matrigel plugs were harvested for photography and 
hemoglobin content assays.  Hemoglobin quantification was carried out by the Drabkin 
method.  Briefly, after dissecting away all the surrounding tissue, Matrigel pellets were 
melted at 4 °C and assayed for hemoglobin content (Drabkin's reagent kit, Sigma). 
Angiogenesis measurements - Angiogenesis quantification was performed in a 
double-blinded fashion by the staff at the Analytic Microscopy Core of Moffitt Cancer 
Center and Research Institute.  SPOT Advanced imaging software (v. 3.4.5) was used to 
capture bright-field images from two fields for each sample.  Data for these image files 
were collected using the Count/Size function of Image-Pro Plus software (v. 5.0).  The 
blood vessel
unt function was then used to total the number of regions (CD31-positive areas). 
Measurement was selected within the Count/Size function and the Area tool was utilized 
to calculate the area of CD31-positive blood vessels in each entire field.  Every field in 
each of the entire tumor section was examined and included in the analysis. 
 
Results 
 
Activation of IL-6R induces HIF-1α expression - VEGF upregulation in cance
cells is induced by a large number of receptor and nonreceptor oncoproteins (8, 13, 16, 21
28, 30, 31).  While many of these oncogenic growth-signaling molecules have been  
        63 
shown to induce HIF-1α protein synthesis (9), whether IL-6 could upregulate HIF-1α 
express
evated 
F-1β –
tal Akt protein 
ecific for Akt1. 
IL-6 treatment also increases Stat3 DNA-
binding activity, and expression of VEGF. 
This figure worked by Xu, Q. 
blot analysis indi
c).   
     
ion has not yet been reported.  As IL-6R overactivation has been observed in a 
number of human cancers (25), we addressed whether IL-6R engagement activates HIF-
1α. HIF-1α protein levels in MCF-7 human breast tumor cells were induced by IL-6 in a 
dose-dependent manner (Fig. 15a). 
It has been well documented that while hypoxia-induced HIF-1α expression is 
regulated at the protein stability level, HIF-1α expression induced by oncogenic growth 
signaling is regulated at the protein synthesis level (8, 9. 31).  An earlier report has also 
shown that HIF-1α expression is controlled at the RNA level in rodent cells (32).  We 
therefore determined how IL-6R activation might regulate HIF-1α expression.  Northern  
 
Figure 15.  Activation of IL-6 receptor 
induces HIF-1α expression.  (a) MCF-7 
breast cancer cells treated with IL-6 for 6 h 
at the indicated concentrations had el
expression of HIF-1α – but not HI
 
protein.  Nuclear proteins were used for the 
Western blot analysis.  (b) Northern blot 
analysis of HIF-1α mRNA levels in MCF-7 
tumor cells treated with IL-6 at the indicated 
concentrations for 6 h.  Ribosomal RNAs 
(28S and 18S) are internal controls for RNA 
loaded in each lane.  (c) Inhibiting protein 
synthesis by cycloheximide (CHX)/(100 µm) 
indicated a reduction of HIF-1α protein with 
time, as shown by Western blot analysis. 
Cells were treated by IL-6 (20 ng/ml) for 6 h 
before adding CHX.  (d) IL-6 at 20 ng/ml 
increases levels of both total and activated 
Akt proteins in MCF-7 tumor cells as shown 
by Western blots.  The antibody used for 
detecting phospho-Akt (pAkt) recognizes both 
Akt1 and Akt2.  For the to
detection, the antibody is sp
 
cates that HIF-1α induction is not regulated at the mRNA level in MCF-
7 breast cancer cells exposed to IL-6 (Fig. 15b).  Blocking protein synthesis by 
cycloheximide (CHX) abrogated the increase in HIF-1α level induced by IL-6 (Fig. 15
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As the half-life of HIF-1α is only approximately 5 min, the disappearance of HIF-1α 
protein in the presence of CHX for 15 min or longer suggest that IL-6 signaling affects 
HIF-1α expression at the protein synthesis level, consistent with the previously reported 
mechanism for growth signaling-induced HIF-1α regulation (8, 31). 
It has been also demonstrated that PI3K/Akt pathway is required for growth 
signalin
cells, which have little endogenous constitutive S at3 activity, stimulated Stat3 DNA-
binding (Fig. 1d). Activation of Akt and Stat3 by I
of both HIF-1α and VEGF (Fig. 1c and d). 
 
Stat3 is obligatory for IL-6-induced HIF-1
study showed that in cervical cancer cells with co
Stat3 caused inhibition of VEGF expression (16). 
upstream Akt and thereby is expected to inhibit HIF
VEGF expression (16).  To investigate whether S
expression, we first determined HIF-1α inductio
stably expressing siRNA/Stat3.  MCF-7 tumor 
control plasmid vector (pSilencer 1.0-U6) or the
The effect of the siRNA inhibition of Stat3 in the t
selection was confirmed by Western blot analysis a  
urthermore, while control cells exhibit detectab α 
rotein was detected in MCF-7 cells stably transfected with siRNA/Stat3 with and 
g-induced HIF-1α upregulation (8, 31).  The ability of IL-6 to activate PI3K/Akt 
signaling has been reported (26).  Activation of IL-6R in MCF-7 cells increased Akt 
activity as shown by phosphorylation of AKT, and to a lesser degree, the total protein 
level of AKT1 (Fig. 15d).  In addition to PI3K/Akt, the ability of IL-6 signaling to 
activate Jak/Stat3 pathway has been documented (19).  Activation of IL-6R in MCF-7 
t
L-6 was accompanied by an induction 
α and VEGF expression - A previous 
nstitutively-activated IL-6R, blocking 
 In contrast, targeting PI3K, which is 
-1α expression, did not interfere with 
tat3 has a regulatory role in HIF-1α 
n by IL-6R signaling in tumor cells 
cells were transfected with either a 
 same vector encoding siRNA/Stat3.  
umor cells surviving G418 antibiotics 
nd by EMSA (Fig. 16a, bottom panels). 
little HIF-1F le HIF-1α expression, 
p
without IL-6 stimulation (Fig. 16a).  Moreover, whereas a significant induction of 
VEGF by IL-6 stimulation was observed in control MCF-7 cells, no VEGF expression 
was detectable in IL-6-treated MCF-7 cells expressing siRNA/Stat3 (Fig. 16a).  These  
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data suggest that Stat3 is necessary for both basal and IL-6-induced upregulation of HIF-
1α and VEGF. 
 
 Figure 16. HIF-1α and VEGF 
determined by EMSA, and Stat3 protein 
level was assessed by Western blot 
analysis.  (b) Blocking Stat3 in v-Src 
transformed Balb/c 3T3 cells inhibits 
cells wer
SA
expression induced by both IL-6 receptor 
and Src is Stat3 dependent.  (a) Both 
HIF-1α and VEGF expression is 
abrogated in Stat3 knockdown MCF-7 
tumor cells.  Western blot analysis of 
HIF-1α and VEGF protein levels in 
control empty vector-transfected and 
siRNA/Stat3 expressing MCF-7 tumor 
cells.  Nuclear protein was used for 
detection of HIF-1α and cytoplasmic 
proteins from the same cells were 
analysed for VEGF expression levels. 
Stat3 DNA-binding activity was 
HIF-1α expression. 3T3 and v-Src/3T3 
e infected with MSCV 
containing either a control vector 
encoding GFP or a dominant-negative 
Stat3 mutant, Stat3D.  Western blot 
analysis to detect protein levels and 
EM  to detect Stat3 DNA-binding 
activity were shown.  SP-1 nuclear 
protein was used here as an internal 
loading control.  (c) Blocking Stat3 
signaling by siRNA in the A2058 tumor 
cells, which exhibit activated c-Src, 
decreased the expression of both HIF-1α 
and VEGF proteins.  A decrease in 
Stat3 DNA-binding and Stat3 protein 
levels in the siRNA/Stat3 A2058 tumor 
cells is shown by EMSA and Western blot 
analysis, respectively. This figure worked 
by Xu, Q 
 
Stat3 is required for HIF-1α and VEGF induction by activated Src and Her-2/Neu 
- Like IL-6R signaling, Src tyrosine kinase is known to activate both Jak/Stat3 and 
PI3K/Akt pathways (23, 33).  Our previous work has demonstrated that Src tyrosine  
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kinase activity-induced VEGF expression requires Stat3 in mouse 3T3 fibroblasts (21), 
while other studies have shown that Src activity induces the protein synthesis of HIF-1α 
1).  The question remains whether Stat3 is also required for HIF-1α upregulation 
duced by Src activity.  Our published data de
Src3T3 cells inhibits VEGF expression (21).  Data
3T3 cells with v-Src leads to an increase in HIF-1α
signaling in v-Src/3T3 cells with Stat3D, a domina
Src-induced HIF-1α expression (Fig. 16b).  We 
would inhibit Src-induced HIF-1α expression in h
exhibit activated endogenous c-Src and is res
Interrupting Stat3 signaling in A2058 tumor cells 
protein expression (Fig. 16c).  Moreover, VEGF
activity in A2058 melanoma cells were downregu
(Fig. 16c).  These data demonstrate that blocking
both HIF-1α and VEGF induced by c-Src activi
PI3K/Akt pathways. 
In addition to Src tyrosine kinase, activat
induce HIF-1α expression through the PI3K/Akt p
heregulin induces HIF-1α expression in MCF-7 ce
displayed little endogenous activated Stat3, stimula
detectable levels of activated Stat3 (Fig. 17a).  Th
to an increase in HIF-1α expression in control but 
cells (Fig. 17b).  Moreover, Her-2 activation by he
in control but not Stat3/siRNA MCF-7 tumor cells
Stat3 in Her-2-induced HIF-1α and VEGF 
ngagement/overactivity is known to activate Stat3 signaling (22).  Our results using 
Stat3 a
(3
in monstrated that blocking Stat3 in v-
 in Figure 16b show that transforming 
 protein level, whereas blocking Stat3 
nt-negative Stat3 mutant, abrogates v-
further tested whether blocking Stat3 
uman A2056 melanoma cells, which 
ponsible for Stat3 activation (23).  
by siRNA/Stat3 also reduced HIF-1α 
 expression and Stat3 DNA-binding 
lated in the presence of siRNA/Stat3 
 Stat3 signaling inhibits expression of 
ty known to activate both Stat3 and 
ion of Her-2/Neu has been shown to 
athway (8).  As shown in Figure 17a, 
lls.  While MCF-7 breast cancer cells 
tion with heregulin at 100 ng/ml led to 
is upregulation of Stat3 corresponded 
not siRNA/Stat3 MCF-7 breast cancer 
regulin upregulates VEGF expression 
, suggesting a critical requirement for 
expression.  Like Her-2, EGFR 
e
ntisense oligonucleotide indicate that Stat3 is also required for both HIF-1α and 
VEGF upregulation by EGF stimulation in DU145 human prostate cancer cells (data not 
shown). 
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Stat3 regulates Akt gene expression - Our data thus far demonstrate that Stat3 is 
required for HIF-1α induction by various growth signaling molecules.  The question 
remains as to how Stat3 might regulate HIF-1α expression. Several reports have shown 
that HIF-1α induction by Her2/neu and Src is mediated by the PI3K/Akt signaling 
pathway (8, 9, 31, 34).  While the ability of Her2/neu to activate Akt has been 
demonstrated (35, 36), whether Stat3 is involved in regulating Akt1 expression or activity 
remains to be explored.  IL-6 signaling-induced total Akt1 protein level was less in Stat3 
knockdown MCF-7 breast cancer cells than control MCF-7 cells (Fig. 18a, left).  To 
eliminate the possibility that tumor cells might have unique mutations that 
nonspecifically influence these findings, we performed the same experiments using 
primary mouse embryonic fibroblasts (MEFs) with or without the Stat3 alleles (Fig. 18a, 
right). 
 
Figure 17. Her-2/Neu-induced HIF-1α 
and VEGF expression is Stat3 dependent. 
(a) Heregulin upregulates HIF-1α 
expression in MCF-7 breast cancer cells 
 
binding activity by heregulin in MCF-7 is 
detected by EMSA.  (b) HIF-1α and 
VEGF upregulation by Her-2 activation 
requires Stat3.  Western blot analysis of 
control vector and siRNA/Stat3-
transfected MCF-7 cells showed a 
requirement for Stat3 in both basal and 
Her-2-induced HIF-1α and VEGF 
upregulation. .  This figure worked by Xu, 
Q. 
 
We next investigated whether Stat3 might regulate Akt gene expression. 
Transcriptional regulation of the Akt1 gene by Stat3 was investigated by cloning a 2.2 kb 
Akt1 promoter DNA fragment, beginning 2.2 kb upstream from the ATG translation start 
site, into the luciferase reporter vector, pGL3.  Cotransfecting the pGL3/Akt1 promoter 
construct with an expression plasmid encoding a constitutively activated Stat3 mutant, 
Stat3C, into NIH 3T3 cells resulted in upregulation of Akt1 promoter activity (Fig. 18b). 
The 2.2 k
(Western blot).  Increased Stat3 DNA-
 
b Akt1 promoter region contains 13 consensus STAT DNA-binding  
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sequen
transfected with either a control vector or 
the siRNA/Stat3 expression vector in the 
presence or absence of IL-6 (left panel). 
ME
trea
subj
pan
prom
afte
repo
(Sta
DNA
the 
HEK
vect
Stat
primers r
2.2 Akt-1 promoter (Pro). This figure 
d  
ces,TT(N)4-6AA.  We identified Stat3 binding to the Akt1 promoter region by 
chromatin immunoprecipitation (ChIP) assays, followed by PCR using two pairs of Akt1 
promoter specific primers.  For the ChIP assays, expression vectors encoding v-Src and 
wild-type Stat3 were transfected into HEK293 cells.  Results from ChIP assays indicate 
that Stat3 protein binds to both fragments of the 2.2 kb Akt1 promoter region (Fig. 18c).  
This together with Western blot analyses data demonstrate that Stat3 participates in 
regulating Akt1 expression, suggesting that Stat3 increases HIF-1α levels through Akt1. 
 
Figure 18. Stat3 signaling is required and 
sufficient for Akt1 expression.  (a) 
Western blot analysis of protein samples 
prepared from MCF-7 cancer cells 
 
worked by Park, S. 
 
Effects of small-molecule Stat3 inhibitors on HIF-1α and VEGF expression - To 
date, several Stat3-selective small molecule inhibitors – phosphopeptide (37) an
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Fs with or without the Stat3 alleles 
ted with vehicle or IL-6 were also 
ected to Western blot analysis (right 
el).  (b) Stat3 increases Akt1 
oter activity.  Luciferase activity 
r cotransfecting the Akt promoter/luc 
rter construct and an activated Stat3 
t3C) expression vector at indicated 
 concentrations.  (c) Stat3 binds to 
Akt1 promoter.  ChIP assays of 
293 cells transfected with expression 
ors encoding v-Src and wild-type 
3, followed by PCR using two pairs of 
ecognizing two fragments of the 
peptidomimetics (38) as well as platinum (IV) complexes (38) – have been shown to 
inhibit Stat3 signaling with IC50 values in the range of 5–250 µM.  We therefore 
determined whether interrupting Stat3 signaling by some of the new small-molecule Stat3 
inhibitors could block HIF-1 and VEGF expression.  Of the three tumor cell lines used 
in this study, A2058 and DU145 display constitutively activated Stat3 (23, 39), whereas 
MCF-7 tumor cells do not (Figure 16).  Treating DU145 and A2058 tumor cells with a 
Stat3 inhibitor CPA-7 led to a reduction in Stat3 DNA-binding activity and expression of 
oth HIF-1α and VEGF (Fig. 19a, b). 
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Targeting Stat3 inhibits tumor angio
PI3K/Akt pathways - Our data thus far identif
VEGF expression induced by several major 
whether blocking Stat3 would result in inhibiti
human melanoma tumors, which display activated Stat3 due to activation of endogenous 
c-Src, were allowed to reach approximately 5 mm in diameter before mice were treated 
with the Stat3 inhibitor, CPA-7.  Although in vivo Stat3 inhibition by CPA-7 in tumors 
sted only one day, treating mice with CPA-7 twice a week (i.v.) significantly inhibited 
mor growth (Fig. 20a).  To assess whether antiangiogenesis effects might contribute to 
CPA-7-
or  
b
igure 19. Targeting Stat3 by a small-
olecule Stat3 inhibitor reduces HIF-1α 
nd VEGF expression in tumor cells.  (a) 
reatment of DU145 prostate cancer cells 
ith CPA-7 (20 µM) resulted in lowered 
tat3 DNA-binding activity (bottom, 
MSA) and expression of both HIF-1α and 
EGF proteins (Western blot).  (b) CPA-7 
reatment (20 µM) of A2058 melanoma 
umor cells resulted in inhibition of Stat3 
ctivity and HIF-1α and VEGF expression. 
his figure worked by Xu, Q. 
genesis induced by both Jak/STAT and 
y Stat3 as an effective target for blocking 
activators of VEGF. We next determined 
on of tumor angiogenesis in vivo.  A2058 
la
tu
induced tumor growth inhibition, we harvested three tumors from mice treated 
with both vehicle and CPA-7 on day 8 to compare their vascular density.  Since tum
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volumes of CPA-7-treated mice were smaller than control mice, which might potentially  
 
Figure 20. Blocking Stat3 inhibits tumor growth and angiogenesis induced by both Stat3 and Akt. 
(a) Targeting Stat3 in human tumors inhibits tumor growth, which is accompanied by a reduction 
in tumor vessel density.  Nude mice bearing subcutaneous A2058 tumors were treated with a 
Stat3 inhibitor, CPA-7, at 5 mg/kg twice weekly.  Top: in vivo tumor Stat3 activity after treating 
with CPA-7 at indicated times.  Bottom: tumor growth after CPA-7 treatment, DMSO=10%. n=8 
for each group; *P<0.05.  (b) CPA-7 inhibits tumor angiogenesis.  Representative microscopic 
photos of CD31 antibody-stained tumor sections (  10).  The bar graph shows the means of 
neovascular densities s.d.  The entire area of each tumor was photographed and included in 
the analysis; three tumors from each group were analysed.  Two additional DMSO-treated 
small-sized tumors were also included, **P=0.004.  (c) Tumor angiogenesis as determined by the 
Matrigel assays.  Top: proliferation rates of MCF-7 cells stably transfected with either a control 
vector or Stat3siRNA expression vector.  Bottom: microphotos of indicated Matrigel plugs 
harvested from mice 5 days after implantation.  Control and Stat3 knockdown (siRNA) MCF-7 
tumor cells were treated with IL-6 to activate both Stat3 and PI3K/Akt pathways.  For each 
group, n=4 This figure worked by Briggs, J. 
 
influence tumor vessel density and therefore complicate interpretation of data, we  
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included an additional control group that was given vehicle treatment when tumor 
volumes were considerably smaller.  Thus, several vehicle-treated tumors of comparable 
sizes to CPA-7-treated tumors were obtained for measuring microvessel density.  
Microvessel density was significantly reduced in tumors from CPA-7-treated mice when 
compared to vehicle-treated groups (no difference was detected between the two vehicle-
treated groups) (Fig. 20b). 
Data from the above experiments indicate that targeting Stat3 inhibits tumor 
growth involving antiangiogenesis effect.  Since blocking Stat3 is known to induce 
tumor cell death and/or growth inhibition, we used an independent system, which does 
not involve tumor cell apoptosis, to verify Stat3 as an effective target for antiangiogenesis.  
Our results indicate that siRNA/Stat3 transfected MCF-7 tumor cells, having minimal 
endogenous Stat3 activity, survive well in short-term culture.  While MCF-7 tumor cells 
failed to form tumors beyond 1–2 mm, which prevents us from analyzing microvessel 
density within tumors, control and siRNA/Stat3 MCF-7 tumor cells offer a unique 
opportunity to use Matrigel assays to determine Stat3's role in tumor angiogenesis 
independent of tumor cell survival/apoptosis.  For the duration of the Matrigel assay, we 
monitored proliferation rates of control and siRNA/Stat3 MCF-7 cells in culture.  No 
obvious differences in their growth rates were noted during the 5 days – time needed for 
completing the Matrigel assay in vivo (Fig. 20c, left panel).  As our results demonstrate 
eir siRNA/Stat3 counterpart (Fig. 20c).  These results demonstrate that blocking Stat3 
 and  
that Stat3 is required for HIF-1α and VEGF upregulation mediated by both Jak/STAT and 
PI3K/Akt pathways, Stat3 knockdown tumor cells might have reduced tumor 
angiogenesis even when both signaling pathways are activated.  To test this hypothesis, 
control and siRNA/Stat3 MCF-7 tumor cells were serum-starved for 4 h, followed by IL-
6 stimulation to activate both Jak/STAT and PI3K/Akt pathways.  The MCF-7 tumor 
cells were then mixed with Matrigel and implanted in vivo. Angiogenesis was 
considerably reduced in the Matrigel containing siRNA/Stat3 MCF-7 tumor cells 
compared to that of control MCF-7 cells (Fig. 20c).  Moreover, when stimulated by IL-6, 
the control MCF-7 tumor cells were able to induce substantially more angiogenesis than 
th
in tumor cells abrogates tumor angiogenesis induced by activation of both PI3K/Akt
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Jak/Stat3 pathways. 
 
Discussion 
 
Our data demonstrate that Stat3 is a key regulator of VEGF induced by multiple 
oncogenic growth signaling pathways commonly activated in cancer (19, 22).  The 
ability of Stat3 to activate the VEGF gene as a direct transcriptional activator has 
previously been demonstrated (14, 15).  The data presented here show that Stat3 is also 
required for growth signaling-induced expression of HIF-1, the only other known 
inducible transcription factor of the VEGF promoter.  A requirement of Akt1 signaling 
for growth signal-induced HIF-1α protein synthesis has been previously established (9).  
Our results also identify Akt1 as a target gene of Stat3.  Moreover, our data show that 
blocking Stat3 signaling inhibits tumor growth, reduces angiogenesis and abrogates 
tumor angiogenesis induced by simultaneous activation of Jak/Stat3 and PI3K/Akt 
signaling pathways.  However, whether Stat3 contributes to HIF-1 expression/activity 
independent of Akt remains to be determined. 
Our data substantiate how targeting a single transcription factor potentially 
neutralizes the oncogenic potential of a multitude of upstream genetic aberrations (20, 
22).  As proposed by Darnell, transcription factors pose ideal targets for cancer therapy 
because a large array of diverse oncogenic/angiogenic proteins feed into a relativelysmall 
number of signaling pathways (20).  Oncogenic signaling pathways in turn converge 
upon a limited set of nuclear transcription factors, the final 'switches' determining gene 
expression patterns and ultimately leading to malignancy (20).  Recent work by Gray et 
al. also demonstrates that binding of both Stat3 and HIF to the VEGF promoter is 
required for optimal VEGF expression under hypoxia (40).  Together with our findings, 
these results add a new dimension to the importance of targeting key transcription factors 
for cancer therapy. 
Although direct inhibition of specific transcription factors with small molecules 
has been perceived to be a major challenge, Stat3 peptide inhibitors based upon rational 
design have been obtained (37).  Moreover, combinatorial chemical libraries are being  
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used to systematically convert these short peptides to peptidomimetics.  The 
hosphopeptide sequence, PY*LKTK, and its peptidomimetic derivatives disrupt Stat3 
 with biological implications (38).  In addition to structure-based rational 
pproaches, the availability of constructs in which luciferase expression is under the 
control
tube formation (41-43).  It has been 
demons
dendritic cells, leading to inhibition of dendritic cell maturation.  
Conver
p
dimerization
a
 of a Stat3-dependent responsive element allows cell-based, high-throughput 
screens of random chemical libraries for identifying specific inhibitors of Stat3.  Our 
results here demonstrate that Stat3 inhibitors identified from such screens (38) also block 
the expression of HIF-1α and VEGF.  Furthermore, inhibiting Stat3 by CPA-7 in vivo 
can inhibit tumor growth and tumor angiogenesis.  The success of generating the first 
lead compounds inhibiting Stat3 activity and angiogenesis raises the possibility that 
targeting Stat3 with potent small-molecule drugs, actively being developed and/or 
modified, may provide an exciting novel approach for clinical antiangiogenesis therapy. 
This work demonstrates that Stat3 is required for both HIF-1 and VEGF 
expression induced by oncoproteins commonly activated in cancer.  Stat3 also regulates 
angiogenesis at another critical level:  Stat3 signaling is necessary for endothelial cell 
proliferation, migration and microvascular 
trated that VEGFR signals through Stat3 in endothelial cells (42).  Blocking 
Stat3 in endothelial cells has been demonstrated to completely inhibit their migration and 
vessel formation (43).  Moreover, Stat3 in endothelial cells is obligatory for the 
signaling of bFGF receptor (41).  Our present study provides proof-of-concept that 
targeting Stat3 effectively blocks production of VEGF and tumor angiogenesis.  Based 
upon these findings, Stat3 emerges as a molecular target whose inhibition not only 
prevents tumor cell production of angiogenic factor(s) but also endothelial cells' response 
to these factors.  Interestingly, a similar relationship between tumor Stat3 activity and 
dendritic cell Stat3 signaling has been recently described (44).  These studies show that 
Stat3 activity promotes the production of tumor factors, including VEGF, that activate 
Stat3 signaling in 
sely, blocking Stat3 signaling in either tumor or dendritic cells abrogates tumor-
induced inhibition of dendritic cell maturation (44).  Thus, Stat3 plays a central role in 
propagating oncogenic signals from tumor cells to effector cells involved in tumor  
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angiogenesis and immune evasion.  It has been well established that blocking Stat3 
signaling in tumor cells with constitutively activated Stat3 inhibits tumor cell 
proliferation and induces apoptosis (20, 22). In diverse human cancers displaying 
dependence on persistently activated Stat3 for survival/proliferation (20, 22), targeting 
Stat3 is expected to evoke potent antitumor effects through direct tumor cell death, 
antitumor immune responses and antiangiogenesis. 
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Chapter 4 
 
dentification of 24p3 as a direct target of FOXO3a that is regulated by IL3 through 
PI3K/Akt pathway 
 
Abstract 
Pro-apoptotic protein 24p3, a member of lipocalins, is induced upon interleukin 
(IL)-3 deprivation and plays a pivotal role in induction of apoptosis in hematopoietic 
cells (1).  However, the molecular mechanism by which IL3 regulates 24p3 expression 
is currently unknown.  Here, we show that 24p3 is a direct target gene of FOXO3a and 
that PI3K/Akt mediates IL3 action on 24p3 through regulation of FOXO3a.  Inhibition 
FL5.12 cells induced 24p3 expression and 
ed cell death in the presence of IL3.  Further, constitutively active Akt largely 
ttenuated the 24p3 expression and apoptosis in response to IL3 withdrawal.  FOXO3a 
irectly binds to 24p3 promoter and induces the promoter activity.  Akt abrogates wild-
pe FOXO3a, but not Akt nonphosphorylatable FOXO3a-3A function toward 24p3 
xpression and promoter activity.  Therefore, these data indicate for the first time that 
4p3 is a direct target gene of FOXO3a and that PI3K/Akt but not MAPK mediates IL3-
gulated 24p3 expression in hematopoietic cells.  
troduction 
Apoptosis is a genetically controlled cell suicide program that has been implicated 
e development, homeostasis of multicellular 
organisms and defense mechanism against pathogens (2, 3, 4).  Apoptosis in 
hematopoietic cells can be induced by withdrawal of cytokines such as IL3 (5).  The IL3  
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exerts its survival and proliferative functions through a common signaling subunit, the βc 
ceptor.  Signal transduction events that regulate survival by IL3 are in part mediated 
y cytosolic tyrosine kinases (6).  In the absence of IL3, IL3-dependent progenitor cells 
go apoptosis (7, 8). 
Another signaling molecule that is activated by IL3 is phosphoinositide 3-kinase 
types (11).  Akt is a downstream  able to support the survival of a 
number of cell types after survival factor deprivation (4, 12, 13).  Previous study has 
also examined the ability of activated fo  to protect cells from death induced by 
ithdrawal of IL-2 in BAF/3 cells (14).  Akt activity is induced rapidly by IL3 and the 
activati
one marrow cells, human primary 
eutrophils and human peripheral blood lymphocytes.  In contrast, human primary 
HeLa cells, and Jurkat cells were not susceptible to 24p3-mediated 
poptosis (1).  In addition, 24p3 receptor (24p3R) was recently identified in the FL5.12 
cells an
re
b
under
(PI3K) (9, 10).  PI3K has been implicated in the regulation of survival in various cell 
 target of PI3K and is
rms of Akt
w
on of Akt by IL3 depends upon the activity of PI3K.  Previous studies 
demonstrated that Akt prevents IL3-dependent FL5.12 cells from IL3 depletion-induced 
apoptosis through phosphorylation of BAD (15, 16). 
Proapoptotic protein 24p3, however, has been shown to be significantly elevated 
at mRNA and protein levels in FL5.12 cells after IL3 withdrawal, which was 
demonstrated to be essential for IL3 deprivation-induced apoptosis (1).  The conditioned 
medium from IL3-deprived cells, which contains secreted 24p3, induced apoptosis in 
naïve cells, even when IL3 was present.  The 24p3 also induces apoptosis in a wide 
variety of leukocytes, indicating that IL3 deprivation enhances 24p3 transcription and 
leads to synthesis and secretes 24p3, which induces apoptosis through an autocrine 
manner (1).  In addition to murine FL5.12 pro-B cells, many other cell types were 
susceptible to 24p3-mediated apoptosis, which include murine primary thymocytes, 
murine primary splenocytes, murine primary b
n
macrophages, 
a
d found to bind to iron-bound and iron-free forms of 24p3 (17).  However, their 
effects on cell survival are different.  Iron-bound 24p3 increases intracellular iron 
concentration without promoting apoptosis; iron-free 24p3 decreases intracellular iron 
levels, which induces expression of the proapoptotic protein Bim, resulting in apoptosis.   
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Recent studies also showed that BCR-ABL oncoprotein activates expression of 
24p3 but inhibits 24p3R transcription in BCR-ABL positive cells.  The secreted 24p3 
leads neighboring cells to apoptosis (17, 18).  By inhibiting BCR-ABL, 
imatinib/Gleevec inhibits 24p3 transcription and induces 24p3R expression.  As a result, 
BCR-A
es IL3 down-regulation of 24p3.  
Activa
BL positive chronic myeloid leukemia cells undergo the programmed cell death 
(18).   
Members of forkhead transcription factor family play a proapoptotic role in 
neurons or hematopoietic cells subjected to growth factor or cytokine withdrawal.   Akt 
antagonizes FOXO proapoptotic function through phosphorylation of serine/threonine 
residues leading to FOXO translocation from the nucleus to the cytoplasm (19).  In this 
report, we show that FOXO3a, a major member of the FOXO family, directly binds to 
24p3 promoter and induces 24p3 transcription in response to IL3 withdrawal.  Inhibition 
of PI3K/Akt but not MAPK pathway antagoniz
tion of Akt inhibits 24p3 expression and apoptosis that are induced by IL3 
deprivation in FL5.12 cells through phosphorylation of FOXO3a. 
 
Material and methods 
 
Cell Culture, Reagents and Transfection – IL3-dependent FL5.12 murine pro-B 
cells were cultured in RPMI-1640 medium supplemented with 10% fetal bovine serum 
and 10% WEHI-3B-conditioned medium (a source of IL3) (20).  PD98059, Wortmannin, 
and LY294002 were obtained from Calbiochem.  Human recombinant IGF-1 was 
purchased from Invitrogen.  Electroporation was used for transfection of FL5.12 cells.  
Cells were electroporated in 1 X 106 cells/400 µl at 275 V, 960 µF with with 25 µg of 
plasmid DNA.  Stable clonal cell lines were established after selection with G418 (600 
µg/ml).   
Plasmids – Human 24P3 gene is amplified with nested PCR using a human 
leukemia myeloid cDNA library (Stratagene).  The primers were 5-1: 5’-
AGCAGCCACCACAGCGCCTG-3’, 5-2: CCGGAATTCGGATCCATGCCCCTAGGT 
CTCCTGTG-3’, 3-1: 5’-TCAATGGTGTTCGGGCTGGTG-3’, 3-2: 5’TGCTCTAGACT 
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CGAG
TATCGCTCTGTTCCAGGC-3’, 5’-2: TTCAGATCTCCAGGCTAAAG 
TGCAA
f empty vector.  After 
6 h of transfection, luciferase activity was measured using a luciferase assay reagent 
on efficiency was normalized by co-transfection with 　-
alactosidase expressing vector.  The 　-galactosidase activity was measured by using 
Galato
s performed according to standard procedure.  Briefly, the cells were lysed 
with N
 
GCCGTCGATACACTGGTCGATTG-3’.  Amplified DNA fragments were 
subcloned into the FLAG-tagged mammalian expression vector pcDNA3.5-GW-FLAG 
and Glutathione S-Transferase fused vector pGEX-4T-1.   For cloning of human 24p3 
promoter, a DNA fragment containing 24p3 promoter sequences were amplified from 
human genomic DNA using the nested PCR and primers (5’-1: 5’-
AAGACAGAA
AGGGG-3’, 3-1: 5’-CTGCTGGGCCTGGCAGGGGTGGAAG-3’, 3-2: 5’-
CCCAAGCTTAGGAGGTGGCGAGTGAGAGG-3’).  Amplified DNA fragments were 
subcloned into the luciferase reporter vector pGL3 (Promega).  The integrity of all 
constructs was confirmed by DNA sequencing.  HA-FOXO3a and Flag-FOXO3a-3A 
were kindly provided by Dr. B M T Burgering and Akt plasmids have previously been 
described (21). 
Luciferase Reporter Assay – FL5.12 or HEK293 cells were cultured in 12-well 
plates and transiently transfected with pGL3/24p3-Luc, Foxo3a and/or Akt.  The amount 
of DNA in each transfection was kept constant by the addition o
3
(Promega).  Transfecti
g
-Light (Tropix).  Luciferase activity was expressed as relative luciferase activity. 
Northern and Western Blot Analysis – Northern blot analysis of total cellular RNA 
was performed according to standard procedure.  Briefly, total RNA was 
electrophoresed in 1.0% formaldehyde-agarose gels, transferred to Duralon-UVTM 
membrane (Srtatagene), and then hybridized with [32p]-labeled 24p3 cDNA probe.  
Membrane was exposed to X-ray film and the mRNA levels were visualized and 
quantitated using PhosphorImager analysis (Molecular Dynamics).  Western blot 
analysis wa
P-40 lysis buffer (50 mM Tris-HCl pH 8.0, 150 mM NaCl, 1% NP-40, 1% Sodium 
deoxycholate, 1 mM EDTA, 1 mM PMSF, 5 µg/ml aprotinin and 5 µg/ml leupeptin), 
separated in a SDS-PAGE and immunoblotted with appropriate antibodies as indicated in
the figure legends. 
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Cell Viability – Cell viability was determined by 3-(4,5-dimethylthiazol-2-yl)-5-
(3-carboxymethoxyphenyl)-2-(4-sulphophenyl)-2H-tetrazolium (MTS) dye-reduction 
assay measuring mitochondrial respiratory function (22).  FL5.12 cells (104 cells/well) 
were plated in 96-well plate and treated with various conditional media and inhibitors as 
indicated in the figure legends.  Cells were incubated with MTS dye (20 µl/well) for 2 h 
and solubilized with 25 µl/well of 10% sodium dodecyl sulphate (SDS) at room 
temperature for 4 h.  Absorbance was determined in a Titertek plate reader at 490 nm.   
ChIP Assay – ChIP assay was performed essentially as previously described (23). 
Briefly, solubilized chromatin was prepared from a total of 2 X 10
  
 16.7 mM Tris•HCl, pH 8.1, 0.01% SDS, protease inhibitors), and 
preclea
 
sites w
e activity was measured with the Caspase-Glo® 3/7 Assay system  
7 asynchronously 
growing FL5.12 cells that were electrophorated with HA-Foxo3a.  The chromatin 
solution was diluted 10-fold with ChIP dilution buffer (1.1% Triton –100, 1.2 mM EDTA, 
167 mM NaCl,
red with protein-A beads.  The precleared chromatin solution was divided and 
utilized in immunoprecipitation assay with either an anti-Foxo3a antibody (Upstate) or 
anti-actin antibody.  Following wash, the antibody-protein-DNA complex was eluted 
from the beads by resuspending the pellets in a buffer (1% SDS and 0.1 M NaHCO3) at 
room temperature for 20 min.  After reverse-crosslink, protein and RNA were removed 
by incubation with 10 µg of proteinase K and 10 µg of RNase A at 42 °C for 3 h.  
Purified DNA was subjected to PCR with primers specific for 3 putative Foxo3a-binding
ithin the 24p3 promoter.  The sequences of the PCR primers used are as follows: 
region 1 forward (-): 5’-CAGGAGCAGCAAACAGGTAAATCAATGGCC-3’, reverse (-
): 5’-CATCCCTCTGTCCCTGGCCATAACCTTG-3’; region 2 forward (-): 5’- TACCT 
TTGAAAGCAGCCACAAGGGCGTGG-3’, reverse (-): 5’-AACAGACCCTGTGCAGC 
TTCCTTGTCTGG-3’; region 3 forward (-): 5’- TTGCTCAACCTTGCACAGTTCCGA 
CCTGG-3’, reverse (-): 5’-GGCCATGGTTTCCACAGCTACATGGTCTG-3’.  
Amplified PCR products were resolved in 1.2% of agarose gel and visualized by 
BioImage. 
DNA Fragmentation and Caspase Activity –Approximately 2 g DNA obtained 　
from cells treated with different reagents was separated on 1.5% agarose gel and 
visualized.  Caspas
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accordi
PI3K/Akt, but not MAPK, pathway mediates IL3 regulation of 24p3 and cell 
s were treated with indicated agents and immunoblottted with 
indicate
ng to manufacture’s procedure (Promega). 
 
 
Figure 21.  
survival.  (A) FL5.12 cell
d antibodies.  (B and C) FL5.12 cells were treated with indicated agents and cell 
death was measured by MTS and DNA fragmentation.  (D and E) FL5.12 cells were 
stably transfected with constitutively active Akt or DN-Akt and treated with indicated 
agents.  Cell death was examined as panels B and C. 
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Results 
 
PI3K/Akt but not MAPK pathway inhibits 24p3 expression induced by IL3-
deprivation and mediates IL3 survival signal in FL5.12 cells.  Previous studies have 
demonstrated that IL3 activates Akt that leads to phosphorylation of BAD and cell 
survival in IL3-dependent FL5.12 cells.  Deprivation of IL3 reduces Akt activation and 
BAD phosphorylation that results in programmed cell death (15, 16).  Transcription 
induction of 24p3, however, has been shown to play a pivotal role in induction of 
apoptosis in response to IL3 withdrawal (1).  To determine if PI3K/Akt pathway is 
involved in IL3 regulation of 24p3, FL5.12 cells were cultured in IL3 free medium for 12 
h and switched into the medium containing IL3, PI3K inhibitor LY294002 or MEK 
inhibitor PD98059.  Immunoblotting analysis revealed that upon IL3 withdrawal, 24p3 
was increased approximately three fold.  Addition of IL3 into the medium significantly 
reduced the 24p3 expression.  However, inhibition of PI3K/Akt pathway with either 
LY294002 or dominant negative Akt largely abrogated the IL3-repressed 24p3 whereas 
MEK inhibitor PD98059 had no effect on 24p3 expression.  Furthermore, stable 
expression of constitutively active Akt inhibited 24p3 induced by IL3 deprivation (Fig. 
21A). 
 Figure 22.  PI3K/Akt 
pathway regulates 24p3 
at transcriptional level. 
(A and B) Northern blot 
analysis.  FL5.12 cells 
were transfected and 
treated with indicated 
plasmids and agents. 
Total RNA was isolated 
and subjected to Northern 
blot analysis using [32P]-
dCTP labeled 24p3 cDNA 
as probe (upper panels). 
 were 
ontrol 
 
        84 
The 28S and/or 18S
used as a loading c
(bottom panels).   
 
 
 
We further examined the role of PI3K/Akt and MAPK pathways in IL3-dependent 
ell survival.  FL5.12 cells were treated with or without LY294002 or PD98059 in the 
presenc
wal-induced 24p3 whereas dominant negative Akt partially abrogated IL3-
pressed 24p3 mRNA expression (Figs. 22A and 22B).     
 
Isolation of human 24p3 promoter and IL3 inhibition of 2
through PI3K/Akt pathway.  To further analyze the transcript
gene by Akt, we defined transcription start site using 5’ race an
region of the human 24p3 gene (Fig. 23A).  Sequence analy
binding sites (TTGTTTAC) for Foxo3a (–1178/-1163, -903/-892, and –69/-52), and one 
site for NF-κB, CREB and C/EBP in the 24p3 promoter.   T
promoter is regulated by IL3, FL5.12 cells were transfected with
galactosidase, and then cultured in a medium supplement with o ure 
3C shows that 24p3 promoter activity was induced about 22 fold upon IL3 withdrawal, 
whereas addition of IL3 reduced the promoter activity.   However, inhibition of PI3K  
c
e or the absence of IL3.   As shown in figure 21B and 21C, inhibition of PI3K 
induced more significant cell death than inhibition of MAPK pathway.  Moreover, 
ectopic expression of constitutively active Akt largely rescued the programmed cell death 
induced by IL3 deprivation (Figs. 21D and 21E), whereas expression of dominant 
negative Akt inhibited IL3-protected apoptosis (Fig. 21E).  These data indicate that 
PI3K/Akt pathway, but not MAPK, mediates IL3 action toward 24p3 and cell survival.   
 
PI3K/Akt inhibits 24p3 expression at transcriptional level.  Having observed 
PI3K/Akt pathway mediating IL3-regulated 24p3 protein expression, we next examined 
if 24p3 is regulated by PI3K/Akt at transcriptional level.  Following culture of FL5.12 
cells in the absence or the presence of IL3 and treatment with LY294002, Akt inhibitor 
API-2 or PD98059, Northern blot analysis shows that mRNA level of 24p3 is elevated 
upon IL3 withdrawal.  Addition of IL3 repressed 24p3 mRNA expression.  Inhibition 
of PI3K or Akt but not of MEK inhibits IL3 stimulation-reduced 24p3 mRNA (Fig. 21A 
and data not shown).  Further, expression of constitutively active Akt inhibited IL3 
withdra
re
4p3 promoter activity 
ional regulation of 24p3 
d cloned the 5’ flanking 
sis revealed 3 putative 
o examine if the 24p3 
 pGL3-24p3-Luc and β-
r without IL3.   Fig
2
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 but not of MAKP largely abrogated IL3-represssed 24p3 promoter activity. 
Furthermore, IL3 deprivation-induced 24p3 promoter activity was reduced by expression 
of constitutively active Akt in a dose-dependent manner (Fig. 23C).  These findings  
 
culture, luciferase 
activity was measured 
and normalized to β-
galactosidase.  Results 
are the mean ±S.E. of 
three independent 
experiments performed 
in triplicate. 
 
  
C/EBP sites are 
underlined and NFκB 
cells with indicated 
plasmids and treated 
with indicated agents. 
Following a 36-h 
 
Figure 23.  Cloning of 
human 24p3 promoter 
and IL3 regulation of 
24p3 promoter activity 
through PI3K/Akt 
pathway. (A) DNA 
sequence of human 
24p3 promoter.  TATA 
box is labeled by bold. 
Putative FOXO3a 
binding sites are boxed, 
site is double 
underlined. (B) A 
diagram displays the 
location of putative 
FOXO3a-binding sites 
indicated by blue 
column within the 1.5-
kb 24p3 promoter.  (C 
and D) IL3 regulates 
24p3 promoter via 
PI3K/Akt pathway. 
Luciferase reporter 
assay was performed by 
transfection of FL5.12 
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suggest that IL3 controls 24p3 transcription by regulation of transcriptional factor(s) 
through a PI3K/Akt-dependent pathway. 
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FOXO3a mediates IL3 signals to regulate 24p3 promo
ave shown that expression of FOXO transcription factor induces cell death and cell 
growth arrest through transactivation of a number of molecules such as Bim, FasL and 
24.  FOXO3a induces 
omoter activity that is 
 by IL3/Akt signaling. 
XO3a induces 24p3 
r activity.  HEK293 
ere transfected with 
4p3-Luc, 　-
dase and increasing 
 of FOXO3a. 
ng incubation for 36 h, 
se activity was measured 
normalized to β-
idase.  (B) Akt inhibits 
a-induced 24p3 
r activity.  HEK293 
ere transfected with 
d plasmids and reporter 
was performed as 
d above. (C) IL3 
s 24p3 promoter through 
sphorylation FOXO3a. 
cells were stably 
ted with wild-type 
a and Akt-
phorylatable FOXO3a-
ell as 24p3-Luc and then 
 in the presence or the 
 of IL3.  The reporter 
was performed as 
d above. 
ter.  Previous studies 
h
Gadd45 (23, 24, 25).  Because 24p3 promoter contains 3 putative FOXO binding sites 
and FOXO is a major target of Akt (25), we next examined if 24p3 promoter is directly 
regulated by FOXO.  HEK293 cells were transfected with pGL3-24p3-Luc,  
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β-galatosidase and increasing amounts of FOXO3a, one of the mostly studied FOXO 
family members.  Figure 24A shows that 24p3 promoter activity was induced by 
OXO3a in a dose-dependent manner. Co-expression of constitutively active Akt 
repressed the promoter activity induced by FOXO3a but no
which can not be phosphorylated by Akt (Fig. 24B).  Mo
promoter activity was largely inhibited by stimulation 
contrast, IL3 treatment had no effect on FOXO3a-A3-stim
(Fig. 24C).  
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F
t FOXO3a-A3, a mutant form 
reover, FOXO3a-induced 24p3 
of F5.12 cells with IL3.  In 
ulated 24p3 promoter activity 
re 25.   FOXO3a regulates 
 expression through a 
phorylation-dependent manner. 
Phosphorylation of FOXO3a 
lates with expression of 24p3 in 
nse to IL3.   FL5.12 cells were 
fected with pcDNA3 or Myr-Akt, 
red in the presence or the 
nce of IL3 and immunoblotted 
indicated antibodies.  (B and C) 
failed to inhibit 24p3 expression 
ced by constitutively active (Akt-
hosphorylatable) FOXO3a-A3. 
12 cells were transfected/treated 
indicated plasmid and agent and 
cted immunoblotting (B) and 
hern blot (C) analyses. 
 
 
To further demonstrate that IL3 regulates 24p3 through Akt-FOXO3a axis, we 
examined the levels of FOXO3a phosphorylation and 24p3 expression in response to IL3 
treatment.  FL5.12 cells were transfected with constitutively active Akt (Myr-Akt) or 
pcDNA3 vector and treated with or without IL3.  Immunoblotting analysis shows that 
IL3 deprivation reduced phosporylation levels of FOXO3a and Akt and increased 24p3 
expression in pcDNA3- but not myr-Akt-transfected cells (Fig. 25A).  Further, 
expression of non-phosphorylatable FOXO3a-A3 abrogated IL3-inhibited 24p3 
expression (Figs. 25B and 25C).  Taken collectively, these data indicate that 24p3 is a 
irect downstream target of FOXO3a and that FOXO3a-regulated 24p3 is controlled by 
IL3-Akt pathway. 
 
d
Figure 26.  Define the FOXO3a response elements in 24p3 promoter.  (A) -1309/-304 of 24p3 
promoter is a FOXO3a response region.  Reporter assay was performed as described above 
except using different deletion mutants of 24p3 promoter-driven luciferase as reporters.  (B) 
FOXO3a directly binds to two putative FOXO sites within the response region in vivo.  FL5.12 
cells were transfected with HA-FOXO3a and subjected into chromatin immunoprecipitation 
assay.  (C) Mutation of the FOXO3a binding sites reduces 24p3 promoter activity.  The F5.12 
cells were transfected with indicated plasmids and reporter assay was performed as described 
above.  
 
Define the FOXO3a response element(s) in the 24p3 promoter.  24p3  
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promot
 
d and third sites in vivo (Fig. 26B).  In addition, luciferase reporter 
ssay using point mutation of each FOXO3a binding site demonstrated that these two 
binding sites are required for the 24p3 promoter to respond to FOXO3a (Fig. 26C). 
 
  
Figure 27.  Activation of Akt not 
only represses 24p3 expression 
induced by IL3 withdrawal but also 
inhibits 24p3-induced cell death. 
(A) Conditioned medium from FL5.12 
but not Myr-Akt-FL5.12 cells induces 
death of naïve FL5.12 but not of Myr-
Akt-FL5.12 cells.  Insert shows 
immunoblot of medium from 
pcDNA3-, Myr-Akt-transfected and 
parental FL5.12 cells cultured with or 
without IL3 for 36 h.  Cell viability 
was examined by MTT assay.    (B) 
IGF1 inhibits apoptosis after IL3 
withdrawal but not 24p3-containing 
CM addition in naïve FL5.12.  CMs 
er contains 3 putative FOXO binding sites, and thus we next defined which 
binding site(s) is required for the promoter to respond to FOXO3a transcription factor. 
A series of deletion mutants of 24p3 promoter were created and used for reporter assay.  
As seen in Fig. 26A, a mutant with deletion of -340/+18 considerably enhanced the 
promoter activity induced by FOXO3a, whereas the mutant with deletion of a region (-
1309/-304) containing the second and/or the third binding site reduced FOXO3a-
stimulated promoter activity, suggesting that major response elements to FOXO3a are 
located in last two FOXO binding sites and that a repression element(s) may reside within 
a region between -304bp and +18bp.  Furthermore, ChIP assay revealed that FOXO3a 
bound to the secon
a
prepared from indicated cells 
cultured in the medium with or 
without IL3 and/or IGF1 were added 
to naïve and Myr-Akt-transfected 
FL5.12 cells.  Cell viability was 
quantitated by MTT assay.   
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Conditioned Medium (CM) from Myr-Akt-FL5.12 Cells Fail to Induce 
Apoptosis; Myr-Akt-FL5.12 Cells Resist to the Apoptosis Induced by CM 
Expressing 24p3.  Previous studies have shown that CM from IL-3 deprived FL5.12 
cells expresses 24p3 and induces apoptosis in a number of hematopoietic cell lines (1).  
Since Akt/FOXO3a mediates IL3 action on 24p3 and constantly active Akt inhibits 24p3 
expression induced by IL3 withdrawal, we further examined the cell viability of naïve 
FL5.12 cells following treatment with different CMs.  We collected medium from 
pcDNA3-, Myr-Akt-transfected and parental FL5.12 cells cultured with or without IL3, 
added the medium to naïve FL5.12 cells, and analyzed cell viability by MTT assay. 
Conditioned medium from pcDNA3-transfected and parental FL5.12 cells cultured 
without IL3 induced cell death.  However, the medium from constitutively active Akt-
transfected FL5.12 cultured in the absence of IL3 had no significantly effect o
 
n cell 
iability, which is comparable to naïve FL5.12 cells treated with the medium from 
L5.12 cultured in the presence of IL3.   In addition, onditioned medium from FL5.12 
and pcDNA3-FL5.12 cultured in the absence of IL
constitutively active Akt-transfected F5.12 cells (Fig.
FL5.12 cells cultured in the absence of IL3 and p
primarily activating PI3K/Akt pathway, had no signi
27B).  These results further support our findings tha
PI3K/Akt/FOXO pathway and that activation of Akt
induced by IL3 deprivation but also reduces 24p3-indu
 
Discussion 
 
Previous studies have shown that Akt mediates 
phosphorylation of Bad, which leads to the switchin
complex into 14-3-3 and the loss of its proapoptotic fu
24p3 has recently been identified as a key mo cule for IL3 withdrawal-induced 
poptosis in IL3-dependent cells (1).  Neutralization of 24p3 using anti-24p3 antibody 
rgely reduces cell death induced by IL3 deprivation (1).  24p3 is transcriptionally  
v
F  c
3 failed to induce cell death in 
 27A).  Further, the medium from 
resence of IGF1, a growth factor 
ficant effect on cell survival (Fig. 
t 24p3 is regulated by IL3 through 
 not only inhibits 24p3 expression 
ced cell death. 
IL3 cell survival signal through 
g of Bad from Bcl-2 and Bcl-XL 
nction (15).   
le
a
la
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regulat
 
poptosis in FL5.12 
ells even the culture medium containing IL3 (1).  However, our data showed that 
y active Akt-transfected FL5.12 cells resist to apoptosis induced by CM 
xpressing 24p3 (Fig. 27).  Since IL3 induces Akt activation, it is hard to understand 
ons are required for 
the und
 
ed by IL3 signaling, i.e., withdrawal IL3 induces whereas additional IL3 represses 
24p3 expression.  We demonstrated in this study that IL3 regulation of 24p3 is mediated 
by Akt/FOXO3a axis.  Transcription factor FOXO3a directly binds to and transactivates 
24p3 promoter.  The regulation of 24p3 by FOXO3a is modulated by IL3 through 
PI3K/Akt but not MAPK pathway.  IL3 activates Akt and leads to phosphorylation and 
inhibition of FOXO3a action on 24p3, whereas IL3 deprivation resulted in 
dephosphorylation and activation FOXO3a and increased expression of 24p3.  Moreover, 
constitutively active Akt inhibits death of FL5.12 cells after deprivation of IL3, which is 
due to suppression of 24p3 transcription through phosphorylation of FOXO3a.   
FOXO transcription factors are crucial regulators of cell fate.  It has been shown 
that FOXO transcription factors control cell survival by regulation of the expression of 
genes.  Common FOXO target genes that are involved in apoptosis include bNIP3 and 
BCL2L11, which encode the pro-apoptotic Bcl-2 family members, bNIP3 and Bim, 
respectively (23, 24).  In addition to direct targets, FOXO also indirectly down-regulate 
the expression of the pro-survival Bcl-XL by inducing the expression of the 
transcriptional repressor Bcl-6 (26). In neurons, FOXO3a triggers cell death circuitously 
by inducing the expression of Fas ligand, which triggers programmed cell death through 
the death receptor pathway (25).  In hematopoietic cells, we showed in this report that 
24p3 is a direct target of FOXO3a and provokes cell death after IL3 deprivation. 
FOXO3a up-regulates 24p3 transcription through directly binding to 24p3 promoter. 
In addition, a previous study demonstrated that 24p3 induces a
c
constitutivel
e
why constitutively active Akt could override 24p3-induced cell death.  A possible 
explanation is that constitutively active Akt inhibits 24p3 receptor cascade and/or other 
proapoptotic molecules prior to 24p3 treatment.  Further investigati
erlying mechanism.  
In summary, we demonstrated that FOXO3a directly regulates 24p3 expression 
and mediates IL3 signaling in hematopoietic cells.  Deprivation of IL3 decreases Akt 
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phosphorylation of FOXO3a, which leads to activation of 24p3 transcription and cell 
death.  Inhibition of Akt but not MAPK increases 24p3 expression, whereas activation 
of Akt reduces mRNA and protein levels of 24p3 and inhibits 24p3-induced apoptosis. 
These findings indicate that 24p3 is a direct target of FOXO3a and that PI3K/Akt but not 
the MAPK pathway mediates IL-3 action on 24p3 in hematopoietic cells.  
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p53 and Akt 
ABSTRACT 
Akt regulates a diverse array of cellular functions, including apoptosis, cellular 
roliferation, differentiation, and metabolism.  While a number of molecules have been 
entified as upstream regulators, such as PI3K, PDK1 and PTEN, or downstream targets, 
uch as MDM2, Bad, and FOXO, of Akt, the mechanisms by which Akt regulates the 
ellular processes remain elusive.  Here, we identify a novel transcription factor, dubbed 
ZP (referring to T
 
 
CHAPTER 5 
 
Identification and characterization of a transcription factor TZP that interacts with 
 
p
id
s
c
T udor and Zinc finger domain containing Protein), which binds to Akt 
nd p53.  TZP is an evolutionarily conserved nuclear protein.  Overexpression of TZP 
hibits cell growth and DNA synthesis as well as cell survival.  TZP not only directly 
egulates p53 at the transcription level but also binds to and stabilizes p53 protein, which 
ads to increase of expression of p53 downstream target genes, such as p21, BAX, and 
ADD45.  Knockdown of TZP significantly reduces p53 expression.  Akt 
hosphorylates TZP in vitro and in vivo which results in its translocation from the nucleus 
 the cytoplasm and attenuation of its function toward p53.  These data suggest that 
ZP plays an important role in maintaining normal p53 function and that Akt induces cell 
rowth and survival through inhibition of TZP/p53 axis. 
ntroduction 
Akt was originally discovered as an oncogene transduced by the acute 
ansforming retrovirus (Akt-8), which was isolated from an AKR thymoma (1, 2), and  
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tr
subsequently found to encode a serine/threonine protein kinase (3).  Akt is also known 
s protein kinase B (4, 5).  Viral akt is highly activated and oncogenic due to the fact 
at v-akt is associated with the cell membrane through a myristylated Gag protein 
quence fused to the N-terminus  The important role of Akt in 
transformation and cancer was shortly therea AKT2 
cancers (6-8).  In mammals, there a ms of Akt, termed Akt1, Akt2, and 
Akt3.  These isoforms are products of distinct genes but are highly related, exhibiting 
80% protein sequence identity and sharing the same structural organization.  The 
membe
mor suppressor PTEN, which is 
equently mutated in human malignancy (26-29).  Akt phosphorylates and/or interacts 
 of molecules to exert its normal cellular functions, which include roles in 
ell proliferation, survival, differentiation and metabolism (30). 
  
a
th
se  of Akt (3). 
fter strengthened by the cloning of the 
gene (6) and the discovery that AKT2 is frequently amplified and overexpressed in human 
re three isofor
>
rs of Akt family are activated by various stimuli in a phosphatidylinositol 3-kinase 
(PI3K)-dependent manner (9-12).  Activation of Akt depends on the integrity of the 
pleckstrin homology (PH) domain, which mediates its membrane translocation, and on 
the phosphorylation of Thr308 in the activation loop and Ser473 (13-16).  
Phosphoinositides, PtdIns-3,4-P2 and PtdIns-3,4,5-P3, produced by PI3K bind directly to 
the PH domain of Akt, driving a conformational change in the molecule, which enables 
the activation loop of Akt to be phosphorylated by PDK1 at Thr308 (17).  Full activation 
of AKT1 is also associated with phosphorylation of Ser473 (18) within a C-terminal 
hydrophobic motif characteristic of kinases in the AGC kinase family.  Although the 
role of PDK1 in Thr308 phosphorylation is well established, the mechanism of Ser473 
phosphorylation is controversial.  A number of candidate enzymes responsible for this 
modification have been put forward, including integrin-linked kinase (19), PDK1 when in 
a complex with the kinase PRK2 (20), Akt itself, through autophosphorylation (21), 
PKCα (22), PKCβII (23), DNA-dependent kinase (24), and the rictor-mTOR complex 
(25).  The activity of Akt is negatively regulated by tu
fr
with a number
c
The p53 gene represents one of the most studied tumor suppressor genes in 
biology.  It is frequently mutated in a wide range of tumors and plays an essential role in
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maintaining genomic integrity (31–35).  Exposure of a normal cell to genotoxic stress 
leads to an increase in p53 protein levels.  The increase in p53 protein results in an 
increase in p53-dependent transcription of p53 target genes, which subsequently leads to 
cell cycle arrest or apoptosis (36–39).  The practical implication of these facts is that 
when a cell undergoes alterations that predispose it to become cancerous, p53 is activated 
to trigger checkpoints that either take care of the damage through its DNA repair function 
or eliminate the affected cells through induction of apoptosis, thereby preventing the 
development of tumors (34, 40).  Therefore, regulation of p53 activity is critical to allow 
both normal cell growth and tumor suppression.  The current dogma is that p53 
regulation in DNA damage-activated cell cycle checkpoints occurs at the level of protein 
degradation and protein stability.  This includes regulation of p53 protein stability, 
posttranslational modifications, protein-protein interactions, and subcellular localization. 
These mechanisms keep a strong check on p53 in normal circumstances but allow rapid 
activation in response to cellular stress that might be caused by or contribute to oncogenic 
progression (33, 34).  However, little is known about the transcriptional regulation of 
the p53 gene and the contribution of this transcriptional control of p53 itself to DNA 
damage–induced cell cycle checkpoints.  Previous studies have shown that p53 is 
transcriptionally up-regulated by the homeobox protein HOXA5 (41, 42).  Recently, the 
Bcl6 oncoprotein was found to suppress p53 expression through binding to p53 an  
inhibiting p53 promoter activity (43).  Several studies have raised the possibility that 
p53 may also be regulated at the transcriptional level in response to genotoxic stress (44, 
45).  However, the underlying mechanism and functional consequences remain unclear. 
A link between Akt and p53 pathway was established by identification of Akt 
phosphorylation of MDM2 (46).  MDM2 is an E3 ubiquitin ligase that negatively
 
d
 we identified a novel 
transcr
 
regulates p53 transcriptional activity (47).  Phosphorylation of MDM2 on serine166 and 
serine186 by Akt stimulates translocation of MDM2 to the nucleus, where it binds to p53 
and targets p53 degradation by proteasome (48-50).  Here,
iption factor TZP that interacts with both p53 and Akt.  TZP directly binds to p53 
promoter and upregulates p53 at mRNA level.  Notably, TZP also forms a complex with  
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p53 and enhances p53 stability.  As a result, TZP inhibits cell growth, cell cycle 
progression and DNA synthesis as well as cell survival.  Akt phosphorylates TZP on  
serine-291 within TZP nuclear localization signal, which leads to the translocation of TZP 
from the nucleus to the cytoplasm and loss of its function toward p53. 
 
Material and methods 
 
Yeast Two-hybrid Screening and Expression Constructs—Yeast two-hybrid system 
was employed to identify Akt interaction protein(s) using the C-terminal regulatory 
region of Akt as bait following the manufacturer's procedure (Clontech).  A human fetal 
brain library (Clontech) was screened.  Full-length cDNA of TZP, amplified from a 
human Marathon-ready skeletal muscle cDNA (Clontech) by PCR, was subcloned into 
3X Flag-pcDNA3, pEGFP-C1 and pTRE-tight vectors. TZP mutants were created with 
the QuikChange multiple site-directed mutagenesis kit (Stratagene). The 
cytomegalovirus-based expression constructs encoding HA-tagged, p53, MDM2, and 
ubiquitin as well as pGL3-p21-Luc and -p53-Luc have previously been described (51, 
52).  
 
with Af el pr ein A ( io-Rad
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Cell Culture and Transfection - HEK293, MCF7, HeLa, HCT116, and A-T cell 
lines GM9067 and GM9067-AT were obtained from ATCC and cultured in Dulbecco’s 
modified Eagle’s medium (DMEM) containing 10% fetal bovine serum.  Lipofectamine 
plus (Invitrgen) was used for transfection.   
Glutathione S-transferase (GST) Fusion Protein and Generation of Anti-TZP
 Antibody - Different portions of TZP, including AT-hook region, C2H2 zinc finger domain, 
C-terminal motif, and the regions containing each Akt phosphorylation site, were 
subcloned into pGEX-4T1.  Expression and purification of the GST fusion protein were 
carried out as previously described (53).  Polyclonal anti-TZP antibody was raised in 
New Zealand White rabbit.  Approximately 300 µg of GST fusion protein (GST-TZP/AT-
hook and GST-TZP/C-terminal) was used to immunize rabbit every 2 weeks; rabbits were 
bled 10 days after each booster injection.  The anti-TZP antibodies were affinity purified 
  fi-G ot B ).
Northern Blot Analysis – Northern blot analysis of total cellular RNA was 
performed according to standard procedures.  RNA was extracted using the RNeasy 
 (Srtatagene), and 
en hybridized with randomly primed 　α-32P-labeled cDNA probes for TZP or p53.  
d to autoradiography and the mRNA levels were visualized and 
uantified using PhosphorImager analysis (Molecular Dynamics).  
AGE and in vitro kinase assay.  Protein expression was determined by probing 
Wester
ncubated with whole cell lysate (
purification kits (QIAGEN Inc.).  Total RNA was electrophoresed in 1.0% 
formaldehyde-agarose gels, transferred to Duralon-UVTM membrane
th
Membranes were expose
q
Immunoprecipitation and Immunoblotting Analysis - Cells were lysed in a lysis 
buffer containing 20 mM Tris-HCl (pH 7.5), 137 mM NaCl, 15% (v/v) glycerol, 1% 
Nonidet P-40, 2 mM phenylmethylsulfonyl fluoride, 2 µg/ml aprotinin and leupeptin, 2 
mM benzamidine, 20 mM NaF, 10 mM NaPPi, 1 mM sodium vanadate, and 25 mM β-
glycerolphosphate.  Lysates were subjected to immunoprecipitation and immunoblotting 
analysis as previously described (54).  Briefly, lysates were precleared with protein A-
protein G (2:1)-agarose beads.  Following the removal of the beads by centrifugation, 
lysates were incubated with appropriate antibodies in the presence of protein A-protein G 
(2:1)-agarose beads for 2 hours.  After wash, the immunoprecipitates were subjected to 
SDS-P
n blot of the immunoprecipitates or total cell lysates with the appropriate 
antibodies as noted in the figure legends. 
GST Pull-down Assay - Glutathione-agarose beads coupled to GST alone, GST-
p53, and GST-deletion mutants of p53 were i 800 µg of 
protein
 
 of incorporated radioactivity were determined by  
) for 2 h at 4 °C.  After wash four times with lysis buffer, the beads were 
subjected to Western blot analysis with appropriate antibodies. 
In vitro Kinase Assay—Akt kinase assay was performed as previously described 
(55, 56).  Briefly, reactions were carried out in the presence of 10 µCi of [γ-32P] ATP and 
3 µM cold ATP in 30 µl of buffer containing 20 mM Hepes (pH 7.4), 10 mM MgCl2, 2 
mM MnCl2, and 1 mM dithiothreitol.  GST-TZPs were used as exogenous substrate. 
After incubation at room temperature for 30 min, the reactions were stopped by adding 
protein loading buffer and separated in SDS-PAGE gels.  Each experiment was repeated 
three times.  The relative amounts
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autorad
d by autoradiography 
(57). 
 
 
ce with 5ml of 10% TCA 
for 10 
iography and quantified with a Phosphorimager (Amersham Biosciences). 
In Vivo [32P]-orthophosphate Cell Labeling – HEK293 cells were co-transfected 
with FLAG-TZP and constitutively active Akt or pcDNA3 and labeled with [32P]-
orthophosphate (0.5 mCi/ml) in phosphate- and serum-free minimum essential medium 
for 4 hours.  Cell lysates were subjected to immunoprecipitation with anti-FLAG 
antibody (Sigma).  The immunoprecipitates were separated by SDS-PAGE and 
transferred to membrane.  The phosphorylated TZP was examine
Cell proliferation, Viability and DNA Synthesis Assays - TZP-, TAP/Akt and 
pcDNA3-transfected cells were plated in 35-mm dishes at a density of 1.0 x 105 cells/dish. 
Cell numbers were measured with a Coulter Counter (Coulter Electronics, FL) daily for 
up to 3 days following seeding.  MTS assays were performed according to the 
manufacturer’s recommendations (Promega, Madison, WI).  The cells were plated in 
96-well microtiter plates at a density of 1.0 x 103 cells/well in Dulbecco's modified 
Eagle's medium with 10% FBS.  The number of cells at 1, 2, and 3 days was determined 
using cell counter and the colorimetric CellTiter96 Aqueous (MTS) assay (Promega). 
Results were depicted as absorbance at 490 nm as a function of time.  Cell viability was 
examined with Trypan blue staining following treatment of cells with doxorubicin (1 M) 
for 12 h. 
Thymidine incorporation was used to investigate the effect of TZP on DNA 
synthesis.  The cells were grown to 80% confluence in 6-well plates, and during the last 
16 h of growth they were subjected to 5 Ci/ml of [　 3H] thymidine.  After rinsing twice 
with ice-cold serum-free medium, the cells were incubated twi
min on ice and lysed in 500 ul 1% SDS in 0.3N NaOH for 30 min at 37°C.  
Incorporated radioactivity was quantitated with a spectrometer. 
Luciferase Reporter Assay – NIH3T3 or HEK293 cells were cultured in 12-well 
plates and transiently transfected with pGL3/p53-Luc, p21-Luc, TZP and/or Akt as well 
as pSV2-β-galactosidase.  The amount of DNA in each transfection was kept constant 
by the addition of empty vector.  After 36 h of transfection, luciferase activity was 
measured using a luciferase assay reagent (Promega).  Transfection efficiency was  
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normalized by co-transfection with 　β-galactosidase expressing vector.  The 　β-
galacto
TGTC(N)26GAGGCGAATTCAGTGCAACTGCAGC-3’; primer A, 5’-GCTGCA 
GTTGC
raphy, excised from gels, and eluted overnight at 37 °C in DNA-elution buffer 
contain
cleotide sequences of 34 
indepe
sidase activity was measured by using Galato-Light (Tropix).  Luciferase activity 
was expressed as relative luciferase activity. 
Cyclic Amplification and Selection of Targets (CASTing) - A 76-bp 
oligonucleotide containing 26 random nucleotides in the center flanked by sequences 
complementary to primers A and B was synthesized (Invitrogen).  The sequences of the 
oligonucleotides are as follows: 76-base oligonucleotide, 5’- CAGGTCAGTTCAGCGG 
ATCC
ACTGAATTCGCCTC-3’; primer B, 5’- CAGGTCAGTTCAGCGGATCCTGT 
CG-3’.  A random sequence library of double-stranded radiolabeled oligonucleotides 
was prepared by annealing the oligonucleotide to 5-fold excess of primer B followed by 
extension with Klenow enzyme.  EMSAs (electrophoretic mobility-shift assays) were 
performed by adding 5 µg of Flag-TZP containing nuclear extract to radiolabeled DNA in 
DNA binding buffer (5% glycerol, 10 mM Hepes, pH 7.9, 75 mM KCl, 1 mM DTT, 2.5 
mM MgCl2, 1 mM EDTA) in the presence of 0.5 µg of poly (dA.dT) and 1 µg of bovine 
serum albumin.  The reaction was incubated at room temperature for 30 min and 
subsequently the DNA-protein complexes were resolved by electrophoresis.  The 
complexes formed specifically in the presence of Flag-TZP proteins were detected by 
autoradiog
ing 0.3 M NaCl, 1 mM EDTA, and 0.1% SDS.  The eluted DNA was extracted 
once in phenol-chloroform, and then precipitated with ethanol.  Purified DNA was 
subjected to re-amplification by PCR in the presence of [α-32P] dCTP.  The amplified 
radiolabeled DNA was purified using G-50 Nick columns (Amersham) and was used in 
subsequent EMSA experiments.  After four cycles of CASTing, the final amplified DNA 
was cloned directly using pGEM-T Cloning kit (Promega).  Nu
ndent clones were determined.  The degenerate portion of the sequences was 
compiled and analyzed for shared sequence patterns by visual inspection and by weblogo 
software (http://weblogo.berkeley.edu).  
ChIP and EMSA Assay - ChIP assay was performed essentially as previously 
described (58).  Solubilized chromatin was prepared from a total of 2 X 107  
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asynchronously growing HEK293 or HCT116 cells that were transfected with wild type 
TZP or mutant TZP.  The chromatin solution was diluted 10-fold with ChIP dilution 
buffer (1.1% Triton –100, 1.2 mM EDTA, 167 mM NaCl, 16.7 mM Tris•HCl, pH 8.1, 
0.01% 
 
 
 
 
[pH 7.9], 10 mM KCl, 1.5 mM MgCl2, 0.34 M 
sucrose
ncubated  
SDS, protease inhibitors), and precleared with protein-A beads blocked with 2 µg 
sheared salmon sperm DNA and pre-immune serum.  The precleared chromatin solution 
was divided and utilized in immunoprecipitation assay with either anti-Flag, or -TZP 
antibody.  Following wash, the antibody-protein-DNA complex was eluted from the
beads by resuspending the pellets in 1% SDS, 0.1 M NaHCO3 at room temperature for 20
min.  After crosslink, protein and RNA were removed by incubation with 10 µg
proteinase K and 10 µg RNase A at 42 °C for 3 hour.  Purified DNA was subjected to 
PCR with primers specific for putative TZP-binding site within the p53 promoter. 
Amplified PCR products were resolved by 1.2% of agarose gel electrophoresis and 
visualized by BioImage.  EMSA was performed as described above.  The sequences of 
oligonucleotides used for EMSA and ChIP assays are: p53 EMSA primer: 5’-GTCCAGC 
TTTGTGCCAGGAGCCTC-3’, 5’-CCCCTCCCATGTGCTCTCAAGACTGG-3’, 5’-G 
GATTGGGGTTTTCCCCTCCCATGTG-3’; p53 ChIP primer: 5’-CAATTCTGCCCTC 
ACAGCTCTGGCTTGC-3’, 5’-CTCAAAACTTTTAGCGCCAGTCTTGAGC-3’ and 
p21 ChIP primer: 5’-GGGGAGGGAGGTCCCGGGCGGCGTCGG-3’, 5’-GACATGGC 
GCCTCCTCTGAGTGCCTCG-3’. 
RNA Interference (RNAi) - The RNAi duplexes were synthesized by Dharmacon 
Research Inc.  The cDNA-targeted region and the sequence of TZP RNAi duplexes are: 
AAGAGGAUGGAUCUUCUGAAU and AAAGCAUUGGAGGAGGAUAAU.  The 
RNAi duplexes were reconstituted to 20 µM in sterile RNase-free water.  Transfection 
of RNAi for targeting endogenous genes was performed using oligofectamine reagent 
(Invitrogen) according to the manufacturer’s instruction. 
Chromatin Association - Chromatin was isolated as described previously with 
small modifications (59).  Briefly, Flag-TZP stably transfected HeLa cells were 
resuspended in buffer A (10 mM HEPES, 
, 10% glycerol, 1 mM DTT, 5 µg/ml aprotinin, 5 µg/ml leupeptin, 0.1 mM 
phenylmethylsulfonyl fluoride).  NP-40 (0.1%) was added, and the cells were i
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for 5 min on ice.  Nuclei (P1) were collected by low-speed centrifugation (5 min, 1,300 
g, 4 °C).  The supernatant (S1) was further clarified by high-speed centrifugation (15 
min, 20,000 g, 4 °C).  Nuclei were washed once in buffer A, and then lysed in buffer B 
(3 mM EDTA, 0.2 mM EGTA, 1 mM DTT, protease inhibitors as described above). 
Insoluble chromatin was collected by centrifugation (5 min, 1,700 g, 4 °C) and washed 
once in buffer B.  The final chromatin pellet (P3) was resuspended in sonication buffer 
(50 mM Tris, [pH 8.1], 10 mM EDTA, 1%SDS) and sonicated 2 x 10s in a Branson 
sonicator using a microtip at 10% amplitude.  Chromatin was diluted 1:10 with dilution 
buffer (0.01 % SDS, 1.1 % Triton, 1.2 mM EDTA, 16.7 mM Tris-Cl pH 8.2, 167 mM 
NaCl, 10µg/ml PMSF, 10µg/ml leupeptin, 10µg/ml aprotinin) and Flag-TZP was 
immunoblotted with α-Flag antiserum.  To release chromatin-bound proteins by 
nuclease treatment, cell nuclei (P1) were resuspended in prewarmed buffer A plus 1 mM 
CaCl
 
 
 
12 h to synchronize cells at G2/M phase.  The cells 
were w
2 and 0.3 U of micrococcal nuclease (Sigma).  After incubation at 37°C for 1 min, 
the nuclease reaction was stopped by the addition of 1 mM EGTA.  Nuclei were 
collected by low-speed centrifugation and lysed according to the chromatin isolation
protocol described above. 
Flow Cytometry and Cell Cycle Analysis - For flow cytometry, TZP HeLa/Tet-on 
cells were treated with or without 1 µg/ml doxycycline for 12 h and then incubated with 
40 ng/ml nocodazole for additional 
ashed and further cultured in fresh medium without nocodazole for different time 
points.  Cells were fixed in prechilled 70% ethanol for 2 h.  Following wash with PBS, 
cells were resuspended in propidium iodide (PI) staining solution (0.1% Triton X-100/0.2 
mg/ml DNase-free RNase A/20 µg/ml PI prepared in PBS) for 15 min at 37 °C and then 
analyzed by flow cytometry.  DNA content histograms and FACS data were analyzed 
using FLOWJO software.  
In vivo Ubiquitination Assay - H1299 cells were co-transfected with wild type p53, 
TZP, and ubiquitin together with or without MDM2, and then treated with 50 μM of 
proteasome inhibitor MG132 (Sigma) for 2 hours prior to harvest.  Following wash 
twice with ice-cold PBS, harvested cells were lysed in a lysis buffer [50 mM Tris HCl, 
pH 7.4, 150 mM NaCl, 1 mM EDTA, (1% w/v) Triton X-100, Glycerol (10% w/v) and  
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protease inhibitor mixture].  Cell lysates were immunoprecipitated with anti-p53 
antibody and then blotted with an anti-ubiquitin antibody.   
 
Results 
 
Identification of Akt binding protein, TZP.  In an attempt to identify protein(s) 
that interacts with Akt, the C-terminal regulatory domain of Akt (amino acids 410-480) 
was used as bait in a yeast two-hybrid screening.  A human fetal brain cDNA library 
was used in this screen, because Akt is highly expressed in brain (60, 61).  Altogether, 
32 clones that specifically interacted with the bait were identified.  Sequence analysis 
revealed that three of the clones contained overlapping sequences of a cDNA.  The 
largest clone contained a 262-amino acid open reading frame with a conserved tudor 
domain and a A-T hook motif.  Additional cDNA clones were isolated from a human 
skeletal cDNA library by plaque hybridization using the largest clone as radiolabeled 
probe.  Sequence analysis revealed that the full-length open reading frame of cDNA 
 
 
TZP that interacts with Akt. 
Figure 28. Identification of 
(A) Schematic structure of 
TZP.  TZP contains two 
tudor, an AT-hook, a C2H2 
Zinc finger, and a PHD 
finger domain and three 
nuclear localization signals 
(NLS).  (B) Northern blot 
analysis shows the 
expression of TZP in 
multiple human tissues. 
(C) TZP binds to Akt. 
HEK293 cells were co-
transfected with Flag-TZP 
and HA-Akt.  After 
incubation for 48 h, cells 
were lysed and 
immunoprecipitated, and 
immunoblotted with 
indicated antibodies. 
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encodes an 1,012-amino acid protein, which is composed of two tudor domains, a A-T 
hook motif, a zinc-finger domain and a PHD finger motif (Fig. 28A).  Therefore, we 
amed it as TZP (accession number AY027523).   In addition, TZP contains three 
ocalization signals and two putative Akt phosphorylation consensus sites (Fig. 
8A).  The expression pattern of TZP is similar to that of Akt1, being abundant in 
skeleta
pic 
changes of cells expressing ectopic TZP.  Since HeLa (wild type p53 degraded by 
PV18-E6 oncoprotein; ref. 62) and MCF7 (wild type p53; 
levels of endogenous TZP, we stably transfected the pCMV
FLAG-TZP into HeLa/MCF7 and HeLa-Tet-on/MCF7-Tet-of
controls, pCMV-3xFlag vector was also introduced into the cel
from each transfectant were established after selection.  
confirmed by Western blot analyses (Fig. 29A).  Cell gro
survival and cell cycle progression were evaluated in these clo
in Fig. 29B, cell growth was significantly inhibited by ectopic e
Furthermore, [3H]-thymidine incorporation experim
represses DNA synthesis (Fig. 29C).  In addition, expression o
(~40%) induced by doxorubicin (Fig. 29D).  Nocodazole cel
and doxycyclin induction of TZP revealed that overexpressio
transition both from G1 to S and from M to G1 phase (Fi
ndings were further confirmed in TZP-stably transfected HCT116 and A2780S cell lines  
n
nuclear l
2
l muscle, brain, pancreas, and heart (Fig. 28B).  To confirm the association Akt 
with TZP identified by yeast two-hybrid screening, HEK293 cells were cotransfected 
with Flag-TZP and HA-Akt.  Immunoprecipitation was performed with anti-Flag and 
detected with anti-HA antibody or vice versa.  As shown in Figure 28C, HA-Akt was 
detected in the Flag-TZP immunoprecipitates and TZP was coimmunoprecipitated with 
anti-HA antibody.  These data suggest that TZP could be a transcription factor, which 
may be regulated by Akt. 
 
Expression of TZP inhibits cell proliferation, DNA synthesis and cell survival, 
and induces G1 and G2/M cell cycle arrest.  We next examined the phenoty
H ref. 63) cells express low 
-3xFlag-TZP and pTRE-
f cells, respectively.  As 
ls.  Eight clonal cell lines 
Expression of TZP was 
wth, DNA synthesis, cell 
nal cell lines.  As shown 
xpression of TZP.  
ents revealed that TZP 
f TZP enhanced cell death 
l synchronization analyses 
n TZP delayed cell cycle 
g. 29E and 29F).  These 
fi
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(data not shown).   Thus, we conclude that the TZP is a growth inhibition gene and its  
 
Figure 29. TZP inhibits cell 
growth, DNA synthesis and 
survival and induces cell cycle 
arrest. (A) Western blot analysis 
shows expression of TZP in an 
inducible TZP HeLa/Tet-on cell 
line.  (B) TZP inhibits cell 
growth. TZP stably transfected 
HeLa and pcDNA3-HeLa (mock) 
cells were seeded into 12-well 
tissue culture plate.  The cell 
number was counted at indicated 
time points.   (C) TZP inhibits 
DNA synthesis.  Indicated cells 
were labeled with  [3H] 
thymidine.  The thymidine 
incorporation was count by 
liquid scintillation.  (D) TZP 
re 
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doxycycline for 48 h and 
examined for cell cycle 
distribution. 
sensitizes cells to DNA damage-
induced death.  Inducible TZP 
HeLa cells were seeded in 96-
well plate and treated with 
doxorubicin for indicated time. 
Cell survival was evaluated with 
MTS.  (E) TZP induces cell 
cycle arrest.  MCF7/Tet-off/TZP 
inducible cells were treated with 
or without doxycyclin and 
synchronized at G2/M phase.   
After wash, cells were further 
cultured in fresh medium without 
nocodazole for another 1–4 h 
and then fixed and analyzed by 
flow cytometry.  (F) HeLa/Tet-
on/TZP inducible cells we
treated with and without 1 µg/ml 
protein product regulates cell proliferation, survival, and G1/S and G2/M cell cycle 
heckpoints. 
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TZP associates with chromatin and binds to s 
been demonstrated that AT-hook binds to the A/T r  
accessibility of the promoter to transcription factor (64).  C2H2 zinc-finger and PHD 
finger domains are known to involve DNA binding and protein-protein interaction (65). 
Since TZP has three putative DNA binding motifs, i.e., an AT-hook, a C2H2 zinc finger, 
and a PHD finger domain, we examined whether TZP associated with DNA in the form 
f chro onation scheme illustrated in Fig. 
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c
 
Figure 30. TZP binds 
DNA. (A and B) Associati
of TZP with chromatin. (C
Schematic procedure o
CASTing analysis. (D
Sequence alignment of TZ
binding consensus sequenc
(E) Electrophoretic mobil
shift assay were performed 
described in experiment
procedures.  (F) Lucifera
assay.  TZP consensus
binding sequence was cloned
to pGL3-basic vecto
HEK293 cells w
transfected with indicat
plasmids. Following 36-
culture, luciferase activit
was measured and normaliz
to β-galactosidase.  Resul
are the mean ± S.E. of thr
independent experime
performed in triplicate. 
a DNA consensus motif.   It ha
ich DNA sequence and enhances
o matin.  We used a small-scale biochemical fracti
30A.  HEK293-Flag-TZP cell lysates prepared with a nonionic detergent were divided 
by sequential centrifugation into soluble cytosolic components called S2 and nuclear 
fraction.  The nuclear fraction was divided into two aliquots, treated with (+) or without 
-) micrococcal nuclease and further fractionated into soluble nuclear components called 
S3 and insoluble nuclear pellets called P3.  Immunoblott
protein was not in S2 cytoplasmic fraction and that the m
fraction becomes soluble (S3) after MNase treatment (Fig. 
 
 
ion. 
HCT116 p53+/+ cells were 
seeded into 6-well plate and 
treated with TZP/RNAi or 
scramble RNAi and subjected 
into Western (left panels) and 
Northern (right panels) blot 
analysis. 
 
(
ing analysis showed that TZP 
ajority of the TZP in the P3 
30B). 
Figure 31. TZP 
transcriptionally upregulates 
p53. (A) HCT116 p53+/+ 
cells were transfected with 
TZP and immunoblotted with 
indicated antibodies.  (B and 
C) TZP inducible HeLa/Tet-on 
and MCF7/Tet-off cells were 
treated with or without 
doxycyclin for indicated time 
and then immunoblotted with 
indicated antibodies. (D) 
Northern blot analysis of TZP 
inducible MCF7/Tet-off cells 
with [32p]dCTP-labeled p53 
and actin cDNA as probes. 
(E) Knockdown of TZP 
reduces p53 express
Next, we searched the TZP-DNA binding consensus sequence using cyclic 
amplification and selection of target (CASTing) assay (Fig. 30C).  The oligonucleotide 
library selected after four rounds of TZP binding was cloned into pGEM-T, and the 
isolated clones were sequenced.  Of 60 sequenced clones, all contained at least one 
RGTGNR (R = A or G and N = A, G, C or T; Fig. 30D).  To confirm this result, EMSA 
was carried out with the [32p]-ATP labeled TZP consensus sequence containing  
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oligonucleotide.  As shown in Fig. 30E, TZP bound to the oligonucleotide that was 
competed by excess of cold probe while the supershift was not observed.  Further, we 
cloned three repeats of TZP binding consensus sequence (TBCS) into pGL3 luciferase 
vector (pGL3-3xTBCS-Luc).  Reporter assay was performed with HEK293 cells 
 the form of chromatin 
nd induces transcription by binding to a specific DNA element. 
TZP transcriptionally upregulates p53.  Since TZ
survival and regulates both G1 and G2/M cell cycle checkpoi
of TZP on expression of a dozen molecules involving both 
progression.  Immunoblotting analysis revealed that p53 w
different cell lines, including HCT116, HeLa and MCF7 
However, TZP was unable to induce p53 expression in HCT
not shown).  Accordingly, downstream targets of p53, such
were also upregulated (Fig. 31C).  Furthermore, mRNA leve
inducing TZP expression (Fig. 31D).  In addition, knock
reduced p53 expression at both mRNA and protein leve
conclude that TZP transcriptionally regulates p53 and is ess
expression level of p53. 
 
TZP binds to p53 promoter and induces the pr
xamined if TZP induces p53 promoter activity.  HeLa cells were transfected with 
pGL2-p
 two  
transfected with pGL3-3xTBCS-Luc and increasing amounts of TZP.  Fig. 30F shows 
that the promoter activity was induced by TZP in a dose dependent manner.  Taken 
collectively, these data indicate that TZP associates with DNA in
a
 
P inhibits cell growth and 
nts, we examined the effects 
cell survival and cell cycle 
as upregulated by TZP in 
examined (Figs. 31 A-C). 
116-p53 null cell line(data 
 as p21, Bax and GADD45, 
l of p53 was increased after 
down of TZP significantly 
ls (Fig. 31E).  Thus, we 
ential for maintaining basal 
omoter activity.  We next 
e
53/-2.4 or its deletion mutants (pGL2-p53/-110, pGL2-p53/-240, and pGL2-p53/-
460) and increasing amounts of TZP.  Following 36 h incubation, luciferase reporter 
assay was performed and showed that TZP considerably induced p53/-110 promoter 
activity, but to much lesser extent in other p53 promoter fragment-driven luciferase 
reporters (Fig. 32B).  This suggests that repression element(s) resides in a region 
between -110bp and -2.4kb of the promoter.  Further, sequence analysis revealed
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putative TZP-binding consensus sites in the p53 promoter at -29/-34 and -79/-84 (Fig. 
32A).  Mutations of these 2 sites by converting the core sequence GTG to AAA largely 
abrogated pGL2-p53/-110 promoter activity induced by TZP (Fig. 32C).  
To determine if TZP directly binds to the TZP-binding site of p53 promoter in 
vivo, we carried out chromatin immunoprecipitation (ChIP) assay, which detects specific 
genomic DNA sequences that are associated with a particular transcription factor in intact 
cells.  HEK293 cells were transfected with Flag-TZP and immunoprecipitated with anti-
Flag antibody.  The TZP bound chromatin was subjected to PCR using oligonucleotide 
rimers that amplify region spanning TZP-binding site within the p53 promoter.  As 
show i
ere they interact.  Since TZP contains two putative Akt 
hosphorylation consensus sites (Fig. 33A), we next determined whether TZP is 
phosph
p
n Fig. 32D, the anti-Flag antibody pulled down TZP binding site (-268/-4).  In 
contrast, immunoprecipitation with an irrelevant antibody (anti-IgG) resulted in the 
absence of band in this site.  Since the two TZP binding sites (-29/-34 and -79/-84) are 
very close to each other in the p53 promoter, ChIP assay is unable to distinguish which 
site directly binds to TZP.  However, mutation analysis of the promoter showed that the 
both TZP-binding sites are required for p53 promoter to respond to TZP (Fig. 32C). 
Furthermore, EMSA assay revealed that TZP is capable of binding to the DNA 
oligonucleotides corresponding to the two TZP-binding sites while supershift was not 
detected (Fig. 32E).  Nevertheless, these data indicate that p53 is a direct target of TZP. 
 
Akt phosphorylates TZP and induces TZP translocation from the nucleus 
into the cytoplasm wh
p
orylated by Akt.  HEK293 cells were co-transfected with Flag-TZP and 
constitutively active Akt or pcDNA3 vector and then labeled with [32P]-orthophosphate.  
The labeled TZP was immunoprecipitated with anti-Flag antibody, separated and blotted 
on a membrane.  PhosphoImager quantification analysis revealed that the incorporation 
of 32p into TZP was 8-fold higher in Akt/TZP transfected cells as compared to the cells 
transfected with pcDNA3/TZP (Fig. 33B).  Further, in vitro kinase assay showed that 
Akt phosphorylation of TZP on serine-291 but not serine-265 (Figs. 33C and 33D).  
These results indicate that Akt phosphorylates TZP in vitro and in vivo. We further  
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Figure 32. TZP binds to and induces p53 promoter. (A) p53 promoter contains two 
putativ
analysi
e TZP binding regions highlighted by underlines.  Primers used for Chip 
s are highlighted.  (B and C) Luciferase assay.  MCF7 cells were seeded 
into 12-well plate and transfected with indicated plasmids and then subjected into 
luciferase assay.   (D) ChIP assay shows that TZP binds to p53 promoter in vivo. 
HEK293 cells were transfected with Flag-TZP and assayed with chromatin 
immunoprecipitation as described in experimental procedures.  (E) TZP binds 
p53 promoter in vitro.  EMSA was performed as described in experimental 
procedures. 
 
examined if Akt phosphorylation of TZP affects their interaction.  Phosphomimic and 
nonphosphorylatable TZP were created by mutation of serine-291 into aspartic acid 
(TZP-D) and alanine (TZP-A), respectively.  Co-immunoprecipitation analysis revealed 
that wild type TZP and phosphomimic TZP-D bound to Akt whereas 
nonphosphorylatable TZP-A failed to interact with Akt (Fig. 33E), implying that  
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phosphorylation of TZP by Akt is important for their interaction. 
Since serine-291 of TZP locates at a nuclear localization signal, we next tested 
whether Akt phosphorylation of TZP affects its subcellular localization.   MCF7 cells 
were transfected with Red-Myr-Akt and/or GFP-TZP.  GFP-TZP was exclusively 
localized in the nucleus in the cells transfected with GFP-TZP alone.   
 
 
tive 
ells 
led 
thophosphate (0.5 mCi/ml) for 4 h.  Cell lysates were immunoprecipitated 
ith anti-Flag antibody, separated by SDS-PAGE and transferred to a membrane.  The 
rom  
Figure 33. Akt phosphorylates TZP in vitro and in vivo.  (A) TZP contains two puta
Akt phosphorylation sites.  (B) TZP is phosphorylated by Akt in vivo.  HEK293 c
were co-transfected with Flag-TZP and constitutively active Akt or pcDNA3 and labe
with [32P]-or
w
phosphorylated TZP band was examined by autoradiography.  (C and D) Akt 
phosphorylates TZP on Ser291.  In vitro Akt kinase assay was performed using full-
length TZP (c), GST-fused wild-type and mutant TZP (d) as substrates.  (E) Co-
immunoprecipitation. HEK293 cells were co-transfected with Flag-tagged wild type and 
the phosphorylation site mutated TZP and HA-Akt.  After 48 h incubation, cells were 
lysed, immunoprecipitated and immunoblotted with indicated antibodies. 
 
However, co-transfection of constitutively active Akt resulted in TZP redistribution f
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the nucleus to the cytoplasm.  Interestingly, Akt was colocalized with TZP in the 
cytopla
nucleus into the 
ytoplasm where TZP interacts with Akt and 14-3-3. 
Figur
cotransfected with GFP-TZP and Red-active Akt.  Nucleus was stained with DAPI. 
(B) TZP binds to 14-3-3.  HEK293 cells were transfected with Flag-TZP.  After 
48 h culture, immunoprecipitation was performed with anti-14-3-3 antibody and the 
 
 
 
ctivity induced by TZP was also inhibited by Akt in a dose-dependent manner (Fig. 35C).  
sm (Fig. 34A).  Further, coimmunoprecipitation revealed the interaction between 
TZP and 14-3-3 in normal culture condition and the interaction was slightly increased by 
serum stimulation (Fig. 34B).  Collectively, these results suggest that TZP is 
phophorylated by Akt which leads to TZP translocation from the 
c
 
e 34.  Akt phosphorylation to TZP results in TZP nuclear exclusion and 
slightly increases TZP interaction with 14-3-3 protein. (A) MCF7 cells were 
immunoprecipitates were immunoblotted with ant-Flag antibody. 
 
Akt phosphorylation of TZP inhibits TZP transactivation activity.  To
determine role of Akt phosphorylation of TZP in TZP function, Gal4 fused TZP construct 
was created and used for the reporter assay.  As shown in Figs. 35A and 35B, Gal4-TZP 
but not TZP considerably induced the activity of pTK-Luc, a luciferase gene under the
control of the thymidine kinase minimal promoter.  Expression of constitutively active
Akt inhibited the promoter activity induced by Gal4-TZP.  Further, p53 promoter 
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a
Accordingly, TZP-induced p53 expression was reduced when cells were co-transfected 
with constitutively active Akt (Fig. 35D).  To examine if TZP regulation of p53 
dependson phosphorylation of serine-291, HCT116 cells were transfected with TZP-
S291A or TZP-S291D together with or without constitutively active Akt.  As shown in 
Fig. 35D, expression of TZP-S291A but not TZP-S291D increased p53 expression and 
Akt had no effect on p53 expression in both TZP-S291A and TZP-S291D-transfected 
ells.  These findings suggest that TZP transactivation activity and TZP-regulated p53 
are inhibited by Akt through a phosphorylation-dependent manner.  
 
 Figure 35.  Akt inhibits 
TZP transcriptional 
activity.  (A-C) Reporter 
assay.  HeLa cells were 
seeded into 12-well plate 
and transfected indicated 
plasmids  Following 36 h 
incubation, luciferase 
activity was measured and 
normalized to β-
galactosidase.  Results 
are the mean ± S.E. of 
three independent 
 in 
tern 
116 
co-
ated 
lture 
 h, cells were lysed 
and immunoblotted with 
doxoru thern and Western blotting  
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c
experiments performed
triplicate.  (D) Wes
blot analysis.  HCT
p53+/+ cells were 
transfected with indic
plasmids.  After cu
for 36
indicated antibodies. 
 
Increase of TZP expression at mRNA and protein levels in response DNA 
damage.  While p53 is upregulated primarily through stabilization in response to DNA 
damage, several studies have shown that p53 is also regulated at the transcriptional level 
in response to genotoxic stress (44, 45).  Thus, we next asked if TZP is regulated by 
DNA damage and mediates stress-induced p53.  HCT116 cells were treated with 
bicin or etoposide for different time points.  Nor
analyses revealed upregulation of TZP at mRNA and protein levels after the treatment for 
30 min.   Accordingly, elevated protein and mRNA levels of p53 were detected in 
response to the treatment (Fig. 36A-D).  These findings were further confirmed in HeLa 
and MCF7 cell lines (Fig. 36E and 36F and data not shown).  These results indicate that 
TZP is a DNA damage-response gene and could mediate transcriptional upregulation of 
p53 by genotoxic stress. 
 
TZP mediates the upregulation of p53 by DNA damage.  To demonstrate 
hether TZP is responsible for stress-induced p53 expression, we knocked-down TZP 
ith RNA interference (RNAi) prior to challenging HCT116
etoposide.  Immunoblotting analysis showed that the knock
reduced p53 levels induced by doxorubicin or etoposide in wil
HCT116 cells (Figs. 37A and 37B).  Accordingly, p53 downs
Bax were decreased (Fig. 37A).  Moreover, chromatin immu
the ability of p53 to bind to p21 promoter was considerably
TZP (Fig. 37C). 
 
w
w  cells with doxorubicin or 
down of TZP significantly 
d-type p53 but not p53-null 
tream target genes p21 and 
noprecipitation showed that 
 reduced by knockdown of 
Figure 36. TZP is induced 
by DNA damage.  (A and 
B) Northern blot analysis. 
HCT116 p53+/+ cells 
were seeded into 6-well 
plate and challenged with 
100 µM etoposide (A) and 
10 µM doxorubicin (B) for 
indicated time.  Total 
RNA was extracted and 
assayed by Northern blot 
analysis.  (C-F) 
Immunoblotting analysis. 
HCT116 p53+/+ (C, D), 
HeLa (E), and MCF7 (F) 
cells were treated with 100 
µM etoposide (C, E) and 
10 µM doxorubicin (D, F) 
for indicated time and then 
immunoblotted with 
indicated antibodies. 
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Accumulated evidences demonstrate that upregulation of p53 by DNA damage is 
largely due to its protein stabilization through phosphorylation by stress kinases such as 
Chk1/2, ATM/ATR, DNA-PK and JNK (66).  Thus, we further examined if TZP also 
regulates p53 stability.  Pulse-chase assay was performed in pcDNA- and TZP-
transfected HCT116.  Fig. 38A shows that the degradation rate of p53 was significantly 
decreased in TZP-HCT116 cells.  Further, the possible effect of TZP on p53 
biquitination was examined in p53-null H1299 cells.  After transfection with p53,  u
 
 
Figure 37. Knockdown of TZP reduces p53 expression induce
B) Western blot analysis.  HCT116 p53+/+ and p53-/- c
scramble and TZP SiRNA.  After 68 h of the transfection, cel
doxorubicin or 100 µM etoposide for 4 h and then immunoblotted with indicated 
antibodies for p53.  (C) Knockdown of TZP decreases p53 
HCT116 p53+/+ cells were transfected with scramble and
treatment with doxorubicin, p53 DNA binding activity was 
using the primers derived from p21 promoter. 
d by DNA damage. (A and 
ells were transfected with 
ls were treated with 10 µM 
binding to p21 promoter. 
 TZP SiRNA.  Following 
examined with ChIP assay 
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Mdm2, and ubiquitin together with or without TZP, immunoblotting of p53 
immunoprecipitates with anti-Myc (ubiquitin) antibody revealed that ubiquitination of 
p53 induced by Mdm2 was considerably reduced by TZP (Fig. 38B). 
 
Figure 38. TZP stabilizes and interacts with p53.  (A) Western blot analysis.  HCT116 
p53+/+ cells were transfected with pcDNA3 (left) and TZP (right).  After 36 h of the 
transfection, cells were treated with cycloheximide (CHX) for indicated time and then 
immunoblotted with indicated antibodies.  (B) TZP inhibits mdm2-mediated p53 
ubiquitination.  P53-null H1299 cells were transfected with HA-p53, mdm2, Flag-TZP, 
and Myc-ubiquitin.  Following 48 h incubation, cells were immunoprecipitated with 
anti-HA antibody and immunoblotted anti-myc antibody (top panel).   Panels 2-4 show 
expression of transfected plasmids.  (C) Co-immunoprecipitation.  HEK293 was 
cotransfected with Flag-TZP and GFP-p53.  After 48 h of the transfection, cells were, 
lysed, immunoprecipitated and immunoblotted with indicated antibodies.  (D) TZP 
directly binds to p53.  GST pull down assay was performed as described in experimental 
procedures.    
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To explore underlying mechanism, co-immunoprecipitation showed that TZP 
physically interacts with p53 (Fig. 38C).  GST-pull down assay revealed that GST-p53 
directly bound to TZP (Fig. 38D).  These data indicate that TZP not only 
anscriptionally upregulates p53 but also binds to and stabilizes p53 protein and that TZP 
plays an important role in regulation of p53 at both physiological and DNA-damage 
conditions. 
 
 
Figure 39. Akt inhibits the 
interaction between TZP and p53. 
(A) HEK293 cells were transfected 
with TZP, p53, active Akt (Ac) and 
dominant negative Akt.  After 48 h 
of the transfection, cells were lysed, 
immunoprecipitated and 
immunoblotted with indicated 
antibodies.  (B) H1299 cells were 
transfected with Flag-tagged wild 
type TZP, nonphosphorylatable TZP-
A, phospho-mimic TZP-D and Red-
p53.  After 48 h incubation, cells 
were lysed, immunoprecipitated and 
immunoblotted with indicated 
antibodies. 
 
Akt inhibits the interaction between TZP and p53.  Akt was shown to 
phosphorylate TZP and reduce its transactivation activity (Figs. 33-35).  Since TZP also 
binds to p53, we further asked if Akt phosphorylation of TZP affects TZP/p53 complex 
 
tr
formation.  Immunoprecipitation revealed that expression of constitutively active 
Aktreduced the ability of TZP to associate with p53 while dominant negative Akt had no 
detectable effect on the complex (Fig. 39A).  Consistent with these findings, 
phosphomimic TZP-D reduced its capability of binding to p53 and nonphosphorylatable 
TZP-A exhibited no significant change of interacting with p53 as compared to wild type 
TZP (Fig. 39B).  In combination with the findings in Figs. 33-35, our data suggest that 
Akt inhibits TZP transcriptional activity toward p53 and reduces the TZP association with 
p53 through phosphorylation of serine-291. 
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Discus
ZP as a transcription factor that interacts with Akt and p53.  TZP binds to 
nd transactivates p53 promoter resulting in induction of p53 mRNA.  Further, TZP also 
interacts with p53 protein and inhibits Mdm2-med
degradation.  Akt phosphorylates TZP and promotes TZP
to the cytoplasm, which lead to downregulation of p53
Importantly, we showed that TZP is required to maintain 
genotoxic stress-induced p53.  These findings indicate t
both Akt and p53 signaling and establish additional con
cascades. 
TZP contains multiple functional domains includin
C2H2 zinc finger and PHD finger domains.  The tudor d
daptor mediating intramolecular as well as intermolecular protein-protein interactions 
67).  AT-hook binds to the A/T rich DNA 
sequence
mors and to transcriptionally activate p53 
 Our data showed that expression of TZP inhibits cell proliferation and induces cell  
       119 
sion 
 
Akt was shown to regulate p53 through phosphorylation of Mdm2.  
Phosphorylated Mdm2 leads to its retention in the nucleus where Mdm2 inhibits p53 
transactivation function and targets p53 degradation (46, 50).  In this report, we 
identified T
a
iated p53 ubiquitination and 
 translocation from the nucleus 
 at mRNA and protein levels.  
of basal level of p53 as well as 
hat TZP plays a pivotal role in 
nection between Akt and p53 
g tudor motif, AT-hook region, 
omain was thought to act as an 
a
and protein-nucleic acid associations (
 and enhances accessibility of the promoter to transcription factor (64).  C2H2 
zinc finger and PHD finger domains are known to involve in DNA binding and protein-
protein interaction (65).  We showed in this study that TZP directly associates with 
chromatin and transactivates p53 promoter through binding to DNA motif (RGTGNR).  
Recent reports suggest that tudor and PHD-finger domains bind to methylated lysine 
residue of histone (68, 69).  Further studies are required to examine if TZP binds to 
methylated histone and involves in chromatin modification.   
In addition to p53 gene mutation, frequent downregulation of p53 messenger 
RNA has been detected in human cancer (70, 71).  However, little is known about the 
transcription factors that regulate p53 synthesis.  HOXA5 was shown to be co-
downregulated with p53 in some of breast tu
(72). 
death and cell cycle arrest (Fig. 23).  TZP localizes at chromosome 20q11 where is 
equently deleted in human cancer (73, 74), suggesting that TZP could be a putative 
tumor s
f TZP by genotoxic stress remains to be investigated. 
 
Refere
fr
uppressor gene, which needs to be further investigated.  
Akt mediates extra- and intra-cellular signals to regulate a variety of cellular 
processes (14).  However, the role and mechanism of Akt in DNA-damage response has 
not been well documented.  Several studies suggest that Akt overcomes DNA damage-
induced G2/M arrest by inhibition of Chk1 and Chk2 kinase activity (75).  However, 
only Chk1 was found to be directly phosphorylated by Akt (76).  Activated Chk1 and 
Chk2 were known to phosphorylate and stabilize p53.  Our data showed that TZP 
upregulates p53 at both transcriptional and posttranslational levels.  In response to 
genotoxic stress, both TZP and p53 were induced and knockdown of TZP decreased p53 
level.  Akt phosphorylates and abrogates TZP function.  Thus, these findings provided 
another direct link between Akt and p53 in the stress pathway, while the mechanism of 
induction o
In summary, TZP is a transcriptional factor and a binding partner of p53 and Akt. 
It exhibits tumor suppressor activity and plays a critical role in maintaining basal level of 
p53 and stress-induced p53.  TZP not only transcriptionally regulates p53 but also 
stabilizes p53 protein.  Akt phosphorylates TZP leading to its translocation from the 
nucleus to the cytoplasm and attenuation of its growth inhibition function.  Further 
investigations are required for the ability of TZP to bind to methylated histone and the 
role of TZP in histone modification.  Importantly, tumor suppressor activity of TZP and 
its possible involvement in human malignancy need to be further studied.  In addition, 
the genome wide TZP target genes need to be identified in order to illustrate normal 
cellular function of TZP. 
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Chapter 6 
 
 surrounding tissue, 
re K/Akt signal transduction pathway has been 
giogenesis and migration.  It has been 
hu r.  Increasing evidences have shown that expression of constitutively active 
nu argets of Akt have been identified, the mechanism of Akt in 
by gulating downstream molecules which are 
arried out three projects during last five years: 1) Cloning of Akt1 promoter and 
 
 
 
Discussion and Conclusion 
During cancer development, tumor cells acquire a number of phenotypic changes 
that allow them to proliferate both rapidly and limitlessly, invade the
survive lacking their normal microenvironment, and finally, metastasize to other sites.  
These features are usually accompanied with up-regulation of oncogenic and/or down-
regulation of tumor suppressor signaling.  As a result of concentrated worldwide 
search activity in the last several years, PI3
shown to play an essential role in tumor development-related cellular processes, 
including cell survival, apoptosis, proliferation, an
demonstrated that three isoforms of Akt are frequently altered in a various types of 
man tumo  
Akt in many cell types promotes cellular transformation by two distinct mechanisms: 
inducing cell proliferation under conditions in which cells should normally be growth 
 arrested and promoting cell survival under conditions in which they should die.  While a 
mber of downstream t
human oncogenesis remains elusive.    
 
The central hypothesis of this thesis is that Akt contributes to human oncogenesis 
 mediating oncogenic signals and re
associated with cell survival, growth and angiogenesis.  To test this hypothesis, I have 
c
identification of Akt1 as direct target gene of Stat3; 2) Downregulation of pro-apoptotic 
protein 24p3 by Akt through phosphorylation of FOXO3a and 3) Identification and 
characterization of a transcription factor TZP that interacts with p53 and Akt.     
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Alterations of the AKT1 at the DNA level have been reported in a single gastric 
ancer.  However, a number of tumors exhibit elevated levels of mRNA, protein and/or 
kinase of AKT1, implicating that the AKT1 is regulated at transcriptional, translational 
and/or posttranslational levels.  Postt regulation of AKT1 has well been 
documented.  To examine transcription regulation of AKT1, I have cloned the human 
AKT1 promoter and demonstra et gene of Stat3.  The AKT1 
romoter activity is significantly induced by constitutively active Src and Stat3.  
Knockd
ation-induced 24p3 expression and cell death.  
orkhead transcription factor FOXO3a binds to and activates 24p3 promoter leading to 
express
Akt  
c
ranslational 
ted that AKT1 is a direct targ
p
own of Stat3 or dominant-negative Sat3 reduced AKT1 expression induced by 
constitutively active Src.  AKT1 level is low in Stat3-null MEFs and reintroduction of 
the AKT1 rescued the Stat3-null MEF cell death resulted from serum starvation.  In 
addition, we have recently reported that constitutively active Stat3 induces hypoxia 
inducible factor (HIF)-1α and knockdown AKT1 largely abrogates the HIF-1α 
expression stimulated by Stat3 (1, 2).  All these findings indicate that the AKT1 gene is a 
direct downstream target of Stat3 and mediates Src/Stat3 cell survival and angiogenesis 
function.  In addition, elevated levels of AKT1 mRNA and protein could be resulted 
from activation of Stat3 in the same subset of human malignancy.      
 
Previous studies have shown that Akt overcomes IL3 deprivation-induced 
apoptosis through phosphorylation of Bad in hematopoietic cells.  However, expression 
level of endogenous Bad is low in these cell lines.  A proapoptotic protein 24p3 has 
been demonstrated to play a key role in induction of apoptosis upon IL3 withdrawal.  I 
have shown that Akt inhibits IL3 depriv
F
ion of 24p3 in response to IL3 withdrawal.  Akt phosphorylates FOXO3a and 
inhibits its action toward 24p3.  Therefore, these findings indicate for the first time that 
24p3 is a direct target gene of FOXO3a and that Akt mediates IL3-regulated 24p3 
expression in hematopoietic cells.  In addition, 24p3, but not Bad, could be a major 
target of Akt protection cells from apoptosis induced by IL3 withdrawal.   
 
Finally, I have identified a novel transcription factor TZP that interacts with 
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and p53
 
eferences 
 
 
.  Expression of TZP inhibits cell growth and survival and induces both G1 and 
G2/M cell cycle arrest.  TZP directly binds to p53 promoter and induces p53 
transcription.  In addition, TZP interacts with p53 and prevents p53 from Mdm2-
mediated degradation.  In response genotoxic stress, both TZP and p53 were upregulated 
and knockdown of TZP reduced p53 expression.  Akt phosphorylates TZP resulting in 
its translocation from the nucleus into the cytoplasm, and thus inhibits TZP function. 
Therefore, I conclude that TZP is a key transcription factor that regulates p53.  In 
addition to Mdm2 that is positively regulated by Akt, Akt reduces p53 function through 
negative regulation of TZP. 
 
These data suggested that Akt contributes to human oncogenesis by mediating 
oncogenic protein, Src and STAT3, which are associated with cell survival, growth, and 
angiogenesis.  Furthermore, I showed that Akt regulates downstream transcription factor 
Foxo3a and TZP which are associated with cell cycle and cell death. These imply that akt 
is a good candidate as a therapeutic target of human cancer. 
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